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ABSTRACT

SMART INTERVENTIONS FOR EFFECTIVE MEDICATION ADHERENCE

BY

NEETU SINGH

30-JUN-2016

Committee Chair:

Dr. Upkar Varshney

Major Academic Unit: Computer Information Systems

In this research we present a model for medication adherence from information systems and
technologies (IS/IT) perspective. Information technology applications for healthcare have the
potential to improve cost-effectiveness, quality and accessibility of healthcare. To date,
measurement of patient medication adherence and use of interventions to improve adherence are
rare in routine clinical practice. IS/IT perspective helps in leveraging the technology
advancements to develop a health IT system for effectively measuring medication adherence and
administering interventions.
Majority of medication adherence studies have focused on average medication adherence.
Average medication adherence is the ratio of the number of doses consumed and the number of
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doses prescribed. It does not matter in which order or pattern patients consume the dose. Patients
with enormously diverse dosing behavior can achieve the same average levels of medication
adherence. The same outcomes with different levels of adherence raise the possibility that
patterns of adherence affect the effectiveness of medication adherence. We propose that
medication adherence research should utilize effective medication adherence (EMA), derived by
including both the pattern and average medication adherence for a patient.
Using design science research (DSR) approach we have developed a model as an artifact for
smart interventions. We have leveraged behavior change techniques (BCTs) based on the
behavior change theories to design smart intervention. Because of the need for real time
requirements for the system, we are also focusing on hierarchical control system theory and
reference model architecture (RMA). The benefit of using this design is to enable an intervention
to be administered dynamically on a need basis. A key distinction from existing systems is that
the developed model leverages probabilistic measure instead of static schedule. We have
evaluated and validated the model using formal proofs and by domain experts.
The research adds to the IS knowledge base by providing the theory based smart
interventions leveraging BCTs and RMA for improving the medication adherence. It introduces
EMA as a measurement of medication adherence to healthcare systems. Smart interventions
based on EMA will further lead to reducing the healthcare cost by improving prescription
outcomes.
Keywords: Effective medication adherence, smart intervention, context-aware reminder,
performance evaluation, health IT artifact, information systems and technologies
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Chapter 1. Introduction
Information technology (IT) applications for healthcare have the potential to improve costeffectiveness, quality and accessibility of healthcare (Chiasson and Davidson 2004). The
potential benefits of IT in healthcare can be realized by addressing the social issues (Braa et al.
2007; Kaplan 2001; Miscione 2007) related to healthcare. According to the World Health
Organization (WHO 2003), medication nonadherence poses a serious social challenge and needs
to be addressed to improve the healthcare quality and minimize the healthcare cost. In healthcare
literature various interventions have been designed to improve medication adherence (Choi et al.
2008; Maulucci and Somerville 2011; McDonald et al. 2002; Schreier et al. 2013). The
measurement of patient medication adherence and use of interventions to improve adherence are
rare in routine clinical practice (Ho et al. 2009). A theoretical approach to study medication
adherence improvement is largely missing in literature (Ruppar 2010). The research in this field
needs advances, including improved design of feasible long-term interventions, objective
adherence measures, and sufficient study power to detect improvements in patient-important
clinical outcomes (Nieuwlaat et al. 2014). In this research we present a model based on health
behavior change theories to study medication adherence from information systems and
technologies (IS/IT) perspective. IS/IT perspective helps in leveraging the technology
advancements to develop a health IT system for effectively measuring medication adherence and
administering interventions.
Medication adherence is “the extent to which a patient act by the prescribed interval, and a
dose of a dosing regimen.” (Cramer et al. 2008). Adherence to prescribed medication regimens is
critical to the quality of patient outcomes such as symptoms and other aspects of well-being,
functioning, health status, general health perceptions, quality of life, health-related quality of life,
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reports and ratings of healthcare. Nonadherence in patients leads to a substantial worsening of
disease, death, and increased healthcare costs. In general, 80% medication adherence is
considered satisfactory for chronic conditions; however, a higher level (95%) may be needed for
acute conditions (Haynes et al. 2008; Osterberg and Blaschke 2005; WHO 2003).
Approximately 3.2 billion annual prescriptions are dispensed in the United States alone, and
about 50% of these prescriptions are not consumed as prescribed (Osterberg and Blaschke 2005;
Sicre 2007). Figure 1 shows for every 100 prescriptions that physicians write, only 50% - 70%
reach pharmacy, 48% - 66% get filled, 25% - 30% taken properly and 15% - 20% refilled as
prescribed (NACDS 2010).

Figure 1. Gap between a written prescription and actual medication use (NACDS 2010)

A retrospective analysis of insurance claims confirms the earlier findings that poor
medication adherence is a common problem across most chronic conditions (Thier et al. 2008).
Nonadherence is not only prevalent but also has dramatic effects on individual and populationlevel health. Approximately 125,000 deaths per year in the United States are associated with
nonadherence to medication (McCarthy 1998). Although the consequences of suboptimal
adherence to medications are quite variable, poor adherence clearly poses a threat to the health of
the U.S. population (Peterson et al. 2003; WHO 2003) that must be addressed to reduce the gap
2

between potential and actual healthcare quality. Extensive health benefits would result from
improving medication adherence to existing treatments than developing any new medical
treatments (Sabate 2007).
An economic burden of $100 to $300 billion per year came from medication nonadherence
(NEHI 2009). Substantial evidence suggests that benefits attributable to improved selfmanagement of chronic diseases could result in a cost-to-savings ratio of approximately 1:10
(Sabate 2007). As represented in Figure 2, nonadherence accounts for 10% to 25% of hospital
and nursing home admissions. Recent research has found that medication nonadherence results
in:


5.4 times increased risk of hospitalization, re-hospitalization, or premature death for patients
with high blood pressure (Gwadry-Sridhar et al. 2009),



2.5 times increased risk of hospitalization for patients with diabetes (Lau and Nau 2004), and



More than 40 percent of nursing home admissions (Lau and Nau 2004).

Figure 2. Impact of medication adherence on hospitalization risk (Sokol et al. 2005)

Rates of adherence, which is reported as the percentage of the prescribed doses of the
medication taken by the patient over a specified period, have not changed much in the last five
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decades. The extent of nonadherence varies widely, and in different studies, it has been recorded
as low as 10% and as high as 92% (Osterberg and Blaschke 2005; Sokol et al. 2005).
Approximately half of nonadherence is intentional, while the remaining are unintentional
because patients are either unaware that they are not taking medications as prescribed, or the
regimen is just too complex. Adherence rates are typically higher among patients with acute
conditions, as compared against those with chronic conditions. Studies reveal that patients with
chronic illnesses take only approximately 50% of medications prescribed for those conditions.
Adults aged 18–64 were almost twice as likely as adults aged 65 and over to have skipped doses,
forget to take medicine, to have taken less medicine, and to have delayed filling a prescription to
save money (Cohen and Villarroel 2015).
Nonadherence is a multidimensional problem influenced by several factors including patient
views and beliefs, illness characteristics, social contexts, access and healthcare service issues.
The problem is likely to grow as the population ages and as patients take more medications to
treat chronic conditions. The potential burden of medication nonadherence outcomes on
healthcare delivery makes it a significant public health concern as evident from the World Health
Organization and the Institute of Medicine goals to improve medication adherence (Sokol et al.
2005; WHO 2003).
The recognition of the importance of medication adherence has been increasing over the last
decade. To improve health outcomes, healthcare practitioners should engage with patients and
educate them on the importance of proper medication use (Braithwaite et al. 2013). For the
healthcare service providers, helping patients take medication as prescribed would help in
avoiding risks of relapses, antibiotic resistance, and preventable hospitalizations.
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An intervention is the means of interfering with the outcome or course especially of a condition
or process (as to prevent harm or improve functioning). In medicine, an intervention is usually
undertaken to help treat or cure a condition. Medication nonadherence is a growing concern to
clinicians, healthcare systems, and other stakeholders because of mounting evidence that it is
prevalent and associated with adverse outcomes and higher costs of care (Ho et al. 2009).

Section 1.1 Research Problem
Medication adherence is critical to the quality of patient outcomes, but high adherence is
difficult to achieve. Former United States Surgeon General C. Everett Koop once said, “Drugs
do not work in patients who do not take them” (Osterberg and Blaschke 2005). This simplistic
yet accurate statement summarizes the dilemma faced by healthcare providers and patients in the
quest for optimum healthcare. Healthcare providers (as part of a healthcare team within the
health system) are an integral component of the five interacting dimensions of medication
adherence identified by the World Health Organization (2003), which include social and
economic dimension, healthcare system dimension, condition-related dimension, therapy-related
dimension, and patient-related dimension. The multidimensional problem of nonadherence has a
complex environment. Identifying strategies for improving medication adherence is a
collaborative effort of all stakeholders.
This research examines the issue of nonadherence by focusing on (1) measurement of
patient’s medication adherence and (2) use of mobile technologies to improve adherence among
patients who self-administer prescribed medications in routine clinical practice. The premise for
the focus is that concordance between the patient and provider initiates the dosing regimen. The
dosing regimen is observable over a period of medication/therapy persistence. The current
healthcare technologies provide sufficient tools that are leveraged without modifications to
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observe the actual dosing of medicines by the patient. The need, therefore, is to leverage
information systems in designing a system that can help the providers in measuring the
adherence within the persistence period and provide the ability to administer intervention. The
ability to measure and improve medication adherence could lead to overall improvement in the
patient’s health outcome.
Average medication adherence (AMA) is the predominantly used measure of medication
adherence. AMA considers an average dosing rate and is observable after medication
persistence. In the current system, the patient taking the medication self-reports to the provider
towards the end of medication persistence at the time of prescription refill or if there is a concern
from a patient with the prescribed treatment. The best the provider or patient can do is to
schedule reminders to take medications on time (simple intervention). This research recognizes
medication persistence as a window that is monitored to (1) detect when intervention is needed
and (2) identify what intervention to administer.
In the envisioned system, the rate of adherence is a probability estimate based on the
medication behavior (pattern of medication adherence) of the patient and is termed Effective
Medication Adherence (EMA). EMA identifies when and what intervention is administered. In
envisioned system, intervention is not provided if the patient exhibits medication adherence. As
interventions are not scheduled for administration at concordance but dynamically generated
(when), and type is determined (what) based on the EMA, we deem such interventions as
‘context-aware’ or ‘smart’ interventions.

Section 1.2 Research Questions
The goals of this research are to (1) analyze the patterns of adherence with prescribed selfadministered medications and its impact on effectiveness of medication adherence, (2) develop a
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model for intervention (smart intervention) to improve effectiveness of medication adherence
and reduce healthcare costs, and (3) provide a theoretical base to articulate, formalize, and fully
understand the model. The research questions we will address in this study are:
RQ1: How patterns of medication adherence impact effective medication adherence (EMA)?
RQ2: How smart interventions improve effective medication adherence (EMA)?
RQ3: How smart interventions reduce healthcare cost?

Section 1.3 Research Approach
The significant prospect in this research is the development of health information technology
system for smart intervention to address the problem of nonadherence among patients prescribed
self-administered medications for chronic disease. The central exercise for this research is to
develop a model as an artifact for smart intervention based on effective medication adherence so
as to improve simple interventions. A model is developed as an artifact to enable the
representation, analysis, understanding, development and subsequent refinement of smart
interventions. The implementation of artifact is done on wireless based smart medication
management system (Varshney 2011) or smartphones.
The Design Science Research (DSR) Process is a natural fit for developments that are
improvements over an existing model (Vaishnavi et al. 2007). Awareness of common problem
motivates the DSR process. Design science research initiates with a significant prospect,
challenging problem, or creativity/conjecture for some innovativeness in the application
environment (Hevner 2007; Hevner et al. 2004; Iivari 2007; Vaishnavi and Kuechler 2015). The
effective solution of the problem is provided by developing a better interface (Vaishnavi et al.
2007). The focus of design science research is to understand the phenomenon, some or all of
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which may be created artificially instead of naturally occurring, thereby leading to artifact design
and evaluation.
The DSR process model developed and revised by Vaishnavi and Kuechler (2015) is shown
in Figure 3. It also shows cognitive processes used in the DSR process.

* Circumscription is the discovery of constraint knowledge about theories gained through detection
and analysis of contradictions when things do not work according to theory (McCarthy 1980).
Figure 3. Design science research process model (DSR cycle) & cognitive processes

In the DSR process, all design begins with an awareness of the problem. In this step, the
researcher defines the problem to be solved via the research process. Suggestions for solutions to
the problem are drawn from the existing knowledge and theory bases for the problem area
(Peirce 1931) or developed using an appropriate research methodology. The cognitive process of
assimilation of knowledge is abductive at this step. Next, in the development step, the researcher
implements an artifact according to the suggested solution. The implementation is evaluated
according to the functional specification stated implicitly or explicitly in the suggestion step. The
researcher may iteratively perform the suggestion, development, and evaluation steps during the
research. The circumscription (the basis of the iteration) represents the addition of knowledge
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from the development and evaluation steps of the process to the initial awareness of the problem,
so that the problem can be re-examined. The cognitive process of assimilation of knowledge is
deductive at this stage. The conclusion indicates the reflective stage where the research is
concluded with the formulation of propositions relating to the problem domain. The steps of
DSR process steps and output are described in Table 1 and Table 2.
Steps
Awareness of
Problem Step
Suggestion Step
Development Step

Evaluation Step

Conclusion Step

Description
An awareness of an interesting research problem may come from multiple
sources including new developments in industry or a reference discipline. The
output of this phase is a proposal, formal or informal, for a new research
effort.
New functionality is envisioned based on a novel configuration of either
existing or new and existing elements.
The tentative design is further developed and implemented in this phase. The
techniques for implementation will, of course, vary depending on the artifact
to be created. The novelty is primarily in the design, not the construction of
the artifact.
Once constructed, the artifact is evaluated according to implicit expectations
or explicit criteria (Awareness of Problem phase). Deviations from
expectations, both quantitative and qualitative, are explained, and Propositions
are made. The deviations from the theoretical performance are iteratively
refined by including new observations into the suggestion.
Not only are the results of the effort consolidated at this phase, but the
knowledge gained in the effort is frequently categorized as either repeatable or
anomalous. Future research areas are identified, and knowledge contribution
(Gregor and Hevner 2013) is noted.

Table 1. Design science research process steps (Vaishnavi and Kuechler 2015)

Output
Constructs
Models
Frameworks
Architectures
Design Principles
Methods
Instantiations
Design Theories

Description
The conceptual vocabulary of a domain
Sets of Propositions or statements expressing relationships between
constructs
Real or conceptual guides to serve as support or guide
High level structures of systems
Core principles and concepts to guide design
Sets of steps used to perform tasks; how-to knowledge
Situated Implementations in certain environments that do or do not
operationalize constructs, models, methods, and other abstract artifacts; in
the latter case, such knowledge remains tacit.
A prescriptive set of statements on how to do something to achieve a
certain objective. A theory usually includes other abstract artifacts such as
constructs, models, frameworks, architectures, design principles, and
methods.

Table 2. Design science research output (Vaishnavi and Kuechler 2015)
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In this research, the model for smart intervention is developed using the guidelines of
Vaishnavi and Kuechler (2015) and evaluated for effectiveness using the formal proofs and
evaluation by domain experts (Healthcare providers and Health IT experts) (Cleven et al. 2009;
Gregor and Hevner 2013; Parsons and Wand 2008). The DSR process steps and the
corresponding outputs of each step are listed in Table 3 to outline the specific outputs from this
research.
DSR Process Steps
Awareness of Problem
Suggestion
Development
Evaluation
Conclusion

DSR Outputs
Proposal
Tentative Design
Artifact
Performance Measures
Results

Specific Outputs
Medication Adherence (MA) Improvement
Smart Intervention
Model
Effective Medication Adherence (EMA)
Propositions

Table 3. Specific research output at DSR process steps

A literature review is conducted to understand the current state of the research on the topic of
medication adherence and the various interventions that presently exist. Specifically,
environment and the factors that affect the medication adherence are studied. Any theoretical
basis for medication nonadherence is analyzed for gaining a better understanding of the problem
conceptually and the limitations therein. The guiding question for the awareness of problem step
is - If interventions to medication nonadherence can improve medication adherence, why such
interventions are not effective?
The understanding gained from the awareness of problem leads to the formulation of
suggestions that could address the effectiveness of the interventions in improving medication
adherence. The guiding question for suggestion step of the DSR process is – How can the
effectiveness of interventions be improved?
When a suggestion for improving the effectiveness of the intervention is identified, a model
is developed. As existing interventions are designs, a model (sets of propositions or statements
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expressing relationships between constructs) is an appropriate artifact to improve the design as it
provides the lowest possible level of operative environment for the constructs. The guiding
question for development step of the DSR process is - How closely does the new model represent
the original model/design of the available interventions?
The model from development step of DSR process is evaluated to examine the effectiveness
of the improvements as envisioned in the suggestion step and according to the criteria for
effective intervention identified in the awareness of problem step of DSR process. Propositions
are developed about the behavior of the model. If the model does not behave as expected,
revisions to the suggestion are made from the additional information gained in the development
and evaluation steps and the directions suggested by deviations from expected performance. The
development and evaluation steps are then repeated. The guiding question for evaluation step of
the DSR process is – What are the limiting conditions for the effectiveness of interventions
utilizing new model?
The final step in research following the DSR process is the conclusion. In addition to the
practical implication of this research, the theory, and knowledge gained from model development
and evaluation can become a part of design science knowledge base thereby bridging some of the
literature gaps that currently exist from DSR perspective. The guiding question for conclusion
step of the DSR process is – Do the smart interventions improve effectiveness of medication
adherence?

Section 1.4 Research Contributions
This research aims to contribute model for theory based smart interventions that could
improve effective medication adherence in a group of patients who are prescribed selfadministered medication for chronic condition, thereby reducing the healthcare costs.
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The significance of proposed research is three fold. First, it is significant to the healthcare
system as the intervention will help in understanding the patterns of adherence and improves the
effective medication adherence. As better health outcome is achieved, the financial burden of
nonadherence will decrease. Second, it will provide an artifact which can be further evaluated
using the field study. It will add value to the design science research community by providing a
health IT domain specific artifact and by improving domain-specific information systems and
processes. Third, it addresses the need of theoretical interventions for improving medication
adherence.
What is already known about the topic?


Medication nonadherence is a widely acknowledged and pervasive healthcare issue.



Medication adherence holds particular significance for individuals diagnosed with chronic
conditions.



Various interventions have been designed to improve medication adherence, but few theories
describe specifically the processes involved.



Despite five decades of research, current interventions do not consistently enhance
medication adherence.



Current interventions focus on improving average medication adherence. The interventions
are not generated dynamically.



Some of the existing medication adherence applications report the nonadherence to
healthcare providers, but they do not facilitate the advice/scheduling from healthcare
providers.



Existing technologies monitor and report nonadherence toward the end of medication
persistence.
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What this research adds?


The scope of this dissertation research is to describe the IS/IT processes involved in
developing the health IT artifact as an intervention to improve effective medication
adherence.



We address the area of medication adherence using health behavior change theory and
reference model architecture theory. We discuss the application of health behavior change
theory as the basis for an intervention to improve effective medication adherence.



We evaluate that patterns of adherence and average medication adherence are important
predictors of medication adherence improvement.



Using design science research approach, we have developed model for effective medication
adherence (MEMA), a health IT artifact as a system to administer smart intervention to
improve effective medication adherence. Model for effective medication adherence include
interactive presence of following components:
1. Wireless medication box (WMB) which provides the dispensing and consumption
information.
2. Dynamically generated context-aware reminders using the three way interaction between
wireless medication box (WMB), medication management application (MMA) and
medication management server (MMS).
3. Analysis of medication behavior that will be helpful in understanding the impact of
nonadherence on treatment outcome.

Section 1.5 Research Limitations
The limitation of this dissertation lies in the fact that the health IT artifact is not generalizable
to general healthcare area for medication adherence improvement. It is useful for chronic
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conditions and unintentional nonadherence. More specifically, a model for effective medication
adherence applies to unintentional nonadherence, and the intervention improves the effective
medication adherence, i.e., the transition from Quadrant IV to Quadrant I of Figure 4. In this
research, we are not focusing on unwilling patients. Figure 4 shows the intentional and
unintentional nonadherence criteria.
The current design has the limitation that patient should be willing to take medication as this
intervention is for prescribed self-administered medications. Regarding artifact evaluation, it can
be further extended by conducting a field study where the modeled artifact can be made
accessible to patients and healthcare provider to use. It will help in empirical validation of the
artifact in future research.

Figure 4. Intentional and unintentional nonadherence
(Ho et al. 2009; Lehane and McCarthy 2007)
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Chapter 2. Awareness of Problem
The effectiveness of treatment depends on both the efficacy of a medication and patient
adherence to the therapeutic regimen. Patients, healthcare providers, and healthcare systems, all
have a role in improving medication adherence. A single method cannot improve medication
adherence. Instead, a combination of various adherence techniques should be implemented to
improve patient’s adherence to the prescribed treatment.

Section 2.1 Role of Patient
Medication adherence is the extent to which patients follows the prescribed medication
regimens (Cramer et al. 2008). Adherence is the preferred term because compliance suggests
passivity on the part of the patient and a lack of a therapeutic alliance between patient and
provider (Osterberg and Blaschke 2005; Steiner and Earnest 2000).
The manner in which a patient adheres to a prescribed medication regimen influences the
health outcomes, healthcare utilization, and healthcare costs (Chewning and Sleath 1996;
Delgado 2000). Multiple interrelated psychosocial factors affect medication adherence. These
factors are: psychological factors (DiIorio et al. 2009), self-efficacy (DiIorio et al. 2009; Duong
et al. 2001), social support (Duong et al. 2001; Fongwa et al. 2008), and socioeconomic issues
(Fongwa et al. 2008; George et al. 2006).
Self-efficacy is a primary factor affecting whether or not a person will change a behavior and
can affect the ability to adhere to complex medication regimens. A recent study reported that
higher self-efficacy in taking medication was associated with higher medication adherence
(Colbert et al. 2013).
Accurate medication adherence and the self-efficacy are important for chronic disease
patients. Self-reports are the most commonly used tool for measuring adherence. Empowerment

15

of an individual to self-determine benefits and risks of action or behavior are crucial to change
adherence to medication, and the willingness and ability to do it. For chronic patients, the
cognitive and psychological burdens of treatment can often impede the medical outcome. The
patient may not comprehend information about treatment if the amount of information becomes
overwhelming. The patient may become unwilling to ask for help, and can undermine the
importance of medication for the treatment.
Nonadherence to medications can be intentional or unintentional. Intentional nonadherence is
an active process whereby the patient chooses to deviate from the treatment regimen. There may
be a rational decision process in which the individual weighs the risk and benefits of treatment
against any adverse effects. Unintentional nonadherence is a passive process in which the patient
may be careless or forgetful about adhering to the treatment regimen (Ho et al. 2009; Lehane and
McCarthy 2007). Unintentional adherence is also referred to by Vrijens et al. (2008) as the
execution of the prescribed regimen, or how well patients adhere to the dosing regimen. There
are six general patterns of execution:
(1) Close to perfect adherence;
(2) Take nearly all doses with some timing irregularity;
(3) Miss an occasional single day’s dose, and some timing inconsistencies;
(4) Take drug holidays 3 to 4 times per year;
(5) Take drug holidays monthly or more often and have frequent omissions; and
(6) Take few or no doses.
Most deviations in medication taking are due to omissions of doses or delays in taking doses.
Also, it is common for patients to improve their medication-taking behavior shortly before and
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after an appointment with a healthcare provider called “white coat adherence” (Osterberg and
Blaschke 2005).
Estimates of unintentional nonadherence vary considerably and range from 20% to over 50%
(Ho et al. 2009; Lehane and McCarthy 2007). Forgetting to take medication (62%) was the most
commonly reported behavior followed by running out of medications (37%) and being careless
at times about taking the medication (23%) (Gadkari and McHorney 2012). Timely intervention
can influence nonadherence of prescribed self-administered medications. The reasons for poor
medication adherence are often multifactorial, and encompasses a wide range of behaviors. The
consequence is an underuse or overuse of prescribed medications.

Section 2.2 Role of Prescribers
Healthcare providers play a unique and important role in assisting patients to carry out healthy
behaviors (Atreja et al. 2005) and a patient’s beliefs about the benefits and risks of medicines
influence whether or not they take prescribed medication (Wroth and Pathman 2006). The patient
relationship with the healthcare provider influences the acquisition of knowledge and the belief
of the importance of adherence (Phatak and Thomas 2006; Pratt et al. 2001). Collaborative care
involving a working relationship between physicians and pharmacists has been shown to
improve patient care and reduce medication errors (Kuo et al. 2004). Collaborative care is
beneficial in addressing the psychosocial factors that can affect medication adherence.
Another factor is patient and provider concordance - the extent to which patients and their
providers agree on whether, when, and how patient takes medication. Hence, adherence requires
the patient to believe there is a benefit to the prescribed medicine and agree with instructions on
how to take it. Importantly, there cannot be barriers, such as cost, which will prevent medication
access. The prescriber’s role is to gain trust from the patient, understand the patient’s belief
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system, find a way to treat within this belief system, interactively obtain agreement from the
patient on when and how to take prescribed medication, and discuss cost issues to ensure that
patient adheres to the prescription. Building trust and developing skills for successful provider
and patient communications demand time, effort, knowledge, and practice.
In addition to prescribers, the office staff has a role in boosting patient adherence to
medication. Wroth and Pathman (2006) evaluated correlates of medication adherence in a rural
setting and found that when patients felt welcomed and comfortable by the staff, they were more
likely to fill their prescriptions.

Section 2.3 Role of Interventions
Intervention is a treatment, procedure or program of healthcare that has the potential to
change the course of a healthcare condition. Interventions are classified as informational or
behavioral. In general, interventions for improving medication adherence include reminders,
family support, educational interventions and motivational support from healthcare providers
among others (Friedman et al. 1996; McDonald et al. 2002). Health IT interventions implement
some of these (Moore and Benbasat 1991).
There have been major advances in design, implementation, and evaluations of systems for
medication adherence. With increasing deployment of mobile and wireless technologies,
including sensors, RFID, personal area networks, wireless LANs, and cellular networks, some of
these interventions can be implemented on smartphone and smart medication systems (McCall et
al. 2010; Varshney 2009). More specifically, enhancing standard care with reminders, disease
monitoring and management, and education through applications on a smartphone can help
improve health outcomes. These care processes have implications for both patients and providers
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(Krishna et al. 2009). Also, a wireless-based smart medication system (SMMS) can support
(Varshney 2011; Varshney 2013)
(a) Communication with patients,
(b) Monitoring of medication consumption,
(c) Context-sensitive reminders to patients, and
(d) Multiple interventions for medication adherence.
Some of the systems use wearable devices and sensors for medication adherence (Choi et al.
2008; Choi et al. 2013; DiCarlo et al. 2012; Holmes et al. 2014). Lundell et al. (2007) captured
medication adherence by counting medication taking events that occurred within 90 minutes
before and 90 minutes after the scheduled time. Electronic pill box has been developed and used
for continuous monitoring of medication adherence (Hayes et al. 2006). In another study, an
automated medication adherence tool is developed for imparting medication taking directions to
patients (Maulucci and Somerville 2011).
However, existing technologies for monitoring and improving drug adherence are either
costly or too complicated for general patients to use. The current methods of improving
medication adherence for chronic health problems are labor-intensive, and not predictably
effective (Ingersoll and Cohen 2008; Lundell et al. 2007; Maulucci and Somerville 2011; McCall
et al. 2010; Moore et al. 2011; Schreier et al. 2013; Tang et al. 2011). These methods of
intervention do not realize the full benefits of treatment.
Several interventions have been tried to improve the average medication adherence (Choi et
al. 2008; Hayes et al. 2006; Ingersoll and Cohen 2008; Lundell et al. 2007; Maulucci and
Somerville 2011; McCall et al. 2010; McDonald et al. 2002; Moore et al. 2011). Some
interventions are implemented on smartphone (Krishna et al. 2009; Varshney 2009) and
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medication systems (Choi et al. 2013; DiCarlo et al. 2012; Hayes et al. 2006; Holmes et al. 2014;
McCall et al. 2010; Moore et al. 2011; Schreier et al. 2013; Tang et al. 2011; Varshney 2011).
Most systems rely on simple alarms and do not address other determinants of health-related
behavior (Hayes et al. 2006; Schreier et al. 2013). Although quite diverse, these systems support
communications with the patient, medication monitoring, and interventions to improve the
average medication adherence.
Haynes (1976) randomly allocated, through the minimization method, 38 patients who were
both hypertensive and nonadherent (less than 80% of prescribed pills) at the end of a six-month
trial to an intensive adherence intervention or control. The intervention included care provided at
the work site, special pill containers, counseling, reminders, self-monitoring of adherence and
blood pressure, support groups, feedback and reinforcement for adequate adherence and blood
pressure-lowering, all administered with bi-weekly contacts by a lay program coordinator who
was supported by study funds. At six months’ follow-up, there was a significantly higher
adherence in the intervention group.
Most patients do not follow self-administered medical treatments as prescribed and
interventions to help them follow treatments are marginally effective at best, especially for longterm medical regimens. Strategies that appear to have some effect for long-term regimens
involve combinations of counseling, reminders, self-monitoring, feedback, family therapy,
psychological therapy, manual telephone follow-up, and supportive care. For short-term
treatments, simpler means, including counseling, written information about the importance of
taking all doses, and personal phone calls can achieve high adherence.
Coomes et al. (2012) has developed a conceptual framework for using short message service
(SMS) based intervention to improve healthcare quality and clinical outcomes for people living
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with HIV (PLWH). They have posited that SMS-based intervention which are more personalized
as well as consider mutually reinforcing behaviors and factors offer a unique opportunity to
enhance treatment and prevention for PLWH (Coomes et al. 2012). Rosen et al. (2015)
conducted a qualitative study to adapt and develop an mHealth app for HIV patients to improve
medication adherence. The results of this study indicate that a balance of provided and requested
information is important to maintain interest and support adherence (Rosen et al. 2015). These
two studies provide an insight that while developing intervention, user interface and reaction to
visual content of app is essential to adaptation and design of intervention.
Other studies have similarly concluded that behavioral interventions like reminders are
important in improving the medication adherence. The method of administration of reminders as
intervention mechanism to enforce adherence is also an important factor in influencing the
patients (Rosen et al. 2015).
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Chapter 3. Suggestion
Section 3.1 Evaluating adherence
Concordance is the agreement between the provider and the patient; patient/provider
concordance is the extent to which patients and their providers agree on whether, when, and how
to take medication (Zulman et al. 2010). The providers uniformly underestimate the problem of
nonadherence. If it is not suspected, it cannot be corrected. Measuring adherence can lead to
better patient compliance. Adherence is the extent to which a patient’s behavior (regarding
taking medication, following a diet, modifying habits, or attending clinics) coincides with
medical or health advice (Cramer et al. 2008). Persistence is the duration of time from initiation
to discontinuation of therapy. Continuing to take any amount of the medication is consistent with
the definition of persistence (Cramer et al. 2008).

Figure 5: Adherence versus persistence (Cramer et al. 2008)
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Adherence, as represented in Figure 5 is a measure of the percentage of doses taken as
prescribed over the number of day medication is taken without exceeding the permissible gaps.
For example, if a person is prescribed an antibiotic with a dosage of one tablet three times a day
for a week, but only takes two tablets a day for four days, adherence is 38% (8/21).
We value adherence because studies have established that being compliant delivers the most
effective therapeutic benefits of the prescribed medication. The stated method of measuring
adherence gives us an average rate of taking medications and thus could model the therapeutic
benefits arising from consuming average doses. The drawback here is it does not predict or tell
us the effectiveness of such adherence on the derived therapeutic benefits. In an ideal world,
everybody is assumed compliant, and the adherence is 100% and so would the effectiveness of
adherence with 100% therapeutic benefits derived. In practical scenarios, the average dose may
not be an effective dose.
In pharmacology, an effective dose (ED) is the dose or amount of drug that produces a
therapeutic response or desired effect in some fraction of the subjects taking it. Drugs are
seldom administered in a single dose to produce the desired effect. Drugs are frequently
administered in successive doses to bring about lasting and effectual results. Thus, to avoid the
toxic concentrations of a drug as well as to maintain its therapeutically effective concentration
within the plasma, one must properly contrive a multiple dosing regimen.
Multiple Dosing Regimen We consider multiple dosing regimen with the context of
adherence within a persistence to assess the effectiveness of each dose in producing the desired
therapeutic output.
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Figure 6. Repetitive dosing with adherence versus persistence

In Figure 6, we represent a drug administered on a multiple dosing regimen; each successive
dosage(s) administers before the preceding doses eliminate. Accumulation of the drug routinely
occurs within the body yielding a higher plasma drug concentration. The accumulation
phenomenon, however, does not cause the plasma concentration to rise indefinitely. Figure 7
shows the plasma concentration plateaus where the same maximum (Cmax) and minimum (Cmin)
concentrations are repeatedly reproduced (Lins et al. 2003). In designing a dosing regimen then,
one's objectives would be to keep the drug concentration above the minimum effective
concentration (MEC) and below the minimum toxic concentration (MTC).

Figure 7. Plasma concentration plateaus overdosing intervals (Lins et al. 2003)
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3.1.1 Dose Persistence
One cannot overstate the importance of determining the therapeutic range of a drug. The
range between the minimum effective dose (MED) and the maximum tolerated dose (MTD)
defines the therapeutic range. The MED is the lowest dose level of a pharmaceutical product that
provides a clinically significant response in average efficacy, which is also statistically
significantly superior to the response provided by the placebo (Jen-pei 2010). Similarly, the
MTD is the highest possible but still tolerable dose level on a pre-specified clinical limiting
toxicity (Jen-pei 2010). In general, these limits refer to the average patient population. For
instances in which there is a large discrepancy between the MED and MTD, it is stated that the
drug has a large therapeutic window. Conversely, if the range is relatively small, or if the MTD
is less than the MED, then the pharmaceutical product will have little to no practical value (Jenpei 2010).
Figure 8 shows the persistence of the medicine over a dosing interval in the dosing regimen.
Over a period, the effects of the medicine wear off. Dosing regimen specifies the interval to be
duration from intake when the concentration of the drug falls below the therapeutic range.

Figure 8. Dose persistence within the medication /therapy persistence
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3.1.2 Nonadherence
Medication adherence helps in maintaining the effective level of drug in the body. The effects
of the medication wear off due to consumption of the drug in the body. After a period, the
clinical effects of the medicine become ineffective and need replenishment, i.e., taking the next
dose of the medicine. This implies that three types of dosing event (DE) is captured for
medication adherence:


Consuming the medicine before the recommended interval i.e. before the time,



Consuming the medicine after the recommended interval i.e. after the time, and



Consuming the medicine at the recommended interval i.e. on time.

Consuming the medicine before the recommended interval leads to exceeding the minimum
tolerated dose (MTD). If the minimum time (TMIN) between two doses is not medically safe, then
it will lead to undesirable dose event (UDE). On the other hand, consuming the medicine after
the recommended interval exposes patient to below the minimum effective dose (MED) interval.

Figure 9. Nonadherence dose persistence within the medication /therapy persistence
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If the maximum time (TMAX) between two doses is not medically effective, then it will lead
to dose not effective (DNE). Figure 9 shows that consuming the medicine at the recommended
interval is the Prescribed Effective Dose (PED) event and is ideal. If any of the three events do
not register for the prescribed interval, it will imply a skipped or a missed dose.
3.1.3 Patterns of Adherence
A pattern can be generated from such consumption events indicating the deviation or
conformation to the prescribed dosing regimen and becomes the pattern of medication
adherence. The pattern of medication adherence generates from the events associated with the
intake of medication by the patient. Undesirable dose event (UDE) results in a higher
concentration of medicine than the prescribed and thus deemed unsafe level in the body
temporarily (from the time of consumption until the next scheduled time) and may require
immediate intervention by the healthcare provider/physician.
For the purpose of this research, UDE is reported to the healthcare provider and intervention
is not provided. This research focuses upon dose not effective (DNE) because our emphasis is on
the effectiveness of the adherence. Analyzing the patterns of medication adherence along with
the average medication adherence results in a new variable termed effective medication
adherence (EMA). EMA tracks the actual adherence to the prescribed regimen of medicine
intake and the deviations therein considering the periods of the ineffectiveness of the medication
dose. Figure 10 shows the different patterns of adherence to a medication therapy/persistence.
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Figure 10. A simple pattern of adherence within the medication /therapy persistence

Figure 11 shows the pattern of the dose persistence/dose not effective based on a skipped
dose. The sequence in which the dose not effective intervals occur has a bearing on the
persistence outcome. A dose not effective interval occurring earlier in medication persistence
may have an effect quite different than the dose not effective interval towards the end of the
medication persistence. The effectiveness of adherence would be different in both cases on the
therapeutic outcome and thus different EMA values. Figure 12 shows the patterns can vary if we
consider the possibility that the patient can take multiple doses or can take the dose any time
before or after the prescribed interval between the doses, or totally skip the dose. The patterns of
adherence affect the therapeutic effectiveness of the prescription.
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Figure 11. Effect of patterns of adherence due to skip dose on dose persistence

Figure 12. Various patterns of adherence due to skip dose
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Section 3.2 Theoretical Background
Medication adherence is a very complex multi-faceted challenge. As an enabler, Information
Technology has a major role to play. There is a need to study medication adherence
interventions, and theoretical models will be needed to help such study. In this research, we
present a model to study medication adherence from IS/IT perspective, more specifically health
IT enabled interventions.
3.2.1 Factors
There are several factors that can affect the medication behavior of the patient, some within
the control and some outside the control of the patient. The effort to identify the reasons leads to
five interacting dimensions of the medication behavior. Figure 13 shows the details of following
five interacting dimensions of medication behavior – (1) Social and Economic Dimension, (2)
Healthcare System Dimension, (3) Condition-Related Dimension, (4) Therapy-Related
Dimension, and (5) Patient-Related Dimension (WHO 2003). In Appendix A3.1, different
factors affecting medication adherence in each interacting dimension are reported (Meducation
2006).

Figure 13. The five interacting dimensions of medication behavior (WHO 2003)
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As behavior contributes to the cause of much current mortality and morbidity (Michie and
Johnston 2012), interventions to change medication behavior are essential in prevention.
Behavior change interventions are usually complex, comprising many interacting components
(Craig et al. 2008).
3.2.2 Efficacy
Theories summarize the state of cumulative knowledge. They specify key constructs and
relationships and the underlying scientific explanations of the processes of change and link
behavior change to constructs in a systematic way. They describe how, when and why change
occurs. They allow investigators to understand why and how interventions succeed or fail.
Rigorous testing of theoretical principles forms a basis for future interventions. Thus, theories
are fundamental in designing behavior change interventions.
Investigation of theory to support the problem domain is a central exercise in design science
research. Key frameworks for designing and evaluating behavior change interventions (Collins et
al. 2011; Craig et al. 2008) emphasize the importance of using theory to inform intervention
design as well as specifying interventions using component behavior change techniques(BCTs).
Behavior may refer to simple, specific actions, for example, swallowing a pill; about health, it is
used to refer to a more complex sequence of actions. Behavior change techniques (BCTs) are
observable and replicable components of behavior change interventions. They are the smallest
component compatible with retaining the proposed mechanisms of change, and can be used alone
or in combination with other BCTs (Easthall et al. 2013; Michie and Johnston 2012). Precise
specification of BCTs may also enhance the intervention.
Dombrowski et al. (2012) found using a BCT coding scheme that instruction, self-monitoring,
and practice were effective techniques. Taylor et al. (2012) also found that the extent to which
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interventions were explicitly based on theory predicted their effectiveness; a finding consistent
with a similar analysis of collaborative interventions (Webb et al. 2010).
The existing electronic reminder systems have been available for decades, yet there is very
small improvement in the medication adherence behavior. Most of these systems rely on simple
alarms and do not consider another determinant of health-related behavior. Besides the
technology enablement, it is important to consider the personal traits of the patient entrusted with
the prescribed self-administered medication regimen.
For both scientific and practical reasons, it is essential that behavior change interventions
develop a sound scientific basis. In practice, the science will inform the technology (i.e. the
techniques and methods) required to deliver effective, replicable interventions with guidance on
their delivery to ensure use of effective interventions. A science of behavior change needs both
good theory and reliable technology.
In this research, we develop a model to improve medication adherence from information
systems and health IT perspective. Health IT enabled intervention is based on the notion of
collaborative care as it leverages the patient-provider relationship and can help those who are
willing to be helped. When a prescribed medication is self-administered, the choice rests with the
patients and their motivation to take the medicine. An intervention is a mechanism to try and
modify the behavior of the patient, in the best interests of the patient, when the concordance
between patient and the provider breaks.
This research examines the problem with the lens of health behavior change theories to
predict “when” and “what” intervention is required to improve the medication adherence
behavior of patients, thereby making the interventions “smart interventions.” Appendix A3.2
discusses different health behavior change theories as adapted from Revere and Dunbar (2001)
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For the purpose of this research, we are interested in a theory that can support a health IT
artifact for affecting a behavior change. The simplest of BCTs that finds prevalence in system
design are reminders, a component of both Health Belief Model and Stages-of-Change Model.
We also identify effective medication adherence ‘EMA’ as a ‘Goal’ for the patient. Stages-ofChange Model and Theory of Planned Behavior and Theory of Reasoned Action support setting
goals and steering of the patient towards the goal. As the theories listed in Appendix A3.2
support BCTs, we utilize the BCTs to leverage in the theory based model for effective
medication adherence. We focus on when and what reminder (Cues to action/maintenance) to
administer to the patient as smart intervention for improving medication adherence.

Figure 14. Generalized model based on the BCTs affecting medication behavior

Figure 14 shows a generalized theoretical model supporting the health IT system. The most
prevalent Behavior Change Techniques leveraged in the development of the health IT system
model are Action planning, Prompt/cues, Self-monitoring, and Feedback on behavior. These four
techniques are based on the health behavior change theories of Stages-of-Change Model, Health
Belief Model and Theory of Planned Behavior/Theory of Reasoned Action and specifically are
focused on behavior changes tied to Goals and Reminders (Morrissey et al. 2015).
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Action Planning: Prompt, detailed planning of performance of the behavior (must include at
least one of context, frequency, duration, and intensity); context may be environmental or
internal. An example is setting a reminder to take medication at a specific time every day
Prompt/cues: Introduce or define environmental or social stimulus for the purpose of
prompting or cueing the behavior; the prompt or cue would normally occur at the time or place
of performance. A reminder alarm ringing to prompt the user to take medication is a prompt/cue
BCT.
Self-monitoring: Establish a method for the person to monitor and record their behavior(s)
as part of a behavior change strategy. A dialog box that allows users to record whether they took
or skipped their medication is a self-monitoring BCT.
Feedback on behavior: Monitor and provide informative or evaluative feedback on the
performance of the behavior. An example is a log or graph that displays the user’s adherence
levels.
As shown in the generalized model based on the BCTs affecting Medication Behavior, we
see that patient’s medication behavior is a dynamic state that keeps changing, from the
interventions provided by the system, and continuously feeds to the knowledge base of
interacting dimensions of medication behavior. These medication behaviors are examined using
the health behavior change theories. Such examinations can lead to an expansion of the existing
theories or to postulate new theories for explaining a new or changed behavior encountered, and
subsequently to identify new BCTs.
3.2.3 Realization
A key requirement for the envisioned model/health IT system is the ability to be real-time
and dynamic i.e. administer the intervention when needed. The design of such model, or system
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requires a feedback mechanism and ability to exert control as close to the source as possible. We
examine the design from the theoretical perspective of control theories that provide a basis for
real time control systems (Albus and Barbera 2005; Albus and Rippey 1994; Carver and Scheier
1982). Control theory is an interdisciplinary branch of engineering and mathematics that deals
with the behavior of dynamic systems with inputs, and how feedback modified their behavior.
The objective of control theory is to control a system, so its output follows the desired control
signal, called the reference, which may be a fixed or changing value. A controller monitors the
output and compares it with the reference. The difference between actual and desired output,
called the error signal, is applied as feedback to the input of the system, to bring the actual output
closer to the reference. Mapping this to the problem of medication adherence, we model the
control system to have the ability to capture the dosing event. The controller compares the dose
event to the reference prescribed dose event. If the dose is not effective or the dose is
undesirable, a feedback is generated. The feedback is the probable value of effective medication
adherence at next prescribed dosing event. The probable value depends on the past pattern of
medication behavior of the individual. Based on the value of feedback generated, it can be
decided to administer intervention.
To develop a system that can adapt to the medication behavior exhibited in real-time also
leads us to examine the cognitive foundations for system design. A cognitive architecture is the
organizational structure of functional processes and knowledge representations that enable the
modeling of cognitive phenomena. The fundamental cognitive system is composed of a behavior
generation engine driven by a model updated by a perceptual system and governed by a value
system as shown in Appendix A3.3a.
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Controllability and observability are main issues in the analysis of a system before deciding
the best control strategy to be applied. Controllability is related to the possibility of forcing the
system into a particular state by using an appropriate control signal. Observability is measuring
the state of a system. There are several control techniques as represented in Appendix A3.3b
which are applicable to model and strategy chosen.
Hierarchical Control System is close to our problem domain based on the multidimensional
nature of the problem that involves one or more than one feedback influencing the goal or
behavior. In a hierarchical control system, intelligent control can be built as units of the control
system without having to change the design explicitly.
We leverage the existing hierarchical control system Reference Model Architecture (RMA)
theory for Real time Control Systems for its extensible nature (Albus 1993; Albus and Rippey
1994). At its core, the RMA can be mapped directly to the controlled process or real world,
avoiding the need for a mathematical abstraction, and in which time-constrained reactive
planning is implemented. RMA is cognitive theory based architecture designed to enable any
level of intelligent behavior.
RMA consists of a multi-layered multi-resolution hierarchy of computational agents each
containing elements of sensory processing (SP), world modeling (WM), value judgment (VJ),
behavior generation (BG), and a knowledge database (KD). At the lower levels, these agents
generate goal-seeking reactive behavior. At higher levels, they enable decision making, planning,
and deliberative behavior. RCS functional modules may add, subtract, multiply, differentiate,
integrate, compute correlation functions, recognize patterns, generate names or addresses of
symbolic representations, or perform planning functions at a hierarchy of levels. In its most
complete theoretical form, the RCS reference model architecture provides a framework for
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integrating concepts from artificial intelligence, machine vision, robotics, computer science,
control theory, operations research, game theory, signal processing, filtering, and
communications theory.
For the purpose of developing a system for smart intervention, we are considering a single
node that is assigned the task to decide if there is a need for intervention, and when and what
type of reminder to administer. A single RMA node can be used to model this requirement.
Figure 15 shows a node of RMA (Albus 1993; Albus and Rippey 1994). Each node has ability
for:


Behavior generation (BG) - BG modules contain job assignment, planning, and control
algorithms.



Sensory perception (SP) - SP modules process data from sensors. It contains filtering,
masking, differencing, correlation, matching, and recursive estimation algorithms, as well as
feature detection and pattern recognition algorithms.



Value judgment (VJ) - VJ modules contain algorithms for computing cost, risk, and benefit,
for evaluating states and situations, for estimating the reliability of state estimations, and for
assigning cost-benefit values to objects and events. VJ modules may compute statistics on
information about the world based on the correlation and variance between observations and
predictions.



World Model (WM) - The WM modules models the state space of the problem domain. They
contain information storage and retrieval mechanisms, as well as algorithms for transforming
information from one coordinate system to another. WM modules use dynamic models to
generate expectations and predict the results of current and future actions. WM modules may
contain recursive estimation algorithms and processes that compute lists of attributes from
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images, graphics engines that generate images from symbolic lists, and recognition and
detection algorithms that perform pattern matching operations necessary to verify the
identification of features, surfaces, objects, and groups. The WM module maintains a
knowledge database (KD), acts as a question answering system and uses information on from
the KD to predict or simulate the future.

Figure 15. Node of reference model architecture (Albus 1993; Albus and Rippey 1994)

The operation of the Node of RMA is a set of steps defined by a planning period or an
execution clock cycle:
While the planning period is open
{
BG planner hypothesizes a tentative plan;
WM predicts the probable result of the tentative plan;
VJ evaluates the probable result value;
38

BG planner checks to see if the probable result value is greater than the previous probable result
value of the plan already in the current best plan buffer,
{
if it is,
then the tentative plan replaces the current plan in the current best plan buffer;
else continue;
}
};
At the top, the highest level task is defined by the highest level (i.e., mission) goal. At each
successive level in the hierarchy, commanded tasks from above are decomposed into subtasks
and sent to subordinates below. Finally, at the bottom, subcommand outputs are sent to actuators
to generate forces and movements. Also at the bottom, sensors transform energy into signals that
provide sensory input.
Figure 16 shows the dosing event (DE) being evaluated by a node in RMA model to plan and
decide upon intervention based on prescribed dosing regimen (PR), dose not effective (DNE) and
undesirable dose event (UDE). The sensory perception (SP) module registers an actual dose
event (DE) from the patient. The value judgment (VJ) module evaluates the time of the dosing
event by comparing it with the prescribed dosing regimen (PR) and identifying the dose not
effective (DNE) or undesirable dose event (UDE). It then evaluates the value of effective
medication adherence (EMA) for the next prescribed dose event based on a plan from the world
model (WM). The value judgement (VJ) module compares the predicted the value of EMA to the
prescribed value of EMA and takes decision to administer intervention (INTVN) based on
applicable BCT from world model.
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DE* - Dose Event, DNE* - Dose Not Effective, UDE* - Undesirable Dose Event, EMA* - Effective
Medication Adherence, INTVN* - Intervention, MB* - Medication Behavior, PR* - Prescribed
Dosing Regimen, BCT* - Behavior Control Techniques
Figure 16. MEMA implementation of RMA node for smart intervention

The current set of envisioned functionality is to provide a reminder (BCT) to the patients.
The world model is enriched by knowledge module and inputs from other sensors, and the
capability exists for enhancements in future. The usefulness of the node based on RMA model
would be more suited is an enriched use case scenario.

Section 3.3 Enabling Technologies
The current technologies are promising in the terms of advancements they bring. The sensor
technologies for clinical use are advancing rapidly, shrinking in size and becoming personal and
prevalent. The rising cost of healthcare is forcing people to make a conscious choice to stay fit
and healthy. The healthcare providers are enabled with collaborative technologies and are
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becoming more capable of delivering personalized clinical treatments that are self-managed by
the patients. The shift towards self-management is to reduce costs. The mechanisms to monitor
the drug usage in the patients has progressed. Smart medication dispenser that can dispense
doses as necessary (Wireless Medication Box) are available for use.
Unfortunately, the same is not true with the application that supports medication adherence.
We examine some of the applications that allow monitoring of the drug use and find at this time,
only simple applications that measure average medication adherence are available and provide
scheduled reminders. There is an opportunity for much more sophisticated and personalized
mobile applications. Table 4 discusses current top six mobile applications used on Android/IOS
platforms for medication adherence. Analysis of these applications shows that all these
medication adherence applications use reminder and does not focus on goal behavior change
technique.
As we can see from Table 4, most of the existing medication adherence applications seem to
be reminder applications that rely on the schedule generated in advance based on the prescribed
dosing regimen. The dynamic scheduling (where a reminder is scheduled if there is a need) of
intervention is missing in the existing applications. In the view of this limitation of existing apps,
we proposed the model for effective medication adherence. The uniqueness of model for
effective medication adherence is that it does not create a schedule for intervention. It uses
dynamic scheduling.
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Application
Name
Medisafe Meds
& Pill Reminder

Compatibility
& Cost
Android/IOS
Free

MyMedSchedule

Android/IOS
Free

MyMeds

Android/IOS
Free

RxRemindMe

IOS
Free

Med Helper

Android
Free

Features

Limitations

• Synchronizes information to a
“family pillbox”.
• Allows helping family members
with their pills.
• Shares information with
caretakers who can be notified if
the patient has not checked into the
app.
• Provides a list of medications that
are "due today" and check them off
as you go.
• Sync reminders with android wear
a smart watch. Shake your wrist to
mark that you took the medication.
• Allows creating and saving easyto-understand medication
schedules.
• Shows the times of consumption
of medications or supplements,
how much to take, and the purpose.
• Can set up text and email
reminders.
• Provides information to
specialists about the medications
you are taking and you can access
• Provider data input capable
• Tracks the missed doses and
export that data to health providers
for review.
• When the patient properly uses
the app, this feature can provide
information to help healthcare
providers assess medication
adherence.
• Tracks missed doses and export
that data to health providers for
review.
• When the patient properly uses
the app, this feature can provide
information to help healthcare
providers assess medication
adherence.

• May fail to consider
lifestyle factors.
• Users generally enter
their own information.
This can be barrier
among those already
unlikely to follow a
schedule.
• No context-aware
reminders.
• Med-Friend feature
does not work some
times correctly.

• Keeps track of prescriptions Alarms reminds when medication
needs to be taken when doctor’s
appointments are scheduled and
when medicines are running low or
are about to expire.
• Also tracks vital signs and PRN /
take-as-needed medication.
• Can log and export or print
detailed reports for doctor, nurse or
caregiver.

• Does not track missed
and taken doses
• No persistent
reminders
• No context-aware
reminders
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• Does not track missed
and taken doses
• No persistent
reminders
• No context-aware
reminders

• No persistent
reminders
• No context-aware
reminders
• Not capable of
provider data input
• No persistent
reminders
• No context-aware
reminders
• Cloud data storage is
not available
• Not capable of
provider data input

Dosecast

Android/IOS
Free

• Reliable notifications: Nags you
until you take the medicine
• Flexible scheduling: helps you
take doses on a
daily/weekly/monthly schedule,
every X day/weeks, only on certain
days of the week, or even after a
pre-set number of hours or days
since the last dose.
• Customizable dose amounts and
instructions
• Postpone-able reminders
• Smart silencing
• Private and secure: Medicine
information is encrypted

• Does not keep track of
daylight savings time
changes.
• No context-aware
reminders
• Not reliable tracking
of actual dose
consumption as not
connected to a smart
pill-box

Table 4. Current mobile applications for medication adherence

3.3.1 Medication Event Monitoring System (MEMS)
Electronic Monitoring (EM) units vary in design from standard pill containers with a
microprocessor chip embedded in the cap to medication boxes with compartments for individual
doses to metered-dose inhaler canisters that release puffs of medication. Most of the EM devices
monitor medication dosing using special containers that store dosing information on a
microprocessor inside the unit until the data downloads into the specialized software. Patients are
shown how to use the devices and instructed not to open the unit except when medication is
needed for dosing.
On return to the clinic, the unit is inserted into a communicator apparatus that reads the
electronic information and transmits it to the computer. Medication event monitoring systems are
progressively advancing to include wireless communication facilitating the transmission of the
information in real time. Real-time observability at source i.e. when the patient takes the
medication is a key requirement for the design of health IT system based on Effective
Medication Adherence.
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3.3.2 Smart Medication Management System (SMMS)
Smart medication management is performed by systems that can detect, process, and use
context-awareness in creating suitable actions including reminders to patients (Varshney 2013).
Such systems can compensate for the deficit of cognitive abilities of the elderly. Wearable,
portable or environmental technologies capture the vital signs, health parameters, and system
generates current context of the patient (Varshney 2011). The healthcare providers collaborate
with one another and decision making system, which then interacts with medication management
system for generating context-aware reminders/alerts for higher adherence.
The system also provides context-sensitive information to assist the cognitive process
involved in interacting with the system, obtaining and ingesting the medication(s). For example,
the patient may need help in remembering what medications to take, what dose, when and how.
In cases of missed or delayed doses, the system processes on its own or in some cases with the
help of a healthcare provider. The resulting actions could be to either vary the timing and
quantity of left-over doses or skip the dose in the worst case if variations are not possible due to
medical safety.

Figure 17. Smart medication management system model (Varshney 2013)
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Section 3.4 Effective Adherence
The effectiveness of adherence (therapeutic) reduces if there are ‘Dose not Effective’ periods
in the Pattern of adherence, and in some cases could lead to an appearance of ineffectiveness in
the therapeutic value of the medicine. Effective Medication Adherence (EMA) is a probability
measure for assessing the effect of the pattern of adherence due to ‘Dose Not Effective’ periods
in the prescribed dosing regimen on the effectiveness of adherence.
If the adherence is 100% of the time to the prescribed interval of taking the doses, EMA will
be 100%. Any pattern arising from nonadherence should lower the EMA below the 100%. An
analytical model is developed to study the effect of the patterns of adherence on EMA. This
research study allows us to validate the operation of this metric under a set of specified
assumptions.

Section 3.5 Smart Intervention
The objective is to improve the adherence of medication; we intend to use ‘EMA’ as a
construct in our model for deciding ‘when’, and ‘what’ intervention is desirable for
nonadherence. The design of the intervention based on EMA should allow for predicting when it
is most likely that intervention will be needed. The decision is made on the fly, in contrast to the
conventional interventions which work at scheduled intervals. We term intervention based on
EMA as Smart Intervention for the same reason that it will administer if and when there is a need
for intervention. ‘What’ intervention will be needed is based on an assessment of factor by which
the ‘EMA’ will get adversely affected if the patient does not take prescribed medicine at the
suggest time. This research proposes that medication adherence research should utilize EMA,
which includes both the pattern and average medication adherence for a patient and therefore,
can lead to the identification of more effective interventions. Healthcare providers can use the
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insights from EMA and related medical data to establish customized or revised prescription
regimen for different groups of patients based on the patterns of medicine intake and clinical
response to medication. It can also facilitate the design of smart interventions that get
personalized to the patient’s behavior over a period.
In this research, an improvement to existing intervention is envisioned that is termed “Smart
Intervention” to distinguish it from existing intervention. Here, smart intervention mean that
intervention will be necessary and provided to the patient only if the patient did not consume the
prescribed self-administered medication dose at the prescribed duration. This smart intervention
will be affected in the form context-aware reminders to the patient as opposed to simple and
persistent reminders that existing intervention provides.
The context-awareness of smart intervention arises from the awareness and consideration of
DNE events. The decision to administer intervention is then based not only on the prescribed
interval between the doses but also the presence of the DNE events and the pattern in which
patient generates the events. Such interventions are provided only when there is a need and are
more dynamic in nature.
The possibility that patient will follow the intervention is greater when the intervention is
discreet, the patient is not being overwhelmed and is cognizant of the justification for
intervention based on patient’s anomaly in adherence.
Table 5 shows the functional difference between intervention and smart intervention.
Intervention

Smart Intervention

Based on AMA

Based on EMA

Simple and Persistent Reminder

Context-Aware Reminder

Table 5. Intervention vs smart intervention
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This research develops a smart intervention based on BCTs that have underlying theory base
of Health Behavior Change and upon the Reference Model Architecture for real time systems.
The system is designed to act at the source of the problem i.e. when the person takes (or skips
dose at a prescribed time) and generates the probabilistic estimate of the effective medication
adherence to suggest the next intervention. The impact of the smart intervention on effective
medication adherence, healthcare cost and the patient outcome could be profound as the problem
is detected early and action is taken instead of towards the end of medication persistence.
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Chapter 4. Development
The development of the conceptual artifact (smart intervention) is the primary contribution of
this research. This section includes a concise description of the artifact at the appropriate level of
abstraction (Gregor and Hevner 2013). It describes a general approach for monitoring of
effective medication adherence. Also, the input parameters used in the analytical model for
evaluation of the artifact is described in this section. Discussion of parameters along with the
artifact will provide insight into the relationship between the components of the artifact and the
new measurement metric for medication adherence, i.e., effective medication adherence (EMA).

Section 4.1 Constructs
We started with developing a simplified Model for Medication Adherence based on the
literature review and the current clinical environment. The dosing regimen begins with
concordance between the provider who is treating and a patient being treated. In a selfadministered dosing regimen, the patient bears the responsibility to take the medication in
compliance or adherence with the provided advice. If the provider feels the need to monitor the
effectiveness of the medication and the symptoms, they may collect the feedback from the
patient. If all goes well, the therapeutic benefits of the medication are realized towards the end of
the prescription.
The study indicates there are number of factors that affect the adherence of the patient to the
prescribed dosing regimen and thus affect the realization of the therapeutic benefits of the
medicine(s). Adherence is extent to which a patient’s behavior (regarding taking medication,
following a diet, modifying habits, or attending clinics) coincides with medical or health advice
during the period of medication persistence i.e. the time from initiation to discontinuation of
therapy. Almost invariably, the provider comes to know the outcome of the prescribed
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medication after the treatment period is over and if the patient provides feedback to the provider.
If the patient does not self-report, then opportunity to provide timely interventions to improve
patient’s condition are rare. At the time of prescribing medications to the patient, it is assumed
that patient will self-report the symptoms if the condition persists beyond a reasonable duration
of taking the medications.
In cases where the patient self-reports that symptoms persists, the effectiveness of the
medication is assessed by discussing with the patient whether they took all the medications on
the prescribed intervals and estimating the average effectiveness of the doses. Subsequent
treatment plans may lead to increasing dose persistence for few more days. Figure 18 represents
the simplified Model for Medication Adherence:

Figure 18. Simplified model of medication adherence

Section 4.2 Requirements
Our requirement is to administer smart intervention i.e. envision a model that provides an
ability to choose ‘when’ and ‘what’ intervention is needed. We outline the formal requirements
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of the model for effective medication adherence. The realization of this model is a health IT
artifact.
The decision to administer intervention depends on the medication behavior of the patient.
The medication behavior is event based i.e. if the patient takes the medicines at the prescribed
intervals over the duration of the prescription. The dosing events can be mapped against a
timeline for prescribed medication persistence and should ultimately develop a pattern of dosing
events i.e. the medication behavior. An intervention is a mechanism to control the normal
medication behavior of patient if he/she does not conform to the prescribed dosing regimen. The
decision for when an intervention is needed can then be a straightforward rule: if the patient did
not take the medication at prescribed times, administer the intervention. The simplified model of
medication adherence can easily be extended to implement this rule if it can capture dosing
events and the prescribed dosing intervals against a timeline beginning the start of the medication
and ending end of the medication. We call interventions that are administered based on a
schedule of prescribed doses as Scheduled Intervention.
An alarm for a reminder is a good example of scheduled intervention. An alarm can have a
schedule and can remind of the repeating tasks at specified intervals. When coupled with an
event capturing system that can register if a task has been performed, alarm for reminder is
skipped if the task is performed before the next scheduled time. If the task needs to happen
exactly at the specified interval i.e. exactly at the scheduled time, we have a situation when the
alarm for the reminder and the task will occur at the same time. The alarm for reminder cannot
be made to wait for the event unless we decide to schedule the alarm a few moments after the
time of the task. There is theoretical limit to performing tasks when tasks are interdependent. At
a time, only one task of the interdependent tasks can be performed. The usefulness of alarm for a
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reminder is to prompt before the task has to be performed, so as to focus the attention of
performer. In this situation when we want to have reminder before the task, the alarm is
scheduled for few moments before the time of the task. The drawback of this is that it does not
make use of the event capturing system and is repetitive, occurring every time before the
scheduled task.
Extending this analogy to deciding when to administer intervention, we arrive at following
decisive situations: Intervention scheduled before the dosing event, intervention scheduled at the
same time of dosing event, and intervention scheduled after the dosing event. Interventions
scheduled before the dosing event always occurs (persistent). Intervention scheduled at or after
the dosing event is skipped if the dosing event has happened.
Scheduled Intervention is a prescriptive behavior again, and is determined right at the time of
prescription. It has little ability to adapt to the medication behavior of the patient because the
behavior does not exibit at the time of prescription.

Section 4.3 Model
We develop the model for effective medication adherence, henceforth also mentioned as
MEMA, based on effective medication adherence of the patient. In this model, we do not create a
schedule of administering the interventions but decide the next administration of the intervention
dynamically. We create a schedule of prescribed dosing events at the time of prescription and
also register actual dosing event of the patient during prescription. Value for effective medication
adherence (EMA) generates at each dosing event of the patient and the prescribed dosing event.
Based on the value of EMA, an appropriate type of intervention is chosen and scheduled either
before or at the next dosing event for the patient. It may also happen that intervention is not
deemed necessary for the next prescribed dosing event if the patient is 100% following the

51

prescribed dosing regimen. The type of intervention denotes the priority we associate to the next
scheduled intervention in maintaining the EMA above a specified threshold (depending on the
type of care and therapy). Figure 19 shows the priority of the intervention predefined in current
model as ‘Normal’, ‘Warning’, and ‘High’ based on an allocated probability estimate of EMA
for the next prescribed dosing event.

Figure 19. Predefined type (priority) of intervention (reminder) (Varshney 2013)

Deciding the ‘Type of intervention’ requires extensive study of therapy regimens, medication
behaviors, and medical conditions. Developing classification specific to prescriptions can
become an active research topic.
MEMA model is more adapted to the medication behavior of the patient as it keeps up with
the actual dosing events and also provides the ability to decide what intervention is needed.
Figure 20 shows the model for effective medication adherence (MEMA).
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Figure 20. Detailed design of model for effective medication adherence (MEMA)

Figure 20 shows the model for effective medication adherence (MEMA). This model is for
use by the healthcare provider and complements the prescriber’s role in improving the
medication adherence. The relationship between the healthcare provider and patient is the basis
for operationalization of this model. The patient can opt in for smart interventions for a
prescription drug. Upon consent, the medication behavior of the patient is monitored using
Medication Event Monitoring System (MEMS) and at every dose event, the information is
relayed to the Smart Medication Management System (SMMS).
The MEMA implementation of RMA node for smart intervention as depicted in Figure 16 is
a component based on smart medication management system. It can record the dosing event, and
decide if the dosing event is a prescribed dose event, undesirable dose event or dose not effective
event. Based on the outcome, the system can either decide to calculate the effective medication
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adherence value (using dose not effective), or notify the healthcare provider (undesirable dose
event), or calculate EMA and decide to do nothing (prescribed dose event). If the predicted value
of EMA is deemed to fall below a certain value specified for the therapy persistence, the system
will schedule an intervention for the next dosing interval. The frequency and type of intervention
for the next prescribed dosing event is decided based on the value of EMA and pattern of
medication adherence exhibited by the patient in the past.
The MEMA model is implemented as having a systems interface and a user interface. The
systems interface is for the administrator while there are two types of user interface for provider
and the patient. The user interface can be affected via web based, smartphone or desktop
application. The ability to connect over wireless/internet is requirement for the system to operate.

Section 4.4 Design

Figure 21. Model of medication adherence

Figure 21 shows a simplified model of medication adherence. We enhance the existing model
to include the wireless medication box (WMB), and the application logic of medication
management server (MMS) is enhanced based on the Resource Model Architecture to include
the state of the system (world view).
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In the model for effective medication adherence shown in Figure 22, both the patient and
healthcare provider interact with the medication adherence application, which interacts with
medication management server through a variety of wireless networks. The mobile application
interacts with the healthcare provider and the patient. The mobile application also interacts with
the medication management server to keep track of prescriptions provided by the healthcare
providers’ office as well as the consumption of medication by the patient. The IT supports these
interactions and tracking as part of implementing the intervention for medication adherence.
More specifically, medication management server keeps track of adherence, side effects, and
dosing changes which are available through mobile applications based on the reminders provided
to the patient and patient’s response to reminders. Also, medication management server keeps
track of dose consumption and information available through wireless technologies which
provide the prescribed doses to the patient. Finally, based on the interactions with mobile
applications, patients, and healthcare providers, medication management server will generate the
context-aware reminder for the patient. This process continues until the desired rate of effective
medication adherence is achieved. We expect that many more applications on Smartphone and
other smart systems using wireless technologies will become available for improving medication
adherence.
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Figure 22. Model for effective medication adherence (MEMA)

The high level view showing variables used in the analytical model mapped to MEMA is
represented in Figure 23. Healthcare provider enters the prescription information (λ, NPRES) using
mobile application, which is eventually saved in the medication management server (MMS) and
shared with patient through the mobile application. Patient opens the wireless medication box to
consume the prescribed dose. Dose information (NTAKEN) and the dispensing and consumption
information (NTAKEN, λ). is reported to the MMS. Using the adherence information MMS
performs the analysis of consumption and calculates the EMA and UDE for different scenarios
(nor reminders, simple and persistent reminders, and context-aware reminders). Based on the
analysis of consumption, smart interventions (CAR, NP, NR, PD-R, PND-R) are generated and
provide to the patient to maintain the medication adherence as prescribed by the healthcare
provider. If patient misses a dose (NMISSED) it is reported to the healthcare provider and
healthcare provider provides the advice/scheduling based on the current EMA. On the other
hand, if patient consume more than desirable doses (UDE) during the prescribed interval it is
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reported to the healthcare provider too. However, no intervention is provided in the case of
undesirable dose event (UDE). Smart interventions for UDEs will developed in future study.

Figure 23. Variables in model for effective medication adherence (MEMA)

Section 4.5 Verification
The operation of MEMA is verified using the steps:
1. Design a mobile application for medication adherence (MMA)
2. Utilize a smart medication dispenser that can dispense doses as necessary (WMB)
3. Design a Server (MMS) that
•

Can communicate with patient and healthcare providers (via mobile application) as
needed and also with medication dispenser

•

Can receive necessary dose consumption information from smart dispenser and/or the
patient and can process medication consumption context of the patient

•

Can generate simple and persistent, and context-aware reminders (decide when to
send reminders and how often)

•

Can analyze the consumption history and communicate with healthcare provider
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4. Provide multi-network wireless access to various components (device, server) to support
patient mobility
5. Check if various components (mobile medication application, mobile management server and
wireless medication box) can interact with each other and with patient and healthcare
provider
6. Check if medication management server receives informational contents
7. Check if context generates correctly
8. Check the timing of reminders and context-aware reminders
9. Check the number of doses, reminders and consumption history for any inconsistencies
Figure 24a shows the operation of MEMA. Figure 24b represents the algorithm to determine
when and how to generate reminders to patients.
Receive information on medications, doses,
adherence goals, type of reminders
Receive information on the type and duration
of medication monitoring
Determine when and how (smartphone, monitor,
display board) to generate reminders to patients
Communicate with dispenser/patient about
medications at certain times
Yes

Is Dose taken?
No
Is it safe to
take dose now?

No

Yes
Generate contextaware Reminder(s)
Analyze the Pattern of Adherence

Communicate to Healthcare Professionals

Figure 24a. The operation of the MEMA
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Obtain dosing information
If time>=due-dose-time
If Intervention = simple reminder
If (time-limit-reminder = Not-expired)
Display a reminder on patient’s preferred device
Obtain patient-dose-input
If status-dose = taken
Update med-consumption-history (attempts, dose status, timing, quantity)
Else if (message-to-HP = allowed) Inform HP
Else If intervention = persistent reminder
While (status-dose =not-taken) and (time-limit-reminder = Not-expired)
If (number-of reminder-current-dose <Limit-persistence)
Display a reminder on patient’s preferred device
Obtain patient-dose-input
If status-dose = taken
Update med-consumption-history (attempts, dose status, timing, quantity)
Else If (message-to-HP = allowed) Inform HP
Else If intervention = context-aware reminder
Process medication-consumption-history
If (Status-due-dose= Already-taken)
No reminder
Else
While (status-due-dose =not-taken) and (time-limit-reminder = Not-expired)
If (number-of reminder-current-dose <Limit-persistence)
Display a reminder on patient’s preferred device
Obtain patient-dose-input
If status-dose = taken
Update med-consumption-history (attempts, dose status, timing, quantity)
Else If (message-to-HP = allowed) Inform HP
Record the actions (attempts, dose status and times)
Update medication consumption history
Figure 24b. The algorithm to determine reminder generation

Table 6 lists the role of the model in various cases of nonadherence. The model currently
supports reminders as an intervention and can be extended to include educational interventions
for patients to address other reasons for nonadherence.
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Case 1
Case 2
Case 3
Case 4
Case 5
Case 6
Case 7
Case 8

Primary Reason for
Nonadherence
Busy lifestyle
Cognitive Decline
Side Effects
Complexity of Regimen
Length of chronic condition
Cost of medications
Lack of knowledge
Lack of trust / perceived need

Suitable Intervention
Reminders
Reminders
Educational
Reminders/Educational
Family Support
Financial Intervention
Educational Intervention
Behavioral Interventions

Model’s Role in the
Intervention
Currently Supported
Currently Supported
Can be expanded
Can be expanded
Can be expanded
Difficult to expand
Can be expanded
Difficult to expand

Table 6. Nonadherence cases and the model’s role in the intervention
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Chapter 5. Evaluation of Process
Design science research (DSR) includes the building/design of an artifact as well as the
evaluation of its use and performance (Pries-Heje et al. 2007; Vaishnavi et al. 2007). The model
is evaluated using formal proofs and expert interviews (Cleven et al. 2009; Gregor and Hevner
2013; Parsons and Wand 2008). Evaluation with formal proofs such as analytical model
represents an adequate evaluation method for DSR models (March and Storey 2008). The exante perspective, i.e., artificial evaluation methods will help us to control the potential
confounding variables more carefully and to prove or disprove the design propositions, design
theories, and the utility of the developed artifact (Pries-Heje et al. 2008). Evaluations of an
artifact based on formal proofs facilitate the assessment of a solution’s suitability for a certain
problem by implementing the solution generically.
The artifact is further evaluated (empirically) to demonstrate its worth with evidence
addressing criteria such as validity, utility, quality, and efficacy (Gregor and Hevner 2013).
Domain experts (healthcare providers and health IT experts) have compared the smart
intervention with the existing interventions to evaluate the model. We have focused explicitly on
the experts' reasoning about their preferences after comparing the simple and the smart
interventions, and on relating that to the proposed health IT artifact. This evaluation provides the
insights for interventions preferred by experts.

Section 5.1 Analytical Model
Analytical modeling is relevant, suitable, and useful for this work. Analytical models have
been used as formal proofs for a long time to derive performance of systems in Computer
Science, Decision Science, Operations Research, and Engineering (Saaty and Vargas 2012).
These models provide several important insights into the design and operation of artifacts and
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can be used to improve the design and operation of the artifact in an iterative fashion. In some
sense, they provide intermediate and immediate results, which can help improving the design of
artifacts, without waiting for subsequent empirical/multi-method studies. Many times, analytical
models will help to validate the design by providing results that conform to expected
performance of the artifact. We believe that analytical models could be used effectively in the
design science area for both preliminary and intermediate evaluation of artifacts, followed by a
more empirical evaluation.
We should be aware of numerous limitations and challenges in analytical models. The
development of models may take time especially when the artifact's design and operation are still
evolving. Many times, it is not clear what variables and metrics to include and what parameters
to utilize and where to get those values from. The choice of model type is another challenge as a
decision on whether to use deterministic (closed-form) or stochastic (random-events) approach
can affect the suitability and usefulness of the model. The underlying assumptions in the model
along with difficulty in validation, especially with error propagation inherent in some models,
could reduce the usability of analytical models. The complexity of models in deriving accurate
results is another challenge.
We evaluate the performance of smart interventions by MEMA by using the analytical model
as shown in Figure 25. The approach we take in our research is to develop a simple model for the
results that can help verify the basic design and operation of the model and more complex
models that can provide a deeper understanding and more accurate results. In the design of
computing and communications systems, such models have been used for a long time due to
their ability to express complex relationships among many variables or behavior of interests. We
expect that the comprehensive model, although complex, will be useful in predicting artifact’s
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performance. One of the challenges has been the level of complexity in developing models and
subsequent computations.

Figure 25. The use of analytical model in artifact evaluation

To address this, a model of reasonable complexity has been introduced to provide accurate
results. Therefore, for evaluation of interventions for medication adherence, mathematical
models are both suitable and desirable. More specifically, we measure the impact of various
designed solutions and effect of multiple interventions on the rate of achievable medication
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adherence. The model is developed using relationships among several independent (input)
variables and dependent (output) variables discussed in Table 7.
To study patterns of adherence and effective medication adherence (EMA), we considered
two distributions a) Uniform distribution, and 2) Poisson distribution. The goal is to analyze the
pattern of adherence for a patient by utilizing the events when the patient takes the doses. We
derive the probabilities of not being medically effective and not being safe. Patients with enormously diverse dosing behavior (random, skip followed by catch up, drug holidays, and multiple
doses) can achieve the same average levels of medication adherence. Also, some patients with
lower average adherence achieve more or less same outcomes as patients with higher average
adherence (Sokol et al. 2005). The similar outcomes with different levels of adherence raise the
possibility that patterns of adherence have something to do with the effectiveness of medication
adherence. If the minimum time (TMIN) between two doses is not medically safe, then it will lead
to UDE. On the other hand, if the maximum time (TMAX) between two doses is not medically
effective then it will lead to dose not effective (DNE). This study focuses on studying the
patterns of adherence along with average medication adherence (AMA), as effective medication
adherence (EMA).
We started with Uniform distribution to study adherence. However, after comparing the
results of both Uniform and Poisson distributions to study adherence, we observed that the
differences are not huge. On the other hand, we felt that Poisson represents more variance and
also there is evidence that medication consumption by people is closer to Poisson (Knafl et al.
2004). So, we decided to use Poisson distribution for the evaluation of MEMA using analytical
model. The uniqueness of analytical model is that it can estimate EMA for many possible
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scenarios. The scenarios are including and excluding the interventions for computing EMA.
These different scenarios affect the ability to take medications.
5.1.1 Assumptions
A model is needed because data is not available on exact times patients have consumed
various doses. Such data will become available in future. So for now, we make use of the
analytical model to study/compare different interventions and their effectiveness. The model will
evaluate effective medication adherence (EMA) as opposed to average medication adherence
(AMA) in different scenarios and interventions. Several assumptions were made to keep the
analytical model reasonably accurate. The analytical model assumes the following:
Assumption 1: The patients are in independent living and thus manage their medications.
Assumption 2: The dose concentration in the human body declines with time and reaches below
a threshold at the certain maximum interdose-time. A medication dose taken beyond maximum
interdose-time has reduced/negligible medical effectiveness.
Assumption 3: Taking more doses over time or too many doses at the same time does not
improve medication adherence or health outcomes.
Assumption 4: The patients are willing to take medicine, but are not able to due to scheduling
difficulties, forgetfulness, or cognitive challenges.
Assumption 5: The interventions used in the form of simple and persistent reminders, and
context-aware reminders.
Assumption 6: The interventions cannot be used for unwilling patients at present.
5.1.2 Design
The basic input parameters of the model are dosing rate (λ), probability of taking dose due to
reminder (PD-R), probability of not taking dose due to reminder (PND-R), number of persistent

65

reminders (NP), number of reminders in a day (NR), overdose time (t), time at which Ith dose is
taken (TI), time at which I+1th dose is taken (TI+1), minimum time between any two doses to
remain medically safe (TMIN), maximum allowed time between any two doses to remain
medically effective (TMAX). The output parameters are effective medication adherence (EMA)
with and without interventions, healthcare cost (HCCOST), and side effects (UDE). Table 7
represents the summary of all the parameters used for developing the analytical model.
Notation
NPRES
NTAKEN
NMISSED
λ
T
TI
TI+1
TMAX
TMIN
AMA
AMANEW-SR
AMANEW-CAR
NP
NR
Q
M
PD-R
PND-R
NR
SR
CAR
DNE
UDE
EMA
EMANR
EMASR
EMACAR
UDEBASE
UDESR
UDETOTAL
HCCOSTNA
HCCOSTSR
HCCOSTCAR
HCCOST-PAST
INTVNCOST-SR
INTVNCOST-CAR

Meaning
Number of prescribed doses over given time
Number of doses taken by the patient
Number of doses missed by the patient
Ideal rate of dose consumption event (dose/hour)
Observed time
Time at which Ith dose is taken
Time at which I+1th dose is taken
Maximum allowed time between two doses to remain medically effective
Minimum time between two doses to remain medically safe
Average Medication Adherence
Average Medication Adherence due to simple and persistent reminder
Average Medication Adherence due to context-aware reminder
Number of reminders per missing dose event
Number of reminders in a day (one per dose)
Number of reminders that came during the last TMAX
Multiple medications with multiple doses prescribed in a day
Probability of taking dose due to reminder
Probability of not taking dose due to reminder
No reminder
Simple and persistent reminder
Context-aware reminder
Dose not effective
Undesirable dose event
Effective Medication Adherence
Effective Medication Adherence for no interventions
Effective Medication Adherence for simple and persistent reminder
Effective Medication Adherence for context-aware reminder
Probability that the gap between doses is less than T MIN
UDE in case simple and persistence reminders
Probability that the gap between doses is less than T MIN
Healthcare cost in case of nonadherent
Healthcare cost in case of simple and persistent reminder
Healthcare cost in case of context-aware reminder
Disease related healthcare cost (Medical cost + drug cost)
Cost of interventions for simple and persistent reminder
Cost of interventions for context-aware reminder
Table 7. Analytical model parameters/variables
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We present known relationships among variables and derive new relationships. These will
help us in evaluating output variables such as Effective Medication Adherence (EMA),
Healthcare cost (HCCOST), and Undesirable dose event (UDE) under different scenarios and
interventions. Different scenarios and interventions are considered to analyze the difference
between the outcome of smart interventions/context-aware reminder (CAR), simple
interventions/simple and persistent reminder (SR) and no interventions/no reminder (NR).
5.1.2.1 Measuring effective medication adherence – Single medication, multiple doses daily
The average medication adherence during an observed period of prescribed self-administered
medication can be given by
(1)

𝐀𝐌𝐀 = (𝐍𝐓𝐀𝐊𝐄𝐍 /𝐍𝐏𝐑𝐄𝐒 )

NPRES is the number of prescribed doses over the given time and is given as NTAKEN+NMISSED.
NTAKEN and NMISSED are the number of doses taken and the number of doses missed by the
patient, respectively. The adherence level can have any value between 0 to 100%, both included.
In rare cases, adherence level exceeds 100% if the patient took more doses than prescribed.
The time variations between doses are also important in evaluating the medical effectiveness
of doses. The probability that the gap between doses has exceeded the maximum interdose-time
is found using ideal dosing rate (λ) and TMAX for a particular event k. Hence, the probability that
I+1th dose not effective (DNE) is expressed as
𝐃𝐍𝐄 = 𝐏𝐫𝐨𝐛((𝐓𝐈+𝟏 − 𝐓𝐈 ) > 𝐓𝐌𝐀𝐗 ) = (𝛌𝐭)𝐤 ×

𝐞−𝛌𝐭
𝐤!

𝐟𝐨𝐫 𝐤 = 𝟎 𝐚𝐧𝐝 𝐭 = 𝐓𝐌𝐀𝐗

(2)

TMAX is the maximum allowed time between any two doses to remain medically effective; λ is
the ideal rate of dose consumption event, and t is the observed time.
Undesirable Dose Event (UDE) is the likelihood of events when the patient takes doses that
are too close to each other, possibly resulting in toxicity and side effects, which in turn can
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reduce the motivation for taking medications in future. UDEBASE is the probability that the gap
between doses is less than the minimum interdose-time.
𝐔𝐃𝐄𝐁𝐀𝐒𝐄 = 𝐏𝐫𝐨𝐛((𝐓𝐈+𝟏 − 𝐓𝐈 ) < 𝐓𝐌𝐈𝐍 ) = (𝛌𝐭)𝐊 ×

𝐞−𝛌𝐭
𝐤!

𝐟𝐨𝐫 𝐤 = 𝟐 𝐚𝐧𝐝 𝐭 = 𝐓𝐌𝐈𝐍

(3)

TMIN is the minimum interdose-time to remain medically safe, and λ is the ideal dosing rate
(dose/hour).
Effective Medication Adherence (EMA) depends on both the average medication adherence
and the pattern of adherence. Out of the two patterns identified in equations 2 and 3, when doses
are far apart, the effectiveness of the doses is reduced. Taking doses too closely may not improve
the effectiveness due to the potential for side effects or overdose, which may reduce medication
adherence over time. Therefore, we model EMA to include pattern only when doses are far apart.
Thus, Effective Medication Adherence can be given as
𝑬𝑴𝑨 = 𝑨𝑴𝑨 × (𝟏 − 𝑫𝑵𝑬) = 𝑨𝑴𝑨 × (𝟏 − 𝒆−𝛌𝐓𝐌𝐀𝐗 )

(4)

Since we model EMA to be between 0 and 100%, and as in some cases, AMA can exceed
100% where patients are trying to catch up or taking more doses than prescribed. For these cases,
the EMA is normalized as
𝑴𝒊𝒏(𝑨𝑴𝑨 × (𝟏 − 𝒆−𝝀𝑻𝑴𝑨𝑿 ), 𝟏).
Analyzing equations 2, 3 and 4 we can see that EMA is a better predictor for measuring the
medication adherence as compared to AMA. As someone can take all doses in a short period
with much worse health outcomes.
Scenarios
In this section, we consider three different scenarios for the reminders. Figure 26 shows the
considered scenarios (a) without any intervention, (b) with simple and persistent reminders and
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(c) with context-aware reminders. We discuss each of these along with corresponding equations
for EMA, UDE, and HCCOST.

Figure 26. Different scenarios without intervention and with interventions

Scenario 1: Without any Intervention – NR
In this scenario, we compute the EMA keeping in consideration that no intervention/reminder
is sent to the patient, and the patient takes doses by his/her choice and convenience. It shows that
the patient did not follow the prescribed self-administered medication. Varshney and Singh
(2013) have represented that memoryless distributions such as exponential distribution are
suitable for medication consumption. Such behavior is observed in practice (Knafl et al. 2004).
The EMA for no interventions is computed as
𝑬𝑴𝑨𝑵𝑹 = 𝑨𝑴𝑨 × (𝟏 − (𝛌𝐭)𝐤 ×

𝐞−𝛌𝐭
𝐤!

𝐟𝐨𝐫 𝐭 = 𝐓𝐌𝐀𝐗 )

𝑶𝒓 𝑬𝑴𝑨𝑵𝑹 = 𝑨𝑴𝑨 × (𝟏 − 𝒆−𝛌𝐓𝐌𝐀𝐗 )
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(5)

𝑁

λ is given as (𝐴𝑀𝐴 × 24𝑅).
Since the patient is not following the prescribed self-administered medication in this
scenario, it might lead to Undesirable Dose Event (UDE). UDE is as follows:
𝟏

𝑼𝑫𝑬𝑩𝑨𝑺𝑬 = 𝑷𝒓𝒐𝒃((𝑻𝑰+𝟏 − 𝑻𝑰 ) < 𝑻𝑴𝑰𝑵 ) = 𝟐 × (𝛌𝐓𝐌𝐈𝐍 )𝟐 × 𝐞−𝛌𝐓𝐌𝐈𝐍

(6)

We will analyze and compare EMANR in the results section.
Scenario 2: With Simple and Persistent Reminders – SR
In this scenario, simple and persistent reminders are provided to the patient at the due time of
the doses. Here, persistence refers to the repetitiveness of reminder. In this case, the average
adherence and pattern of adherence both may be changed. We will have to study both.
In this case, the patient is following a combination of two patterns: random and deterministic.
So the patient may take doses as before using Poisson distribution and may also take doses based
on reminders. This results in several combinations of patterns for adherence. However, we are
interested in finding out the probability that the gap between doses has exceeded the maximum
interdose-time (TMAX) and probability that the gap between doses is less than the minimum
interdose-time (TMIN).
The probability that the gap between doses has exceeded the maximum interdose-time is
approximated (for simplification) as follows. At any time, the probability will be a product of
two probabilities: the probability that the patient did not take any dose in last TMAX time and
probability that the patient did not take any dose "after all the reminders that came during the last
TMAX".
𝐏𝐫𝐨𝐛((𝐓𝐈+𝟏 − 𝐓𝐈 ) > 𝐓𝐌𝐀𝐗 ) = (𝑷𝑵𝑫-𝑹 )𝑸 × [𝒆−𝛌𝐓𝐌𝐀𝐗 ]

70

(7)

Q is the number of reminders that came during the last TMAX and is given as

𝑇𝑀𝐴𝑋
24
𝑁𝑅

. PND-R is

the probability that the patient does not take the dose based on the reminder and is computed as 1
- PD-R, where PD-R is the probability of consuming dose due to reminder. NR is the number of
reminders in one day (or a number of doses in a day). The simple and persistent reminders are
not based on if the patient has taken the dose recently on his/her own. So average medication
adherence (AMA) in case of simple and persistent reminders can be given as
𝐀𝐌𝐀 𝐍𝐄𝐖-𝐒𝐑 = 𝐌𝐢𝐧[(𝐀𝐌𝐀 + (𝟏 − 𝐏𝐍𝐃-𝐑 ) × 𝛌 × 𝐓𝐌𝐀𝐗 ), 𝟏]

(8)

Moreover, the effective medication adherence for simple and persistent reminders can be
computed as follows
𝐄𝐌𝐀 𝐒𝐑 = 𝐀𝐌𝐀 𝐍𝐄𝐖-𝐒𝐑 (𝟏 − (𝐏𝐫𝐨𝐛((𝐓𝐈+𝟏 − 𝐓𝐈 ) > 𝐓𝐌𝐀𝐗 )))
Using the value of Prob((TI+1 − TI ) > TMAX ) from equation 7, EMASR is represented as
𝐄𝐌𝐀 𝐒𝐑 = 𝐀𝐌𝐀 𝐍𝐄𝐖-𝐒𝐑 (𝟏 − ((𝑷𝑵𝑫-𝑹 )𝑸 × [𝒆−𝛌𝐓𝐌𝐀𝐗 ] ))

(9)

On the other hand, the probability that the gap between doses is less than the minimum
interdose-time would need to include two factors. One is the probability that someone took two
doses in last TMIN time, and the other is that someone took one dose in last TMIN time on his or
her own and took another dose due to the reminder. However, we will have to multiply 2nd
factor by the probability that a reminder even came during TMIN time and can be given as

𝑇𝑀𝐼𝑁
24
𝑁𝑅

.

If TMIN is too small, then no reminder may come during TMIN. Hence, the probability of two
doses taken in less than TMIN time is the sum of the probability of patient taking two doses when
no reminder came and the probability that patient consumes a dose along with a dose due to the
reminder.
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The above possibility can raise adherence level and also improve the pattern in some cases.
On the other hand, it may result in undesirable dose event (UDE). The UDE can occur when the
patient has already taken the medicine at scheduled time and also consumes medicine when the
reminder arrives for the same dose. UDETOTAL or the probability that the gap between doses is
less than the minimum interdose-time is
𝑼𝑫𝑬𝑻𝑶𝑻𝑨𝑳 = 𝑷𝒓𝒐𝒃((𝑻𝑰+𝟏 − 𝑻𝑰 ) < 𝑻𝑴𝑰𝑵 )

= [𝟏 − (

𝑻𝑴𝑰𝑵
𝒆−𝛌𝐭
𝑻𝑴𝑰𝑵
)] × [(𝛌𝐭)𝐤 ×
𝒇𝒐𝒓 𝒌 = 𝟐, 𝒕 = 𝑻𝑴𝑰𝑵 ] +
× 𝑷𝑫-𝑹
𝟐𝟒
𝟐𝟒
𝒌!
𝑵𝑹
𝑵𝑹
𝒆−𝛌𝐭
× [(𝛌𝐭) ×
𝒇𝒐𝒓 𝒌 = 𝟏, 𝒕 = 𝑻𝑴𝑰𝑵 ]
𝒌!
𝐤

= [𝟏 − 𝛌𝐓𝐌𝐈𝐍 ] × [(𝛌𝐓𝐌𝐈𝐍 )𝟐 ×

𝒆−𝛌𝐓𝐌𝐈𝐍
𝟐!

] + 𝛌𝐓𝐌𝐈𝐍 × 𝑷𝑫-𝑹 × [(𝛌𝐓𝐌𝐈𝐍 ) × 𝒆−𝛌𝐓𝐌𝐈𝐍 ]

(10)

The intervention is capable of changing the gap between doses due to simple and persistent
reminders. This may lead to higher UDE. In this possibility, both the pattern and adherence level
go up unless patient's probability of taking doses is zero along with zero AMA. The new
adherence can be more than 100% if the patient follows reminders and has access to more doses
than just the daily doses. It can also increase UDE, but will improve interdose-time.
(11)

𝑼𝑫𝑬𝑺𝑹 = 𝑼𝑫𝑬𝑻𝑶𝑻𝑨𝑳 − 𝑼𝑫𝑬𝑩𝑨𝑺𝑬
Scenario 3: With Context-Aware Reminders - CAR

In this scenario, the patient is sent context-aware reminders based on the consumption of
doses and the due time of dose. More specifically, context-aware reminders keep track of doses.
The context-aware reminders do not generate a dosing rate of their own as the reminders
generates only when the dose (that was due) is missed. So the patient will not run out of doses
due to the context-aware reminders.

72

𝑷𝒓𝒐𝒃((𝑻𝑰+𝟏 − 𝑻𝑰 ) > 𝑻𝑴𝑨𝑿 ) = [(𝑷𝑵𝑫-𝑹 )

𝑻𝑴𝑨𝑿
𝟐𝟒
𝑵𝑹

𝑵𝑷

]

× [(𝛌𝐭)𝐤 ×

𝒆−𝛌𝐭
𝒌!

𝒇𝒐𝒓 𝒌 = 𝟎, 𝒕 = 𝑻𝑴𝑨𝑿 ] (12)

NR is the number of reminders and NP is the number of reminders per missing dose event
(persistence or continuity of the reminders). The optimal value of NP can be decided based on
patient's preferences and abilities, the amount of overhead in generating a reminder among other
factors.
The AMA level will also go up as the patient is taking some doses after context-aware
reminders. The new value of average medication adherence is
𝑨𝑴𝑨𝑵𝑬𝑾-𝐂𝐀𝐑 = 𝑴𝒊𝒏 [(𝑨𝑴𝑨 + (𝟏 − 𝑷𝑵𝑫−𝑹 ) + (𝑷𝑵𝑫−𝑹 )(𝟏 − 𝑷𝑵𝑫−𝑹 )
+ (𝑷𝑵𝑫−𝑹 )𝟐 (𝟏 − 𝑷𝑵𝑫−𝑹 ) + ⋯ (𝑷𝑵𝑫−𝑹 )𝑵𝑷 −𝟏 (𝟏 − 𝑷𝑵𝑫−𝑹 )) , 𝟏]
𝑨𝑴𝑨𝑵𝑬𝑾-𝑪𝑨𝑹 = 𝑴𝒊𝒏[(𝑨𝑴𝑨 + (𝟏 − 𝑷𝑵𝑫−𝑹 )𝑵𝑷 )), 𝟏]

𝑬𝑴𝑨𝑪𝑨𝑹 = 𝑨𝑴𝑨𝑵𝑬𝑾-𝐂𝐀𝐑 (𝟏 − [(𝑷𝑵𝑫−𝑹

= 𝑨𝑴𝑨𝑵𝑬𝑾-𝐂𝐀𝐑 (𝟏 − (𝑷𝑵𝑫−𝑹 )𝛌𝐓𝐌𝐀𝐗 ]

𝑻𝑴𝑨𝑿 𝑵𝑷
𝟐𝟒
) 𝑵𝑹 ]

𝑵𝑷

(13)

𝒆−𝛌𝐭
× [( 𝛌𝐭) ×
𝒇𝒐𝒓 𝒌 = 𝟎, 𝒕 = 𝑻𝑴𝑨𝑿 ])
𝐤!
𝐤

× [ 𝒆−𝛌𝐓𝐌𝐀𝐗 ])

(14)

If the patient already took two doses very close to each other, there will be no context-aware
reminders. In that sense, a context-aware reminder will not increase the probability of
undesirable dose event (UDE). Therefore, the undesirable dose event probability (UDEBASE) can
still be given as
𝐔𝐃𝐄𝐁𝐀𝐒𝐄 = 𝐏𝐫𝐨𝐛((𝐓𝐈+𝟏 − 𝐓𝐈 ) < 𝐓𝐌𝐈𝐍 ) = (𝛌𝐓𝐌𝐈𝐍 )𝟐 ×
5.1.2.2 Healthcare cost and interventions
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𝐞−𝛌𝐓𝐌𝐈𝐍
𝟐!

(15)

Medication nonadherence increases the healthcare cost by $100-300 billion per year (NEHI
2009). To see how smart interventions minimizes the healthcare cost we have derived following
relationships for all three different scenarios a) without any intervention, b) simple and persistent
reminder, and c) context-aware reminder.
In the case of nonadherent patients who does not receive any intervention and consume doses
as per their choice/convenience, their healthcare cost comprises of medical cost and drug cost,
i.e., the all-disease cost. So, healthcare cost for nonadherent patients is calculated as follows:
𝐇𝐂𝐂𝐎𝐒𝐓𝐍𝐀 = (𝐇𝐂𝐂𝐎𝐒𝐓-𝐏𝐀𝐒𝐓 ) × (𝟏. 𝟎𝟓)𝐍

(16a)

where N represents the Nth year from the year of data.
If the patient receives simple and persistent reminders to comply with the prescribed dosing
regimen, then in addition to the all-disease cost they have to pay for the intervention cost. As
well as there will be some additional cost due to undesirable dose events. Therefore, we derive
the healthcare cost in case of simple and persistent reminders as
𝐇𝐂𝐂𝐎𝐒𝐓𝐒𝐑 = (𝐇𝐂𝐂𝐎𝐒𝐓-𝐏𝐀𝐒𝐓 ) × (𝟏. 𝟎𝟓)𝐍 × (𝟏 + 𝐔𝐃𝐄𝐒𝐑 ) + 𝐈𝐍𝐓𝐕𝐍𝐂𝐎𝐒𝐓-𝐒𝐑

(16b)

In the case of context-aware reminder, there will be all-disease cost and the cost for the
context-aware reminder. However, there will not be any additional cost for undesirable dose
event. Because context-aware reminder does not lead to additional UDE as represented in
equation 15. Therefore, we drive the healthcare cost due to context-aware reminder as
𝐇𝐂𝐂𝐎𝐒𝐓𝐂𝐀𝐑 = (𝐇𝐂𝐂𝐎𝐒𝐓-𝐏𝐀𝐒𝐓 ) × (𝟏. 𝟎𝟓)𝐍 + 𝐈𝐍𝐓𝐕𝐍𝐂𝐎𝐒𝐓-𝐂𝐀𝐑

(16c)

Therefore, from equation 16b and 16c we can see that the healthcare cost due to simple and
persistent reminders includes the additional cost for UDE as compared to healthcare costs due to
the context-aware reminder. Also, the intervention cost (INTVNCOST) varies for context-aware
reminders as compared to the simple and persistent reminder.
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Equations 1 through 15 represents the analytical model for prescribed self-administered
medication of single medication in a day. The following section represents the analytical model
for prescribed self-administered medication of multiple medications in a day. These multiple
medications are independent of each other.
5.1.2.3 Measuring effective medication adherence – Multiple medications, multiple doses daily
Scenario 1: Simple and Persistent Reminders - SR
Let us assume,


km is the event



NRm is Number of prescribed doses in a day for mth medicine



λ m is the average arrival rate for mth medicine


where, λm =

NRm
24



T(MAX)m is time (tm) observed for mth medicine



P(D-R)m is the Probability of taking dose due to reminder for mth medicine



P(ND-R)m is the Probability of not taking dose due to reminder for mth medicine
(17)

𝑷(𝑵𝑫-𝑹)𝒎 = 𝟏 − 𝑷(𝑫-𝑹)𝒎


Qm is the number of reminders came in during last T(MAX)m for mth medicine
𝑸𝒎 =



𝑻(𝐌𝐀𝐗)𝐦

(18)

𝟐𝟒
𝑵𝑹𝒎

Probability of number of doses in the last T(MAX)m for mth medicine, i.e., Prob(NRm) is
𝐏𝐫𝐨𝐛(𝐍𝐑𝐦 ) = (𝐏(𝐍𝐃-𝐑)𝐦 )𝐐𝐦

(19)



Mean 𝛍𝐦 = 𝛌𝐦 × 𝐭 𝐦



Probability of number of doses after the last reminder, i.e., Prob(km) is

(20)
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𝒌

𝑷𝒓𝒐𝒃(𝒌𝒎 ) =

[𝝁𝒎𝒎 ×𝒆−µ𝒎 ]

(21)

𝒌𝒎 !

Multiplying equation 19 and 21 we get the probability that the gap between doses exceeded
the maximum interdose-time, i.e., the dose is not effective (DNE). Therefore,
𝐷𝑁𝐸𝑚 = 𝑃𝑟𝑜𝑏[(𝑇(𝐼+1)𝑚 − 𝑇(𝐼)𝑚 ) > 𝑇(𝑀𝐴𝑋)𝑚 ] = (P(ND-R)m )Qm × 𝑃𝑟𝑜𝑏(𝑘𝑚 )
𝒌

𝑫𝑵𝑬𝒎 = 𝑷𝒓𝒐𝒃[(𝑻(𝑰+𝟏)𝒎 − 𝑻(𝑰)𝒎 ) > 𝑻(𝑴𝑨𝑿)𝒎 ] = (𝐏(𝐍𝐃-𝐑)𝐦 )

𝐐𝐦

×

[𝝁𝒎𝒎 ×𝒆−µ𝒎 ]
𝒌𝒎 !

(22)

We Know, 𝐴𝑀𝐴𝑚 = 𝑁𝑚(𝑇𝑎𝑘𝑒𝑛) /𝑁𝑚(𝑃𝑟𝑒𝑠)
𝑨𝑴𝑨(𝒏𝒆𝒘-𝑺𝑹)𝒎 = 𝑴𝑰𝑵[(𝑨𝑴𝑨𝒎 + 𝑷(𝑵𝑫-𝑹)𝒎 × 𝑸𝒏 ), 𝟏]

(23)

𝐸𝑀𝐴(𝑆𝑅)𝑚 = 𝐴𝑀𝐴(𝑛𝑒𝑤-𝑆𝑅)𝑚 − [𝐴𝑀𝐴(𝑛𝑒𝑤-𝑆𝑅)𝑚 × 𝑃𝑟𝑜𝑏[(𝑇(𝐼+1)𝑚 − 𝑇(𝐼)𝑚 ) > 𝑇(𝑀𝐴𝑋)𝑚 ]]
Alternatively, 𝑬𝑴𝑨(𝑺𝑹)𝒎 = 𝑨𝑴𝑨(𝒏𝒆𝒘-𝑺𝑹)𝒎 − [𝑨𝑴𝑨(𝒏𝒆𝒘-𝑺𝑹)𝒎 × 𝑫𝑵𝑬𝒎 ]

(24)

Suppose a patient has to consume 3 medicines in a day, i.e., M=3
Dosing regimen for 1st medicine (m1) is
𝑁𝑅𝑚1 = 2; λm1 =

𝑁𝑅𝑚1
= 0.083;
24

𝐼𝑛𝑡𝑒𝑟𝑑𝑜𝑠𝑒 𝑡𝑖𝑚𝑒 = 12ℎ𝑟𝑠; 𝑆𝑚𝑎𝑙𝑙𝑒𝑠𝑡 𝑇𝑀𝐴𝑋 = 12; 𝐿𝑎𝑟𝑔𝑒𝑠𝑡 𝑇𝑀𝐴𝑋 = 𝑁𝑅𝑚1 × 𝐼𝑛𝑡𝑒𝑟𝑑𝑜𝑠𝑒 𝑡𝑖𝑚𝑒
Dosing regimen for 2nd medicine (m2) is
𝑁𝑅𝑚2 = 3; λm2 =

𝑁𝑅𝑚2
= 0.125
24

𝐼𝑛𝑡𝑒𝑟𝑑𝑜𝑠𝑒 𝑡𝑖𝑚𝑒 = 6ℎ𝑟𝑠; 𝑆𝑚𝑎𝑙𝑙𝑒𝑠𝑡 𝑇𝑀𝐴𝑋 = 6 ; 𝐿𝑎𝑟𝑔𝑒𝑠𝑡 𝑇𝑀𝐴𝑋 = 𝑁𝑅𝑚2 × 𝐼𝑛𝑡𝑒𝑟𝑑𝑜𝑠𝑒 𝑡𝑖𝑚𝑒
Dosing regimen for 3rd medicine (m3) is
𝑁𝑅𝑚3 = 4; λm3 =

𝑁𝑅𝑚3
= 0.167
24

𝐼𝑛𝑡𝑒𝑟𝑑𝑜𝑠𝑒 𝑡𝑖𝑚𝑒 = 5ℎ𝑟𝑠; 𝑆𝑚𝑎𝑙𝑙𝑒𝑠𝑡 𝑇𝑀𝐴𝑋 = 5 ; 𝐿𝑎𝑟𝑔𝑒𝑠𝑡 𝑇𝑀𝐴𝑋 = 𝑁𝑅𝑚3 × 𝐼𝑛𝑡𝑒𝑟𝑑𝑜𝑠𝑒 𝑡𝑖𝑚𝑒
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Overall EMAM due to all three medicines will be a weighted average of EMAm1, EMAm2 and
EMAm3. Where weights are determined based on primary and secondary medicines. We consider
following three scenarios.
Scenario 1: All 3 medicines are primary.
𝟏

𝟏

𝟏

𝑬𝑴𝑨(𝑺𝑹)𝑴 = 𝟑 × 𝑬𝑴𝑨(𝑺𝑹)𝒎𝟏 + 𝟑 × 𝑬𝑴𝑨(𝑺𝑹)𝒎𝟐 + 𝟑 × 𝑬𝑴𝑨(𝑺𝑹)𝒎𝟑

(25)

Scenario 2: Medicine 1st is primary, and 2nd and 3rd are secondary.
𝟏

𝟏

𝟏

𝑬𝑴𝑨(𝑺𝑹)𝑴 = 𝟐 × 𝑬𝑴𝑨(𝑺𝑹)𝒎𝟏 + 𝟒 × 𝑬𝑴𝑨(𝑺𝑹)𝒎𝟐 + 𝟒 × 𝑬𝑴𝑨(𝑺𝑹)𝒎𝟑

(26)

Scenario 3: Medicine 1st and 2nd are primary, and 3rd is secondary.
𝟐

𝟐

𝟏

𝑬𝑴𝑨(𝑺𝑹)𝑴 = 𝟓 × 𝑬𝑴𝑨(𝑺𝑹)𝒎𝟏 + 𝟓 × 𝑬𝑴𝑨(𝑺𝑹)𝒎𝟐 + 𝟓 × 𝑬𝑴𝑨(𝑺𝑹)𝒎𝟑

(27)

Therefore, 𝑬𝑴𝑨(𝑺𝑹)𝑴 = ∑𝑴
𝒊=𝟏 𝐀 𝐢 𝑬𝑴𝑨(𝑺𝑹)𝒎𝒊

(28)

Undesirable dose event in case of Simple and Persistent Reminders
Undesirable dose event (UDE)
𝑈𝐷𝐸𝐵𝐴𝑆𝐸(𝑚) = 𝑃𝑟𝑜𝑏[(𝑇(𝐼+1)𝑚 − 𝑇(𝐼)𝑚 ) < 𝑇(𝑀𝐼𝑁)𝑚 ]
Or, 𝑼𝑫𝑬𝑩𝑨𝑺𝑬(𝒎) = (𝛌𝐦 × 𝒕𝒎 )𝒌𝒎 ×

𝒆−𝛌𝒎 𝒕𝒎
𝒌!

𝒇𝒐𝒓 𝒌𝒎 = 𝟐 𝒂𝒏𝒅 𝒕𝒎 = 𝑻(𝑴𝑰𝑵)𝒎

(29)

𝑈𝐷𝐸𝑚 = 𝑃𝑟𝑜𝑏[(𝑇(𝐼+1)𝑚 − 𝑇(𝐼)𝑚 ) < 𝑇(𝑀𝐼𝑁)𝑚 ]
𝟏

𝟐

𝑼𝑫𝑬𝒎 = 𝟐 (𝛌𝐦 × 𝑻(𝑴𝑰𝑵)𝒎 ) × 𝒆−𝛌𝐦𝑻(𝑴𝑰𝑵)𝒎

(30)

𝑈𝐷𝐸(𝑇𝑂𝑇𝐴𝐿)𝑚 = 𝑃𝑟𝑜𝑏[(𝑇(𝐼+1)𝑚 − 𝑇(𝐼)𝑚 ) < 𝑇(𝑀𝐼𝑁)𝑚 ]
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𝑈𝐷𝐸(𝑇𝑂𝑇𝐴𝐿)𝑚 = [1 −

+[

𝑇(𝑀𝐼𝑁)𝑚
𝑒 −λm 𝑡𝑚
] × [(λm × 𝑡𝑚 )𝑘𝑚 ×
𝑓𝑜𝑟 𝑘𝑚 = 2 𝑎𝑛𝑑 𝑡𝑚 = 𝑇(𝑀𝐼𝑁)𝑚 ]
24
𝑘!
𝑁𝑅𝑚

𝑇(𝑀𝐼𝑁)𝑚
× 𝑃(𝐷-𝑅)𝑚 ]
24
𝑁𝑅𝑚

× [ (λm × 𝑡𝑚 )𝑘𝑚 ×

𝑒 −λm 𝑡𝑚
𝑓𝑜𝑟 𝑘𝑚 = 1 𝑎𝑛𝑑 𝑡𝑚 = 𝑇(𝑀𝐼𝑁)𝑚 ]
𝑘!

Therefore,
2

𝑈𝐷𝐸(𝑇𝑂𝑇𝐴𝐿)𝑚 = [1 − λm 𝑇(𝑀𝐼𝑁)𝑚 ] × [(λm × 𝑇(𝑀𝐼𝑁)𝑚 ) ×

𝑒 −λm 𝑇(𝑀𝐼𝑁)𝑚
]
2!

+ [λm 𝑇(𝑀𝐼𝑁)𝑚 × 𝑃(𝐷-𝑅)𝑚 ] × [ (λm × 𝑇(𝑀𝐼𝑁)𝑚 ) × 𝑒 −λm 𝑇(𝑀𝐼𝑁)𝑚 ]
𝑼𝑫𝑬(𝑻𝒐𝒕𝒂𝒍)𝒎 = ∑𝑴
𝒊=𝟏 𝑼𝑫𝑬𝐦𝐢

(31)

𝑼𝑫𝑬(𝑺𝑹)𝒎 = 𝑼𝑫𝑬(𝑻𝑶𝑻𝑨𝑳)𝒎 − 𝑼𝑫𝑬(𝑩𝑨𝑺𝑬)𝒎

(32)

Scenario 2: Context-aware reminder - CAR
Let us assume,


NRm is Number of prescribed doses in a day for mth medicine at TM intervals, where M is the
number of medicines in a day



NPm is the number of reminders per missing dose for mth medicine



km is the event for mth medicine (km=0)



λm is the average arrival rate for mth medicine
o where, λm =

NRm
24



T(MAX)m is time (tm) observed for mth medicine



P(D-R)m is the Probability of taking dose due to reminder for mth medicine
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P(ND-R)m is the Probability of not taking dose due to reminder for mth medicine
𝑃(𝑁𝐷-𝑅)𝑚 = 1 − 𝑃(𝐷-𝑅)𝑚



Qm is the number of reminders came in during last T(MAX)m for mth medicine
𝑸𝒎 = 𝑵𝑷𝒎 ×



𝑻(𝐌𝐀𝐗)𝐦

(33)

𝟐𝟒
𝑵𝑹𝒎

Probability of number of doses in the last T(MAX)m for mth medicine, i.e., Prob(NRm) is
𝐏𝐫𝐨𝐛(𝐍𝐑𝐦 ) = (𝐏(𝐍𝐃-𝐑)𝐦 )𝐐𝐦

(34)



Mean 𝝁𝒎 = 𝛌𝐦 × 𝒕𝒎



Probability of number of doses after the last reminder, i.e., Prob(km) is

(35)

𝒌

𝑷𝒓𝒐𝒃(𝒌𝒎 ) =

[𝝁𝒎𝒎 ×𝒆−µ𝒎 ]

(36)

𝒌𝒎 !

Multiplying equation 34 and 36 we get the probability that the gap between doses exceeded
the maximum interdose-time, i.e., the dose is not effective (DNE).
𝐷𝑁𝐸𝑚 = 𝑃𝑟𝑜𝑏[(𝑇(𝐼+1)𝑚 − 𝑇(𝐼)𝑚 ) > 𝑇(𝑀𝐴𝑋)𝑚 ] = [(P(ND-R)m )Qm × 𝑃𝑟𝑜𝑏(𝑘𝑚 )]
𝒌

𝑫𝑵𝑬𝒎 = 𝑷𝒓𝒐𝒃[(𝑻(𝑰+𝟏)𝒎 − 𝑻(𝑰)𝒎 ) > 𝑻(𝑴𝑨𝑿)𝒎 ] = [(𝐏(𝐍𝐃-𝐑)𝐦 )

𝐐𝐦

×

[𝝁𝒎𝒎 ×𝒆−µ𝒎 ]
𝒌𝒎 !

]

(37)

We Know, 𝐴𝑀𝐴𝑚 = 𝑁𝑚(𝑇𝑎𝑘𝑒𝑛) /𝑁𝑚(𝑃𝑟𝑒𝑠)
𝑨𝑴𝑨(𝒏𝒆𝒘-𝑪𝑨𝑹)𝒎 = 𝑴𝑰𝑵[(𝑨𝑴𝑨𝒎 + 𝑷(𝑵𝑫-𝑹)𝒎 × 𝑸𝒎 ), 𝟏]

(38)

𝐸𝑀𝐴(𝐶𝐴𝑅)𝑚 = 𝐴𝑀𝐴(𝑛𝑒𝑤-𝐶𝐴𝑅)𝑚 − [𝐴𝑀𝐴(𝑛𝑒𝑤-𝐶𝐴𝑅)𝑚 × 𝑃𝑟𝑜𝑏[(𝑇(𝐼+1)𝑚 − 𝑇(𝐼)𝑚 ) > 𝑇(𝑀𝐴𝑋)𝑚 ]]
Or, 𝑬𝑴𝑨(𝑪𝑨𝑹)𝒎 = 𝑨𝑴𝑨(𝒏𝒆𝒘-𝑪𝑨𝑹)𝒎 − [𝑨𝑴𝑨(𝒏𝒆𝒘-𝑪𝑨𝑹)𝒎 × 𝑫𝑵𝑬𝒎 ]
Suppose a patient has to consume 3 medicines in a day, i.e., M=3 and NPm=2
Dosing regimen for 1st medicine (m1) is
𝑁𝑅𝑚1 = 2; λm1 =

𝑁𝑅𝑚1
= 0.083;
24
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(39)

𝐼𝑛𝑡𝑒𝑟𝑑𝑜𝑠𝑒 𝑡𝑖𝑚𝑒 = 12ℎ𝑟𝑠; 𝑆𝑚𝑎𝑙𝑙𝑒𝑠𝑡 𝑇𝑀𝐴𝑋 = 12; 𝐿𝑎𝑟𝑔𝑒𝑠𝑡 𝑇𝑀𝐴𝑋 = 𝑁𝑅𝑚1 × 𝐼𝑛𝑡𝑒𝑟𝑑𝑜𝑠𝑒 𝑡𝑖𝑚𝑒
Dosing regimen for 2nd medicine (m2) is

𝑁𝑅𝑚2 = 3; λm2 =

𝑁𝑅𝑚2
= 0.125
24

𝐼𝑛𝑡𝑒𝑟𝑑𝑜𝑠𝑒 𝑡𝑖𝑚𝑒 = 6ℎ𝑟𝑠; 𝑆𝑚𝑎𝑙𝑙𝑒𝑠𝑡 𝑇𝑀𝐴𝑋 = 6 ; 𝐿𝑎𝑟𝑔𝑒𝑠𝑡 𝑇𝑀𝐴𝑋 = 𝑁𝑅𝑚2 × 𝐼𝑛𝑡𝑒𝑟𝑑𝑜𝑠𝑒 𝑡𝑖𝑚𝑒
Dosing regimen for 3rd medicine (m3) is
𝑁𝑅𝑚3 = 4; λm3 =

𝑁𝑅𝑚3
= 0.167
24

𝐼𝑛𝑡𝑒𝑟𝑑𝑜𝑠𝑒 𝑡𝑖𝑚𝑒 = 5ℎ𝑟𝑠; 𝑆𝑚𝑎𝑙𝑙𝑒𝑠𝑡 𝑇𝑀𝐴𝑋 = 5 ; 𝐿𝑎𝑟𝑔𝑒𝑠𝑡 𝑇𝑀𝐴𝑋 = 𝑁𝑅𝑚3 × 𝐼𝑛𝑡𝑒𝑟𝑑𝑜𝑠𝑒 𝑡𝑖𝑚𝑒
Overall EMA(CAR)M due to all three medicines will be a weighted average of EMA(CAR)m1,
EMA(CAR)m2, and EMA(CAR)m3. Where weights are determined based on primary and secondary
medicines. We consider following three scenarios.
Scenario 1: All 3 medicines are primary.
𝟏

𝟏

𝟏

𝑬𝑴𝑨(𝑪𝑨𝑹)𝑴 = 𝟑 × 𝑬𝑴𝑨(𝑪𝑨𝑹)𝒎𝟏 + 𝟑 × 𝑬𝑴𝑨(𝑪𝑨𝑹)𝒎𝟐 + 𝟑 × 𝑬𝑴𝑨(𝑪𝑨𝑹)𝒎𝟑

(40)

Scenario 2: Medicine 1st is primary, and 2nd and 3rd are secondary.
𝟏

𝟏

𝟏

𝑬𝑴𝑨(𝑪𝑨𝑹)𝑴 = 𝟐 × 𝑬𝑴𝑨(𝑪𝑨𝑹)𝒎𝟏 + 𝟒 × 𝑬𝑴𝑨(𝑪𝑨𝑹)𝒎𝟐 + 𝟒 × 𝑬𝑴𝑨(𝑪𝑨𝑹)𝒎𝟑

(41)

Scenario 3: Medicine 1st and 2nd are primary, and 3rd is secondary.
𝟐

𝟐

𝟏

𝑬𝑴𝑨(𝑪𝑨𝑹)𝑴 = 𝟓 × 𝑬𝑴𝑨(𝑪𝑨𝑹)𝒎𝟏 + 𝟓 × 𝑬𝑴𝑨(𝑪𝑨𝑹)𝒎𝟐 + 𝟓 × 𝑬𝑴𝑨(𝑪𝑨𝑹)𝒎𝟑

(42)

Therefore, 𝑬𝑴𝑨(𝑪𝑨𝑹)𝑴 = ∑𝑴
𝒊=𝟏 𝐀 𝐢 𝑬𝑴𝑨(𝑪𝑨𝑹)𝒎𝒊

(43)

5.1.3 Model Validation
Analytical models are the representations of mechanisms that govern natural phenomena that
are not fully recognized, controlled or understood (Tedeschi 2006). They have become
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indispensable tools via decision support systems for policy makers and researchers (Tedeschi
2006). The main reason for modeling problems is it permits serious analysis and consideration of
a problem, which has important financial, organizational and practical implications (Guerrero
2010). However, certain techniques must be used to evaluate mathematical models for
objectives, scope and assumptions, appropriateness or validation, and limitations. Essentially, the
model should be appropriate for its intended purpose under the given conditions.
For evaluation of smart interventions for effective medication adherence, our mathematical
model is used to estimate dose-event (dose not effective, undesirable dose event), effective
medication adherence (a single and multiple medications with multiple dosing regimen), and
healthcare cost benefits of smart interventions. The model considers patients are living
independently, their adherence behavior (0-100% medication adherence covering no-adherence,
semi-adherence, and satisfactory adherence), and the type of illness (several chronic conditions),
and prescribed self-administered medications. The model allows the study of


Multiple chronic diseases including Diabetes, Hypertension (high blood pressure/BP),
Hypercholesterolemia, and Chronic Heart Failure (CHF)



Independently living patients i.e. patients who are not living in a healthcare provider
assisted environment



Healthcare cost including medical and drug cost



Simple and persistent reminders and context-aware reminders
The model is appropriate (Tedeschi 2006) for studying adherence in chronic illnesses, where

use of multiple medications extend over a period. The model can approximate the intervention
and their cost. Therefore, the model is a valid and sound model and does what it is supposed to do
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(Tedeschi 2006). Further, the three steps of model validation (Hamilton 1991): verification of the
model, sensitivity analysis, and evaluation of the model, are performed below.
The verification involved step by step checking of the model and debugging where one or
more changes in inputs could lead to unacceptable output (Hamilton 1991; Tedeschi 2006).
Further, the model was calibrated using values from other studies (Gibson et al. 2010; Roebuck et
al. 2011; Sokol et al. 2005). The model builds upon prior models, and other studies also support
the results obtained from this model. The model is validated by testing for many known cases to
verify its functioning. Further, the causal relationships of medication adherence with medical cost,
drug cost, and the intervention cost for multiple chronic conditions were utilized (Sokol et al.
2005). All relationships in the model are verified, and known relationships were utilized for
deriving additional relationships.
The sensitivity analysis was performed to test the behavior of every equation in the model
(Hamilton 1991). There are several ways to perform sensitivity analysis for mathematical models
(Christopher Frey and Patil 2002). We focused on the nominal range sensitivity, which works
well for models where there are no significant interactions among input values and the ranges of
plausible values can be defined (using one’s judgment or from the literature). For our model, we
broadly defined the ranges of all input values, obtained from other studies and expanded even
further to cover more extreme cases. The analysis included combining several input values and
measuring outputs for these combinations of inputs. The results section of this document presents
the outcome of this analysis. It also helps in answering “what-if” questions such as “what if the
patient does not consume the dose within the prescribed interval” or “what if patient consumed
the dose one hour before or after the dose is due” or “what if an intervention stopped working”.
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The evaluation of model was done to test the adequacy (or robustness) of the model based on
precision and accuracy of results (Hamilton 1991; Tedeschi 2006). The model is precise as it
produces values that are close to one another in multiple iterations. The accuracy of model is on
(a) known relationships and (b) calibration of results for decision making. To measure accuracy
further, we tested our model on input data and results from (Gibson et al. 2010; Roebuck et al.
2011; Sokol et al. 2005). We further evaluated our model by computing the savings due to
improved adherence under the all-disease cost of medications (Sokol et al. 2005). These values
are in close agreement, so our results on effective medication adherence, undesirable dose event,
and healthcare cost are validated using published data, while other results on smart interventions
are extrapolated based on known relationships and available data from multiple studies.
Several assumptions (see section 5.1.1) were made to keep the analytical model tractable and
reasonably accurate. In future work, these assumptions may be relaxed.
The model can estimate the savings due to the improved effective medication adherence, the
cost of various interventions, and the overall budget for various interventions. For a given
improvement, knowing when an intervention is cost effective for a given condition can help an
insurance company and/or employer in allocating healthcare resources. The analytical model,
implemented in Excel (Guerrero 2010) and included in Appendix (A2), can be used to derive
effective medication adherence for different dosing events, estimate savings due to improved
medication adherence, and evaluate effective medication adherence for multiple medications.
5.1.4 Limitations
The model is primarily designed to address medication adherence in independent living, and
will need extensions before its use in other more controlled environments such as assisted living
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and hospitals. The model is designed to provide results with reasonable complexity, and in some
cases, more refined results may be obtained by developing more complex models.

Section 5.2 Empirical
To see the validity of the proposed conceptual artifact domain experts (healthcare providers
and health IT experts) have evaluated the artifact by comparing the health IT artifact with
existing simple interventions. The evaluation of conceptual artifact is based on research design
adapted from Parsons and Wand (Parsons and Wand 2008). The artifact evaluation protocol is
available in Appendix (A1). After discussing the dissertation research with IRB, the application
was submitted as non-human subject research to IRB for approval. Appendix (A1) includes the
outcome letter of approval.
We have focused explicitly on the experts' reasoning about their preferences between the
existing and our smart interventions, and on relating that reasoning to the proposed health IT
artifact. The evaluation will provide the insights for interventions preferred by experts.
5.2.1 Participants and Task
Domain experts consisted of six healthcare provider and six health IT experts. More
specifically, healthcare providers are the physicians with extensive experience in advising and
monitoring patients with chronic conditions prescribed self-administered medications. The three
categories of health IT experts includes (1) two researchers in information systems with research
and/or practical experience in medication adherence research, (2) two researchers in information
systems with research and/or practical experience in health IT research, and (3) two health IT
experts with extensive experience in healthcare system modeling and development. Health IT
experts from information systems were chosen because of their familiarity with the medication
adherence and health IT research and expected to be sufficiently motivated to provide thoughtful
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responses. Also, modeling experts were chosen because they were expected to have relevant
practical experience with the reasoning that takes place when developing a health IT system.
Participants were asked to follow the instructions in Appendix A1 to compare Artifact1 and
Artifact2 in Table 1 of the appendix (A1). The objectives for comparison were to:
1. Focus participant’s attention on the differences in Artifact1 and Artifact2,
2. Ask participants to formulate questions that could be asked to clarify the reasons why the
differences arose,
3. Observe which of the two artifact is considered more useful and realistic by the
participants based on their domain experience,
4. Observe which of the two artifacts is considered more reliable by the domain experts,
5. Focus on participants reasoning for which artifact leads to overdose or over medication.
Participants were not informed about the rules used to develop Artifact2.
5.2.2 Analysis of Simple vs. Smart Intervention
As discussed in the development section, following are the major differences between
Artifact1 (Simple Intervention) and Artifact2 (Smart Intervention):
1. Wireless Medication Box is used as an additional support for dose dispensing, and dispensing
and consumption information of dose in Artifact2 as compared to Artifact1
2. Analysis of consumption is done by Medication Management Server component of Artifact2.
3. Medication Management Server in Artifact2 helps in providing context-aware reminders
leading to smart interventions.
4. Advice/scheduling support is available by a healthcare provider.
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Participant
(Healthcare
providerHCP;
Health IT
Experts –
HITE)

What
differences can
be identified
between the
two models?

HCP 1

 2nd is smarter,
assuming the
patient
takes/swallows
the pill.
 2nd is less
annoying – user
friendly.
 1st is More
mechanical,
repetitive.

HCP 2

 Model 2 has
an additional
component
(WMB) which
allow
intelligence to
be incorporated
in the design
leading to
contextual
awareness of
“what”
happened
versus “when”
it happened.

HCP 3

 The second
model involves
the addition of a
wireless
medication box
and active
scheduling with
the healthcare
provider.

HCP 4

 Wireless
medication box
in model 2 is
present,

What
questions
could be
asked to
clarify the
reasons for
these
differences?
 Tell me
more details of
WMB: Is it
portable?
 Does is it
have an alarm
to get
attention?
 What
happens if one
misses the
dose?
Related to
WMB
 Is it
pill/liquid
based meds
 Sensors in
WMB
sensitive to
time alone or
can patient
open it
anytime.

Which of the
two might be
more useful
or realistic
based on
your general
knowledge of
the domain?
 2nd will be
more useful if
above
features
added.

Which one of
these is more
reliable or
less likely to
fail?

Which one of
these will lead
to
overdose/over
medication?

 Second will
be more
reliable as
long as the
patient is
honestly
taking pills.

 First – as it
keeps sending
reminders even
when the
patient has
taken
medicines.

 Model 2
has additional
layers of
information.
However, it
limits the
type of
patients who
can benefit;
namely:
taking solid
pills, having a
specific
frequency
(chronic
medicines).

 Overdosing
is possible with
Table/model 1.

 The
additional
steps could
perhaps help
dispense the
appropriate
dose and
schedule of
medications
and avoid
inappropriate
dosing of
medications.
 Precise dose
dispensing is
important.
 Dose
schedule could

 The second
model is
probably
more useful.

 Reliability
will depend
on the
healthcare
“end” on how
compatible it
is on their
side.
 On the
patient side
model 2, is
better than 1
as it gives
information
and reminders
from the
nurse.
 The second
model is
probably less
likely to fail,
but no system
is perfect.

 Model 2

 Model 1

 Model 2
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 First model.

 Contextaware
reminders and
analysis of
consumption
between MMS
and wireless
network.
 Advice
scheduling
between MMA
and healthcare
provider.
HCP 5

 Model 2 adds
a wireless
medicationdispensing
device and
 Provides for
analysis and
sharing of
dispensing and
consumption
information
with the
healthcare
provider.

HCP 6

 In addition to
going through
compliance and
patterns of use
Artifact 2, has
advice on
scheduling &
WMB;
dispensing and
consumption
information.
*patient
symptom
improvement
could be added
 MMS needs
to be “Smart”,
i.e., needs to
have more
processing
capability to be
able to do the

HITE 1

be altered
depending
upon the
response of
medication.
 In the case of
sub dosing or
overdosing,
analysis of
consumption
and contextaware
reminders will
be of immense
help.
 Don't you
think that for
the
independentminded and
the healthconscious
people, the
fact that there
would be too
much
involvement
and reminders
with pill taking
with model 2may be offputting?
 Will it
increase
adherence/com
pliance and
better outcome
of treatment?

 How do you
decide that
useful input
has been done?
 What is the
difference
between the
MMS of

 Model 2

 Model 2

 Both are
unlikely to lead
to
overmedication
.

 useful
Artifact 2
 Realistic
Artifact 1
because of
less time
consumption.

 Artifact 2 is
more reliable,
& less likely
to fail

 Artifact 1
will lead to
overdose
because no
feedback on
scheduling.

 If the
system can be
designed to
be foolproof
or close to
foolproof,
then Model 2,
(utilizing

 Model 1: If
the adherence
is monitored
by the
doctor/nurse/c
aregiver.
 Model 2: If
technology

 Model 2: If
technology is
not
designed/imple
mented
properly.
 Model 1: If
patient/caregiv
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HITE 2

HITE 3

HITE 4

context-aware
analysis.
 Artifact2 is
heavily reliant
on good input
data, i.e., should
not become a
case of garbage
data in garbage
data out.
 WMB wireless
medication box
has been
introduced for
dispensing the
dose.
 Dispensing
and
consumption
information
have been
stored for
further analysis.
 A contextaware reminder
has been added.
 Healthcare
provider can
provide dose
scheduling
advice through
MMA.
 Advice
scheduling
 WMB, plus
connections
 Contextaware
reminders
 Analysis of
consumption
 “Simple” vs.
“Smart.”
 Smart
Intervention is
contexted.
 Smart
intervention
analyzes the
consumption
information and
provides
updated
dispensing info.

Model 1 &
Model 2?

technology)
would be
more useful.

can be made
reliable
enough
(WMB/MMS)

er are not
careful.

 How
woulddd these
additional
steps
contribute
towards the
speedy
recovery of the
patient?
 How the
information
being stored
would help in
preventive
care?

 diagram 2

 diagram 2

 diagram 1

 What is the
connection
between
contextual
reminders and
the patient?
 Is the MMA
still necessary
with the
WMB?

 Model 1
seems more
practical
 Model 2
has potential
to be more
effective but
may cost
more to
implement

 More likely
Model 2

 More likely
Model 1

 What does
contextawareness
mean? What
factors are
considered?
 Why there is
a separate
entity (WMB)
for the
feedback

 Both are
applicable
solutions,
based on my
experience
with IT
solutions.

 Second
model
(Smart)

 Simple
intervention
Model 1.
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HITE 5

 Model 1
provides
interaction
between the
patient and the
provider based
on simple
information
exchange,
 while under
model 2, the
intervention is
enhanced by
using more
contextual and
personalized
information
based on dose
assumption
information

HITE 6

 The second
one uses
context-aware
reminders.
 The second
one includes the
wireless
medication box,
which can trace
patients'
medicationtaking behavior
more objective
than self-report.
 The mobile
application also
provides
scheduling
advice in the
second model.

provision?
(Separate from
MMA).
 Functionality
 Usability
 The degree
of clinical
decision
support

 How to
guarantee the
medicationtaking
information is
accurate and
reliable?
 Which kind
of reminder
would be more
effective in
changing
patients'
behavior?
 Normal
reminder or
context-aware
reminder?

 The success
of IT
implementati
on or
adoption
depends on
many factors.
By assuming,
that other
factors of the
two models
are same, and
the patient
really has the
capability to
interact
correctly with
the system,
generally
model 2 will
be useful.
 A smarter
solution more
helps the
process of
medical
intervention.
 The second
one will be
more useful.

 The simpler
solution
model 1
would be
more reliable.
 Model 2
integrates
more
information
together and
supports a
higher level
of clinical
decision
support, but it
is more
fragile

 Model 1 may
lead to
overdose as
there is no
reminder based
on
personalized
dose and
consumption
analysis.

 I think more
simple means
more stable.
Thus, I think
the first one is
less likely to
fail.

 I think both
of them should
have a fairly
low possibility
of overdose,
but the second
one may have a
higher
possibility of
taking
medication not
at the
prescribed
time.

Table 8a. Participants feedback on comparison of artifact1 and artifact2
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After analyzing the response of the participants recorded in Table 8a, all of the 12
participants have identified these differences in the two artifacts. However, the clarification
questions for the differences varies among participants. Table 8b categorizes the different types
of questions, corresponding participants and identifying the question as functional or technical
(Artifact2). Functional or technical identification will be helpful in analyzing and improving the
artifact further for future research.
Clarification question category
Category1: Details of WMB such as
portability, sensitivity, types of medicines
supported, will it increase adherence,
confirmation of medication consumption
Category2: Use of two separate entities WMB
and MMA
Category3: Too much involvement and
reminders might be cumbersome for the
patient.
Category4: Connection between contextaware reminder and patient, and analysis of
consumption and context-aware reminder?
Category5: Difference between MMS of
Artifact1 and Artifact2

Participant
HCP1, HCP2, HCP5,
HCP6, HITE2, HITE6

Functional versus
Technical
Functional

HCP3, HITE2, HITE3,
HITE4
HCP5

Functional

HCP4, HITE4, HITE6

Functional

HITE1, HITE5, HITE6

Technical

Technical

Table 8b. Categorizing clarification questions

While developing the artifact we came across same types of questions and the developed
artifact answers all these questions. For example, all the details of WMB are considered while
using it as one of the components. WMB and MMA both are required because WMB is used by
patient and provides dosing consumption information to MMS. On the other hand, MMA
provides an interface between the patient, healthcare provider, and MMS. Similarly questions in
Category 4 and Category 5 addressed in the development section above. The concern of
participant HCP5 about the artifact being cumbersome for the patient is important concern.
However, the system is not as cumbersome as it seems to be. Patient, as well as healthcare
provider, will interact with the MMA. MMA is a simple app to provide three-way interaction
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between patient, healthcare provider and MMS. All the complexity is in MMS for making
intelligent decisions and generating smart interventions and providing the smart intervention in
the form of an informed message to the patient. This further reduces the complexity at the
patient’s point of contact. Since MEMA comprises of functional and technical components and
the clarification questions falls in both categories. It inclines the development process with the
solution to real world problem scenario.
Table 8c summarizes how 12 participants categorize Artifact1 and Artifact2 based on which
model is useful, realistic, reliable or less likely to fail and lead to overdose/over medication.
Model

Artifact1

Useful

HITE4

Realistic

HCP6, HITE3, HITE4

Reliable or less likely to fail

HITE5, HITE6

Lead to overdose/over
medication

HCP1, HCP2, HCP3, HCP4,
HCP6, HITE1, HITE2, HITE3,
HITE4, HITE5

Artifact2
HCP1, HCP2, HCP3, HCP4,
HCP5, HCP6, HITE1, HITE2,
HITE3, HITE4, HITE5, HITE6
HCP1, HCP2, HCP3, HCP4,
HCP5, HITE1, HITE2, HITE4,
HITE5
HCP1, HCP2(patient side),
HCP3, HCP4, HCP5, HCP6,
HITE1, HITE2, HITE3, HITE4
HITE1, HITE6

Table 8c. Categorizing artifact1 and artifact2

As we can see from Table 8c, all the 12 participants identified Artifact2 (smart intervention)
useful as compared to Artifact1. However, participant HITE4 says “Both are applicable
solutions, based on my experience with IT solutions.” Moreover, for the same reason, HITE4
identifies Artifact1 and Artifact2 to be realistic too. Also, participant HITE3 and HCP6
categorizes Artifact1 (simple intervention) to be realistic. Participant HCP6 says “realistic
Artifact 1 because of less time consumption.” All participants except HITE5 and HITE6
categorizes model3 to be reliable or less likely to fail. However, participant HCP2 says
“Reliability will depend on the healthcare “end” on how compatible it is on their side. On the
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patient side model, 2 is better than 1 as it gives information and reminders from nurse”. It shows
that participant is observing the involvement of healthcare provider and compatibility with
technology for the reliability of the system.
The decision for the reliability of a model by participant HITE1 bases on the argument
“Model 1: If the adherence is monitored by the doctor/nurse/caregiver. Model 2: If technology
can be made reliable enough (WMB/MMS)”. Since we have discussed in development section
that in Artifact1 adherence is monitored by the healthcare provider at the end of the prescribed
dosing regimen not during the prescribed dosing regimen, so we have categorized the response
of HITE1 as Artifact2 to be reliable keeping in mind that technology (WMB/MMS) is reliable.
However, as no system is perfect so we would like to identify the limitation of our system
here that if the wireless network is not working then WMB and MMS will not be able to interact,
and the technology will not be reliable at that point of time. All the participants except HITE1
and HITE6 have identified Artifact1 leading to overdose/over medication. Participant HITE1
says “Model 2: If technology is not designed/implemented properly. Model 1: If
patient/caregiver are not careful.” It relates to the same concern HITE1 has with the reliability of
the system.
So we can see that the integration of technology plays a crucial role in the effectiveness of
the smart intervention. On the other hand, participant HITE6, mentions that “I think both of them
should have a fairly low possibility of overdose, but the second one may have a higher
possibility of taking medication, not at the prescribed time.” However, this reasoning does not
align with the difference participant HITE6 mentioned between Artifact1 and Artifact2 in Table
8a “The second one uses context-aware reminders. The second one includes the wireless
medication box, which can trace patients' medication-taking behavior more objective than self-
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report. The mobile application also provides scheduling advice in the second model.” On the
other hand, participant HCP5 mentions that “both unlikely to lead to overmedication.”
The evaluation of smart intervention (Artifact2) with simple intervention (Artifact1) by
domain experts is insightful in identifying that smart intervention seems to be a better
intervention for improving the effectiveness of medication adherence. It is further verified by the
analysis presented in Table 8a, 8b, and 8c as well as from the analysis description. However, as
mentioned above smart intervention can be made more robust after addressing some of the
concerns of healthcare providers and health IT experts related to the techniques and reliability of
the system.

Section 5.3 Results
Using the analytical model, we derived several results for the impact of patterns of
medication of adherence on effective medication adherence; compared effective medication
adherence without any intervention, with simple and persistent reminders, and context-aware
reminders for single medication multiple doses as well as multiple medications multiple doses.
Also, we compared undesirable dose event for different scenarios. Last but not the least we have
derived and compared the healthcare cost savings due to context-aware reminders, and
healthcare cost saving due to simple and persistent reminders with healthcare cost when the
patient was nonadherent.
5.3.1 Patterns of Adherence
To show the impact of the pattern, we take an example of three patients with different
average levels and patterns of medication adherence. Table 9 shows the results, where the patient
3 can achieve satisfactory effective adherence by having a highly desirable pattern.
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Doses consumed
Pattern

Average medication
adherence
Effective medication
adherence
Comment

Patient 1
100%
Lot of variations
(20% probability
of exceeding
maximum
interdose-time)
100%

Patient 2
90%
Some variations (10%
probability of
exceeding maximum
interdose-time)

Patient 3
80%
(0% probability of
exceeding maximum
interdose-time)

90%

80%

80%

80%

80%

Variations resulted
in lower effective
adherence

Variations reduced
effective adherence

The best pattern leads to
satisfactory adherence

Table 9. Different adherence and patterns

The patterns of adherence are studied based on Uniform and Poisson probability
distributions. The results of both the distributions are used to confirm the effectiveness of
medication over a particular interval of time. For example, a patient is prescribed 3 doses in a
day for 30 days. However, the patient takes less than prescribed doses for 5 days and for rest of
the 25 days he tries to catch-up before doctor’s appointment. Alternatively, the patient takes less
than prescribed doses for 10 days and again uses catch-up for 20 days. Here, the average rate of
adherence is important, and the different patterns of adherence could make a difference. While
calculating effective adherence we focused on the average probability of ideal timing and catchup timing.
We considered both Uniform and Poisson distribution to study adherence. As shown in
Figure 27, the differences are not huge, but we felt that Poisson will represent more variance and
also there is evidence that medication consumption by people is closer to Poisson (Knafl et al.
2004). So for rest of the results, we used Poisson distribution.
Next, we study three different patterns of adherence. The average value was 100% as the
patients consumed all doses using different patterns. In Random, every dose followed a random
timing. One of the catch-up patterns involved a patient going easy on doses in the first 5 days (2
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doses as opposed to 3/day) and then did catch up for the next 25 days, while the other catch-up
pattern involved the same for 10 days of easy going and then catch up on 20 days. The effective
medication adherence is present in all three patterns with Random showing the worst Effective
Medication Adherence as compared to other catch up patterns. This is shown in the Figure 28.
More flexible dose regimen (by using higher maximum interdose-time) leads to better Effective
Medication Adherence.
Next, we derive the probabilities of multi-dosing by the patients within the minimum
interdose-time. The probability of 2 doses was higher than 3 or 4 doses as expected in Figure 29.
0.3

Prob. of Unsafe Dosing
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0.15

Poisson

0.1
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Figure 27. Distributions for studying patterns of adherence
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Figure 28. The impact of maximum interdose-time on effective adherence
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Figure 29. The probability of multi-dosing

96

1

0

Next, we study three different levels of average adherence and their resulting Effective
Medication Adherence as shown in Figure 30. As before, the effective medication adherence is
higher as the maximum interdose-time increased.
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Figure 30. Effective adherence for different average values

5.3.2 Effective Medication Adherence for Single Medication
To validate the model, each of the equations for EMA is evaluated for a range of parameter
values and the computed results are compared and analyzed to study the varied patterns of EMA.
The patterns are compared and analyzed for different levels of medication adherence and
probabilities of dose consumption due to reminders (PD-R). The levels of the number of
reminders per missing dose (NP) are also varied to analyze the patterns of adherence in case of
context-aware reminders (CAR). The results shown in the Figures 31, 32 and 33 are graphs
plotted between TMAX in hours (Horizontal axis) versus EMA (Vertical Axis); and the plane
represents the comparison between different scenarios as mentioned in the respective graphs.
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Figures 31 and 32 show the comparison of no reminders (NR), simple and persistent
reminders (SR) and context-aware reminders (CAR) for average medication adherence (AMA)
of 100% and 80% respectively. From the graphs of Figures 31 and 32, we can see that the
patterns of adherence are best in the case of CAR when the probability of taking dose due to the
reminder (PD-R) is higher (85%-100%).
Figure 31a shows EMA of a person when he/she is 100% adherent to medication for NR, SR,
and CAR (with 1, 2, 3 and 4 persistent reminders). Also, the person follows the reminders only
20% of the times. In the case of NR, the EMANR is in the range of 63%-86%. On the other hand,
for SRs, EMASR ranges from 64%-87%. In case of CARs, EMACAR ranges from 70%-91%
(NP=1); 76%-94% (NP=2); 81%-96% (NP=3); 85%-98% (NP=4).

Figure 31a

98

Figure 31b

Figure 31c
Figure 31. Comparing EMA for NR, SR and CAR (AMA=100%)

From Figure 31a, we can conclude that increase in context and persistence of reminders leads
to the increase in EMA and improves the patterns of medication adherence. Figures 31b also
reflects the same increase in EMA for various levels of reminders and persistence. On the other
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hand, Figure 31c shows that if a person is 100% adherent to medication and follows all the
reminders, then the EMA for SR and CAR is 100% as compared to EMA in the range of 63%86% in case of NR.
Figure 32a shows the EMA of a person when he/she is 80% adherent to medication for NR,
SR, and CAR (with 1, 2, 3 and 4 persistent reminders). Figure 32b represents that the person
follows the reminders only 60% of the times. In the case of NR, the EMANR is in the range of
44%-64%. On the other hand, for SRs, EMASR ranges from 54%-71%. In case of CARs,
EMACAR ranges from 65%-77% (NP=1); 74%-80% (NP=2); 77%-79% (NP=3); 79%-80%
(NP=4).

Figure 32a

100

Figure 32b

Figure 32c
Figure 32. Comparing EMA for NR, SR and CAR (AMA=80%)
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So we can conclude that increase in context and persistence of reminders leads to the
increase in EMA and improves the patterns of effective medication adherence. On the other
hand, Figure 32c shows that if a person is 80% adherent to medication and follow all the
reminders, then the EMA for SR and CAR is 80% as compared to EMA in the range of 44%64% in case of NR.
Figure 33 shows the comparison of patterns of adherence for EMA with varied medication
adherence, 2 persistent reminders and varied levels of dose consumption due to reminders.

Figure 33a
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Figure 33b

Figure 33c

Figure 33. EMA - (AMA=100% vs AMA80%); NP=2; PD-R= 80%, 60%, 20%
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We can conclude from Figure 33a and 33b that at some point in time the patterns for CAR
and SR coincide with each other for different PDR. For example, we can see that for NP=2,
AMA=80% and PD-R=80% the pattern of adherence for simple reminders overlaps the pattern of
adherence for context-aware reminders. Similarly, if the patient is 80% adherent to medication
and takes the dose 80% of the time due to two persistent reminders, then the patient can achieve
the same EMA as with 100% adherence to medications.
We observed similar results from Figure 34 and Figure 35 as above after varying other input
parameters such as dosing rate (λ), the number of reminders, and the probability of dose taking
after a reminder. In Figure 34 and Figure 35, 3DD and 2DD represent 3 doses per day and 2
doses per day respectively.

Figure 34. Impact of Np on EMA for varying PDR
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Figure 35. Impact of lambda on EMA with varying TMAX

5.3.3 Undesirable dose event (UDE)
Figure 36 shows the results for UDE. UDE can be a problem as higher UDE can lead to drug
toxicity and/or adverse side effects, thus affecting the future adherence to medications. UDE is
increased by simple and persistent reminders, and even when CAR is not highly reliable.

Figure 36. Comparison of UDE for NR, SR, and CAR
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Results show that the pattern of adherence has a significant impact on EMA. Also, higher
levels of EMA can be achieved for more flexible medication regimen, such as those with higher
values of maximum interdose-time. It is also possible for a patient with lower average adherence
but a desirable pattern of adherence to have higher EMA than a patient with higher AMA and
less desirable pattern. In the case of interventions, results show that (1) simple and persistent
reminders can improve EMA, but lead to higher UDE in some cases; (2) context-aware
reminders can improve EMA without increasing UDE.
5.3.4 Effective Medication Adherence for Multiple Medication
To evaluate the effective medication adherence for multiple medication (M) in a day, with
multiple doses of each medicine, we evaluated EMA (SR) M and EMA (CAR) M. This will compare
the EMA for simple and persistence reminders and context-aware reminders to see which
intervention works better to improve EMA when patient is consuming multiple medications in a
day. EMA is weighted average of EMA of individual medicines based on whether the medicine
is primary or secondary. For the weighted average, the TMAX is considered in the range of 12hrs
to 18hrs because during this time interval all 3 medicines have effective dosing times. However,
individually the TMAX varies from 12hrs to 24hrs for NR1; 6hrs to 18hrs for NR2; and 5hrs to
20hrs for NR3.
Case 1: Patient is prescribed three independent medicines in a day with all three medicines
having the same dosing rate.
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Figure 37. Comparing EMA for SR and CAR (multiple medications) – Case1

Case 2: Patient is prescribed three independent medicines in a day with two medicines
having the same dosing rate and one with different dosing rate.

Figure 38. Comparing EMA for SR and CAR (multiple medications) – Case2
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Case 3: Patient is prescribed three independent medicines in a day with all three medicines
having different dosing rate.

Figure 39. Comparing EMA for SR and CAR (multiple medications) – Case3

5.3.5 Healthcare cost
Healthcare cost for nonadherent patients comprises of medical and drug cost. When a simple and
persistent intervention is administered to a nonadherent patient, it helps in improving the
medication adherence. However, due to additional undesirable dose event and cost of
intervention, it increases the healthcare cost to some extent. Still the analysis shows that simple
and persistent reminders bring the healthcare cost by approximately 15% to 20% (HCCOST_SR
Scenario I and HCCOST-SR Scenario II in Figure 40). On the other hand, smart interventions
improve the effectiveness of medication adherence as well as reduce the healthcare cost by 39%
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(HCCOST-CAR Scenario I). Analysis of healthcare cost is conducted based on the data available
in Sokol (2005) for the all-disease cost (medical and drug cost).

Figure 40. Comparison of healthcare cost saving

Section 5.4 Propositions
5.4.1 Proposition 1
Context-aware Reminders will always outperform Simple and Persistent Reminders in
improving Effective Medication Adherence.
EMA is higher for context-aware reminder (CAR) as compared to simple and persistent
reminders (SR).
Since equation 14 is 𝑬𝑴𝑨𝑪𝑨𝑹 = 𝑨𝑴𝑨𝑵𝑬𝑾-𝑪𝑨𝑹 × [𝟏 − ((𝑷𝑵𝑫-𝑹 )𝛌𝐓𝐌𝐀𝐗 𝑵𝑷 × 𝒆−𝛌𝐓𝐌𝐀𝐗 )]
And equation 9 is 𝐄𝐌𝐀 𝐒𝐑 = 𝐀𝐌𝐀 𝐍𝐄𝐖-𝐒𝐑 × (𝟏 − (𝑷𝑵𝑫-𝑹 )𝑸 [𝒆−𝛌𝐓𝐌𝐀𝐗 ])
So for,
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[𝑨𝑴𝑨𝑵𝑬𝑾-𝑪𝑨𝑹 × [𝟏 − ((𝑷𝑵𝑫-𝑹 )𝛌𝐓𝐌𝐀𝐗 𝑵𝑷 × 𝒆−𝛌𝐓𝐌𝐀𝐗 )]] > [𝐀𝐌𝐀 𝐍𝐄𝐖-𝐒𝐑 × (𝟏 −
(𝑷𝑵𝑫-𝑹 )𝑸 [𝒆−𝛌𝐓𝐌𝐀𝐗 ])]
Either, 𝑨𝑴𝑨𝑵𝑬𝑾-𝑪𝑨𝑹 > 𝐀𝐌𝐀 𝐍𝐄𝐖-𝐒𝐑
𝐍𝐑

Or, 𝛌𝐓𝐌𝐀𝐗 𝑵𝑷 > 𝑄 i.e.,

𝟐𝟒

𝐓𝐌𝐀𝐗 𝑵𝑷 >

𝑻𝑴𝑨𝑿
𝟐𝟒

𝑵𝑹

i.e., 𝑵𝑷 > 𝟏 which is true by definition. Therefore, 𝑬𝑴𝑨𝑪𝑨𝑹 > 𝑬𝑴𝑨𝑺𝑹
Results represented in Figure 31, Figure 32, and Figure 33 aligns with analysis of Proposition 1.
5.4.2 Proposition 2
Simple and Persistent Reminders will generate more UDE than Context-aware Reminders.
Equation 10 is:
𝑼𝑫𝑬𝑻𝑶𝑻𝑨𝑳 = 𝑷𝒓𝒐𝒃((𝑻𝑰+𝟏 − 𝑻𝑰 ) < 𝑻𝑴𝑰𝑵 )
= [𝟏 − 𝛌𝐓𝐌𝐈𝐍 ] × [(𝛌𝐓𝐌𝐈𝐍 )𝟐 ×

𝒆−𝛌𝐓𝐌𝐈𝐍
] + 𝛌𝐓𝐌𝐈𝐍 × 𝑷𝑫-𝑹 × [(𝛌𝐓𝐌𝐈𝐍 ) × 𝒆−𝛌𝐓𝐌𝐈𝐍 ]
𝟐!

Equation 15 is: 𝐏𝐫𝐨𝐛((𝐓𝐈+𝟏 − 𝐓𝐈 ) < 𝐓𝐌𝐈𝐍 ) = (𝛌𝐓𝐌𝐈𝐍 )𝟐 ×

𝐞−𝛌𝐓𝐌𝐈𝐍
𝟐!

Comparing equation 10 and equation 15,
[𝟏 − 𝛌𝐓𝐌𝐈𝐍 ] × [(𝛌𝐓𝐌𝐈𝐍 )𝟐 ×

> (𝛌𝐓𝐌𝐈𝐍
OR, [

(𝟏−𝛌𝐓𝐌𝐈𝐍 )
𝟐
𝟏

OR, [𝟐 −

𝛌𝐓𝐌𝐈𝐍
𝟐

)𝟐

𝒆−𝛌𝐓𝐌𝐈𝐍
] + 𝛌𝐓𝐌𝐈𝐍 × 𝑷𝑫-𝑹 × [(𝛌𝐓𝐌𝐈𝐍 ) × 𝒆−𝛌𝐓𝐌𝐈𝐍 ]
𝟐!

𝐞−𝛌𝐓𝐌𝐈𝐍
×
𝟐!
𝟏

+ 𝑷𝑫-𝑹 ] > 𝟐
𝟏

+ 𝑷𝑫-𝑹 ] > 𝟐

OR, [𝑷𝑫-𝑹 −

𝛌𝐓𝐌𝐈𝐍

OR, [𝑷𝑫-𝑹 −

𝛌𝐓𝐌𝐈𝐍

𝟐

𝟐

𝟏

𝟏

]>𝟐−𝟐
]>𝟎
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Therefore, 𝑷𝑫-𝑹 >

𝛌𝐓𝐌𝐈𝐍
𝟐

𝟑

For example, 𝛌 = 𝟐𝟒 , 𝐓𝐌𝐈𝐍 = 𝟏-𝟒𝒉𝒓, 𝑻𝒉𝒆𝒏 𝑷𝑫-𝑹 >
𝟏
𝟒

, 𝒊. 𝒆. , 𝟐𝟓% 𝒄𝒉𝒂𝒏𝒄𝒆𝒔 𝒐𝒇 𝒕𝒂𝒌𝒊𝒏𝒈 𝒎𝒆𝒅𝒊𝒄𝒂𝒕𝒊𝒐𝒏 𝒅𝒖𝒆 𝒕𝒐 𝒓𝒆𝒎𝒊𝒏𝒅𝒆𝒓𝒔.

Results represented in Figure 36 where the undesirable dose event for 3 different scenarios is
compared aligns with analysis of Proposition 2.

5.4.3 Proposition 3
The EMA will be minimum when the probability of consuming dose due to reminder is
minimum and maximum interdose-time between doses is as prescribed.
Using equation 9, we can derive the lowest value for EMA, i.e., EMAMIN for persistent
reminders.
𝐄𝐌𝐀 𝐌𝐈𝐍-𝐒𝐑 = 𝐀𝐌𝐀 𝐍𝐄𝐖 × (𝟏 − (𝑷𝑵𝑫-𝑹 )𝑸 [𝒆−𝛌𝐓𝐌𝐀𝐗 ])
= 𝐌𝐢𝐧[(𝐀𝐌𝐀 + (𝟏 − 𝐏𝐍𝐃-𝐑 ) × 𝛌𝐓𝐌𝐀𝐗 ), 𝟏] × (𝟏 − (𝑷𝑵𝑫-𝑹 )𝑸 [𝒆−𝛌𝐓𝐌𝐀𝐗 ])
The variables used in this equation are as follows:
𝐀𝐌𝐀, 𝐏𝐍𝐃-𝐑 , 𝛌𝐓𝐌𝐀𝐗 𝒂𝒏𝒅 𝑸 𝒘𝒉𝒆𝒓𝒆 𝑸 = 𝛌𝐓𝐌𝐀𝐗
For EMA to be minimum:
i.

It is desirable that (𝟏 − 𝐏𝐍𝐃-𝐑 ) × 𝛌𝐓𝐌𝐀𝐗 should be minimum, and

ii.

It is required that 𝟏 − (𝑷𝑵𝑫-𝑹 )𝑸 [𝒆−𝛌𝐓𝐌𝐀𝐗 ] = 𝟏 − (𝑷𝑵𝑫-𝑹 )𝛌𝐓𝐌𝐀𝐗 [𝒆−𝛌𝐓𝐌𝐀𝐗 ] = 𝟏 −
(

𝑷𝑵𝑫-𝑹 𝛌𝐓𝐌𝐀𝐗
𝒆

)

is minimum.

Alternatively, we can say (

𝑷𝑵𝑫-𝑹 𝛌𝐓𝐌𝐀𝐗
𝒆

)

should be maximum. It implies, 𝐏𝐍𝐃-𝐑 should be

maximum AND/OR 𝛌𝐓𝐌𝐀𝐗 should be close to zero. Using equation 14, we can derive the lowest
value for EMA, i.e., EMAMIN for context-aware reminders.
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𝑬𝑴𝑨𝑴𝑰𝑵-𝑪𝑨𝑹 = 𝑨𝑴𝑨𝑵𝑬𝑾 × (𝟏 − [(𝑷𝑵𝑫-𝑹 )𝛌𝐓𝐌𝐀𝐗 ]

𝑵𝑷

× [ 𝒆−𝛌𝐓𝐌𝐀𝐗 ])

= 𝐌𝐢𝐧[(𝐀𝐌𝐀 + (𝟏 − 𝐏𝐍𝐃-𝐑 )𝐍𝐏 )), 𝟏] × [𝟏 − ((𝑷𝑵𝑫-𝑹 )𝛌𝐓𝐌𝐀𝐗 𝑵𝑷 × 𝒆−𝛌𝐓𝐌𝐀𝐗 )]
Since equation 14 is 𝑬𝑴𝑨𝑪𝑨𝑹 = 𝑨𝑴𝑨𝑵𝑬𝑾 × [𝟏 − ((𝑷𝑵𝑫-𝑹 )𝛌𝐓𝐌𝐀𝐗 𝑵𝑷 × 𝒆−𝛌𝐓𝐌𝐀𝐗 )]
Moreover, equation 4 is 𝑬𝑴𝑨 = 𝑨𝑴𝑨 × (𝟏 − 𝑫𝑵𝑬) = 𝑨𝑴𝑨 × (𝟏 − 𝒆−𝛌𝐓𝐌𝐀𝐗 )
We know that, 𝑨𝑴𝑨𝑵𝑬𝑾 ≥ 𝑨𝑴𝑨. Using equation 14 and 4 we can say that following
condition must be true, i.e., (𝑷𝑵𝑫-𝑹 )𝛌𝐓𝐌𝐀𝐗 𝑵𝑷 < 𝟏
⇒ 𝑆𝑖𝑛𝑐𝑒, 𝑷𝑵𝑫-𝑹 < 𝟏 𝑆𝑜 𝑓𝑜𝑙𝑙𝑜𝑤𝑖𝑛𝑔 𝑒𝑞𝑢𝑎𝑡𝑖𝑜𝑛 𝑚𝑢𝑠𝑡 𝑏𝑒 𝑡𝑟𝑢𝑒, 𝑖. 𝑒. , 𝛌𝐓𝐌𝐀𝐗 𝑵𝑷 > 𝟏
Now we know that λ is the average arrival rate, and TMAX varies from 8 hours to 16
hours. Also, NP is always greater than 1 being the Number of reminders per missing dose
event. It implies 𝛌𝐓𝐌𝐀𝐗 𝑵𝑷 > 𝟏 holds true. Detailed analysis of results shown in Figure 31,
Figure 32, and Figure 33 confirms with Proposition 3.
5.4.4 Proposition 4
The UDE is maximum when the minimum gap between doses is equal to or greater than
the regular gap between medications.
Evaluating equation 10 (UDE for simple and persistent reminders) for finding UDEMAX
𝑼𝑫𝑬𝑻𝑶𝑻𝑨𝑳 = [𝟏 − 𝛌𝐓𝐌𝐈𝐍 ] × [(𝛌𝐓𝐌𝐈𝐍 )𝟐 ×

𝒆−𝛌𝐓𝐌𝐈𝐍
𝟐!

] + [𝛌𝐓𝐌𝐈𝐍 × 𝑷𝑫-𝑹 ] × [(𝛌𝐓𝐌𝐈𝐍 ) ×

𝒆−𝛌𝐓𝐌𝐈𝐍 ]
Since UDE is a probability, this can have a maximum value of 1.
Let us consider following three parameters if the prescribed doses are 3 in an interval of 8
hours: λ =

𝐍𝐑
24

𝑇𝑀𝐼𝑁 = (𝑀𝑖𝑛, 𝑀𝑎𝑥)

𝑃𝐷-𝑅 = (0, … … .1)

UDEMAX will be .368 when minimum gap between medications is equal to the regular gap
3

between medications, i.e., when λ = 24 , 𝑇𝑀𝐼𝑁 = 8, 𝑃𝐷-𝑅 = 1
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It holds true for 2doses/day at 12hrs intervals as well as 4doses/day at 5 hrs interval. We can
have higher value of UDE beyond the regular gap between medications, but [𝟏 − 𝛌𝐓𝐌𝐈𝐍 ] ×
[(𝛌𝐓𝐌𝐈𝐍 )𝟐 ×

𝒆−𝛌𝐓𝐌𝐈𝐍
𝟐!

] component (the probability of patient taking two doses when no reminder

came) of UDE becomes negative too. After analyzing results represented in Figure 36, we can
confirm the analysis of Proposition 4.
5.4.5 Proposition 5
The maximum healthcare savings due to context-aware reminders is always higher than
simple persistent reminders when there are no failures.
Since equation 16a is: 𝐇𝐂𝐂𝐎𝐒𝐓𝐍𝐀 = (𝐇𝐂𝐂𝐎𝐒𝐓-𝐏𝐀𝐒𝐓 ) × (𝟏. 𝟎𝟓)𝐍
Equation 16b is: 𝐇𝐂𝐂𝐎𝐒𝐓𝐒𝐑 = (𝐇𝐂𝐂𝐎𝐒𝐓-𝐏𝐀𝐒𝐓 ) × (𝟏. 𝟎𝟓)𝐍 × (𝟏 + 𝐔𝐃𝐄𝐒𝐑 ) + 𝐈𝐍𝐓𝐕𝐍𝐂𝐎𝐒𝐓-𝐒𝐑
Equation 16c is: 𝐇𝐂𝐂𝐎𝐒𝐓𝐂𝐀𝐑 = (𝐇𝐂𝐂𝐎𝐒𝐓-𝐏𝐀𝐒𝐓 ) × (𝟏. 𝟎𝟓)𝐍 + 𝐈𝐍𝐓𝐕𝐍𝐂𝐎𝐒𝐓-𝐂𝐀𝐑
Therefore, from equation 16b and 16c we can see that the healthcare cost due to simple
persistent reminders includes the additional cost for UDE as compared to healthcare costs due to
context-aware reminder. Also, the intervention cost (INTVNCOST) varies for context-aware
reminders as compared to simple persistent reminders. Results represented in Figure 40 helps us
in a detailed analysis of Proposition 5.
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Chapter 6. Conclusion
Improving the rate of medication adherence is a serious concern. Most of the studies on
improving medication adherence focus on one or more interventions and measure average rate of
medication adherence. Although the average rate of medication adherence is useful, we note that
patients could achieve the same average medication adherence value with widely different
consumption patterns including those where patients have not consumed any doses for several
days and then taken multiple doses or doses that are more frequent. In this research, we focus on
the idea that in addition to the average rate of medication adherence, the patterns of adherence
and effective medication adherence should also be studied. These are more likely to be a better
predictor of outcomes than average medication adherence alone.
Using design science research (DSR) approach we have developed a model for smart
interventions as health IT artifact. We have leveraged behavior change techniques (BCTs) based
on behavior change theories to design smart intervention. Because of the need for real time
requirements for the system, we are also focusing on hierarchical control system theory and
reference model architecture (RMA). The benefit of using this design will be allowing an
intervention to be administered dynamically on a need basis. A key distinction from existing
systems is that the developed artifact leverages probabilistic measure instead of static schedule.
We have developed a health IT artifact with intelligence and persistence for the reminders.
Interventions that stimulate better adherence to essential medications even slightly may
meaningfully improve public health (Friedman et al. 1996; Haynes et al. 2005). The uniqueness
of our health IT artifact, termed MEMA, is that it does not create a schedule of administering the
interventions but decides the next administration of the intervention dynamically. It creates a
schedule of prescribed dosing events at the time of prescription and also registers actual dosing
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event of the patient during prescription. A probable rate of effective medication adherence
(EMA) generates at each dosing event of the patient and the prescribed dosing event. Based on
the value of EMA, an appropriate type of intervention is chosen and scheduled either before or at
the next dosing event for the patient. It may also happen that intervention is not deemed
necessary for the next prescribed dosing event if the patient is 100% following the prescribed
dosing regimen. The type of intervention denotes the priority we associate to the next scheduled
intervention in maintaining the EMA above a specified threshold (depending on the type of care
and therapy received). It will consider the dosing frequency and time for a particular dosing
regimen. In this way, the context-aware reminders provided by MEMA will not lead to the
undesirable dose event (UDE).
We have evaluated and validated the artifact using analytical model and empirically
evaluated the effectiveness of the health IT artifact by having domain experts assess the simple
and smart intervention. Two categories of domain experts considered are the healthcare provider
and health IT experts. Focus is explicitly on the experts' reasoning about their preferences
between the existing and our smart interventions, and on relating that reasoning to the proposed
health IT artifact. This evaluation provides the insights for interventions preferred by experts. As
discussed in section 5.2, domain experts prefer smart intervention as compared to simple
intervention. There is one limitation of concern to the experts that is the reliability of the health
IT system. Patient-provider concordance is also mentioned by some of the experts as one the
factor for effectiveness of the smart intervention. The smart intervention is developed
considering the patient-provider concordance during the medication therapy/persistence.
The results have significant implication for the healthcare system and researchers studying
medication adherence and interventions. The patterns of adherence will be useful in studying
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effective medication adherence (EMA) for patients to improve medication adherence. Our results
show that (1) simple interventions can improve the pattern of adherence and the average rate of
medication adherence, but can also increase the probability of undesirable dose events
sometimes; (2) smart interventions can improve both the pattern and average value of adherence
without increasing the undesirable dose events.
The results of our analysis have significant implications for healthcare providers, patients,
insurance companies, and health IT researchers interested in improving healthcare delivery and
outcomes. Higher levels of effective adherence can be achieved for more flexible medication
regimen, such as those with higher values of maximum interdose-time. It is also possible for a
patient with lower average adherence but a more desirable pattern of adherence to have higher
effective medication adherence than a patient with higher average adherence with a less desirable
pattern of adherence. Also, the smart intervention will work for patients who are willing and can
take medication when reminded.

Section 6.1 Research Questions and Discussion
The design science research process followed in this research occurred in phases, and each
phase was instrumental in arriving at the conclusions discussed herein. This research recognized
the problem of nonadherence and the tremendous impact it has has upon financial and treatment
outcomes, especially among chronic patients prescribed self-administered medications. The
problem of nonadherence has been prevalent and very little progress in improving the rate of
medication adherence has been achieved so far. The perspective this research carried during
literature reviews to identify possible solutions to this problem was to revisit the fundamental
question related to this problem i.e. what it meant to be nonadherent and the bearing it had on the
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medication adherence. Analysis of this fundamental question provided greater insight into the
effectiveness of medication adherence and arrived at the research problem.
This research examined how patterns of medication adherence impact effective medication
adherence (EMA)? The outcome of this examination was a measure of effective medication
adherence (EMA) that could capture the effectiveness of medication adherence within the
medication persistence. So far, measurements were for average medication adherence that one
could arrive at only towards the end of medication persistence. Improving the rate of medication
adherence needs interventions that are effective for the healthcare providers to administer and
patients to follow. Based upon the measure of EMA, this research developed a health IT model
for effective medication adherence that could allow the healthcare providers to administer smart
interventions. The overall usefulness of smart interventions with results on improving effective
medication adherence and reducing healthcare costs is validated.
The guiding questions at various stages of DSR process are revisited to assess the knowledge
gained at each stage:
• Awareness of Problem: If interventions to medication nonadherence can improve
medication adherence, why such interventions are not effective? Nonadherence is a
multidimensional problem, and current measure of adherence does not support intervention
within the period of medication persistence where it can be effectively intervened.
• Suggestion: How can the effectiveness of interventions be improved? By enabling
healthcare providers to assist patients in improving their medication adherence and adopting the
use of smart interventions that are based on effective medication adherence and provide the
ability to intervene when there is a need. EMA generates at the actual dose event and the
prescribed dose events.
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• Development: How closely does the new model represent the original model/design of the
available interventions? The new model for MEMA is an enhancement to existing model and
augments the existing design with real time intelligent decision system.
• Evaluation: What are the limiting conditions for the effectiveness of interventions
utilizing new model? Besides the theoretical limits to improving the effective medication
adherence, there are practical limitations like developing a classification for the thresholds that
EMA should never fall below or for accessing the impact on a specific prescription based on
medicines administered. Development of classification for different medication regimen is an
identified future research.
• Conclusion: Do the smart interventions improve effectiveness of medication adherence?
Health Behavior Change Theories indicate so, and validations using the sample data proved that
smart interventions improve medication adherence overall and also improve the effectiveness of
medication adherence.

Section 6.2 Research Contribution
6.2.1 Contribution to Information Systems
Baskerville and Myers (2002) suggested that the “potential audience for IS field includes
scholars in any field that is vitally concerned with the development, use, and application of
information technology and systems” (p. 8). They have specifically mentioned this potential in
medical fields (Baskerville and Myers 2002 pp. 8). The healthcare industry poses important
social challenges and interesting research possibilities for researchers interested in the
development and use of information systems and technologies (Agarwal et al. 2010; Chiasson
and Davidson 2004; Romanow et al. 2012). We have leveraged the in-depth knowledge of an IS
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researcher to influence healthcare practice (Agarwal et al. 2010) by increasing effectiveness of
interventions, improving medication adherence and advancing the behavior change techniques.
Without the use of information technology (IT), measuring medication adherence can be
onerous, with feasibility and cost being barriers. Innovations in health IT utilizing the IS
advancements can increase the feasibility of monitoring, accuracy, and widespread usage of
medication adherence tools (Williams et al. 2014). Using IS/IT perspective and application of
behavior change theories (behavior change techniques) we have developed an IT based smart
intervention to address the multidimensional issue of medication adherence. Smart intervention
helps in improving medication adherence which further helps in minimizing the healthcare cost,
improving the healthcare quality and advancing behavior change techniques.
This research contributes a health IT domain specific artifact to the DSR community. The
artifact developed in this study solves a specific problem of low medication adherence among
chronic patients prescribed self-administered medications. The artifact is made a general artifact
(Iivari 2015) by using some of the requirements and design processes presented in this research.
Finally, the research adds to the IS knowledge base by providing the theory based smart
interventions based on BCTs and RMA for improving the medication adherence.
6.2.2 Contribution to Health IT
This research focuses on the effectiveness of medication adherence and the impact of
medication behavior on the overall effectiveness of treatment outcome. Specifically, we propose
that pattern of adherence along with average medication adherence is a better predictor of health
outcomes. Effective medication adherence captures the context for smart interventions that helps
increase the rate of medication adherence and lower the healthcare costs. Propositions 1 through
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5 are validated design rules for the development of smart interventions and can be useful for
future research related to medication adherence and development of new interventions.
The developed model can be utilized to create, implement and evaluate health IT artifacts for
health and wellness, and daily activity monitoring. Although our work can lead to numerous
types of health IT artifacts and related interventions, here we briefly discuss two such examples.
1. Health and wellness: The health IT artifact can be generalized for dieticians to create
dietary charts for patients to track health and wellness. These dietary charts updatesare
updated in the medication management server, and a copy is provided to patients. In this
way, a three way interaction and adherence to the diet can be tracked and improved by
providing smart interventions through the modified system.
2. Daily activity monitoring: The health IT artifact for physiotherapists is used for assisting
patients to manage pain and follow daily exercise routines. It administers Smart
interventions by managing the interaction between medication management server
(which will store the exercise schedule provided by physiotherapist and routine followed
by patients), patient and physiotherapists.
The theory based smart intervention improves medication behavior among nonadherent
patients. The effect of smart interventions on medication behavior can enrich the knowledge base
for Health Behavior Change Theories. New medication behaviors can be examined and can lead
to further theory and behavior change techniques development.

Section 6.3 Limitations and Future Research
The current design has the limitation that patient should be willing to take medication as the
interventions designed for prescribed self-administered medications. Regarding artifact
evaluation, it can be further extended by conducting a field study where the modeled artifact can
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be made accessible to patients and healthcare provider to use. It will help in empirical validation
of the artifact. The ability of patients to interact with mobile devices and applications are studied
in determining the effectiveness of interventions for medication adherence. This research is also
cognizant that deciding the ‘Type of intervention’ requires extensive study of therapy regimens,
medication behaviors, and medical conditions. It can become an active research topic. The future
work can involve
1. comparing patterns of adherence for different conditions: acute vs. chronic,
2. comparing patterns of adherence for chronic conditions over long time,
3. studying the patterns of people living alone vs. people living with a caregiver, and
4. designing highly personalized context-aware interventions for patients based on pattern
as well as average medication adherence and the patient's condition.

121

References
Agarwal, R., Gao, G., DesRoches, C., and Jha, A.K. 2010. "Research Commentary-the Digital
Transformation of Healthcare: Current Status and the Road Ahead," Information Systems
Research (21:4), pp. 796-809.
Ajzen, I., and Fishbein, M. 1975. "A Bayesian Analysis of Attribution Processes," Psychological
Bulletin (82:2), p. 261.
Albus, J.S. 1993. "A Reference Model Architecture for Intelligent Systems Design," An
introduction to intelligent and autonomous control, pp. 27-56.
Albus, J.S., and Barbera, A.J. 2005. "Rcs: A Cognitive Architecture for Intelligent Multi-Agent
Systems," Annual Reviews in Control (29:1), pp. 87-99.
Albus, J.S., and Meystel, A.M. 1996. "A Reference Model Architecture for Design and
Implementation of Intelligent Control in Large and Complex Systems," International
Journal of Intelligent Control and Systems (1:1), pp. 15-30.
Albus, J.S., and Rippey, W.G. 1994. "Rcs: A Reference Model Architecture for Intelligent
Control," From Perception to Action Conference, 1994., Proceedings: IEEE, pp. 218229.
Atreja, A., Bellam, N., and Levy, S.R. 2005. "Strategies to Enhance Patient Adherence: Making
It Simple," Medscape General Medicine (7:1), p. 4.
Bandura, A. 1977. "Self-Efficacy: Toward a Unifying Theory of Behavioral Change,"
Psychological review (84:2), p. 191.
Baskerville, R.L., and Myers, M.D. 2002. "Information Systems as a Reference Discipline," MIS
Quarterly, pp. 1-14.
Braa, J., Hanseth, O., Heywood, A., Mohammed, W., and Shaw, V. 2007. "Developing Health
Information Systems in Developing Countries: The Flexible Standards Strategy," MIS
Quarterly, pp. 381-402.
Braithwaite, S., Shirkhorshidian, I., Jones, K., and Johnsrud, M. 2013. "The Role of Medication
Adherence in the US Healthcare System,".
Carver, C.S., and Scheier, M.F. 1982. "Control Theory: A Useful Conceptual Framework for
Personality–Social, Clinical, and Health Psychology," Psychological bulletin (92:1), p.
111.

122

Chewning, B., and Sleath, B. 1996. "Medication Decision-Making and Management: A ClientCentered Model," Social Science & Medicine (42:3), pp. 389-398.
Chiasson, M.W., and Davidson, E. 2004. "Pushing the Contextual Envelope: Developing and
Diffusing Is Theory for Health Information Systems Research," Information and
Organization (14:3), pp. 155-188.
Choi, J.-H., Lim, M.-E., Kim, D.-H., and Park, S.-J. 2008. "Proactive Medication Assistances
Based on Spatiotemporal Context Awareness of Aged Persons," Engineering in Medicine
and Biology Society, 2008. EMBS 2008. 30th Annual International Conference of the
IEEE: IEEE, pp. 5121-5124.
Choi, Y.M., Olubanjo, T., Farajidavar, A., and Ghovanloo, M. 2013. "Potential Barriers in
Adoption of a Medication Compliance Neckwear by Elderly Population," Engineering in
Medicine and Biology Society (EMBC), 2013 35th Annual International Conference of
the IEEE: IEEE, pp. 4678-4681.
Christopher Frey, H., and Patil, S.R. 2002. "Identification and Review of Sensitivity Analysis
Methods," Risk analysis (22:3), pp. 553-578.
Cleven, A., Gubler, P., and Hüner, K.M. 2009. "Design Alternatives for the Evaluation of Design
Science Research Artifacts," Proceedings of the 4th International Conference on Design
Science Research in Information Systems and Technology: ACM, p. 19.
Cohen, R.A., and Villarroel, M.A. 2015. "Strategies Used by Adults to Reduce Their
Prescription Drug Costs: United States, 2013," NCHS data brief:184, pp. 1-8.
Colbert, A.M., Sereika, S.M., and Erlen, J.A. 2013. "Functional Health Literacy, MedicationTaking Self-Efficacy and Adherence to Antiretroviral Therapy," Journal of advanced
nursing (69:2), pp. 295-304.
Collins, L.M., Baker, T.B., Mermelstein, R.J., Piper, M.E., Jorenby, D.E., Smith, S.S.,
Christiansen, B.A., Schlam, T.R., Cook, J.W., and Fiore, M.C. 2011. "The Multiphase
Optimization Strategy for Engineering Effective Tobacco Use Interventions," Annals of
behavioral medicine (41:2), pp. 208-226.
Control Theory. 2016. "In Wikipedia, the Free Encyclopedia. R." Retrieved 29 April, 2016,
from https://en.wikipedia.org/w/index.php?title=Control_theory&oldid=722587776
Coomes, C.M., Lewis, M.A., Uhrig, J.D., Furberg, R.D., Harris, J.L., and Bann, C.M. 2012.
"Beyond Reminders: A Conceptual Framework for Using Short Message Service to

123

Promote Prevention and Improve Healthcare Quality and Clinical Outcomes for People
Living with Hiv," AIDS care (24:3), pp. 348-357.
Craig, P., Dieppe, P., Macintyre, S., Michie, S., Nazareth, I., and Petticrew, M. 2008.
"Developing and Evaluating Complex Interventions: The New Medical Research Council
Guidance," BMJ (337), p. a1655.
Cramer, J.A., Roy, A., Burrell, A., Fairchild, C.J., Fuldeore, M.J., Ollendorf, D.A., and Wong,
P.K. 2008. "Medication Compliance and Persistence: Terminology and Definitions,"
Value in Health (11:1), pp. 44-47.
Delgado, P.L. 2000. "Approaches to the Enhancement of Patient Adherence to Antidepressant
Medication Treatment," Journal of clinical psychiatry.
DiCarlo, L., Moon, G., Intondi, A., Duck, R., Frank, J., Hafazi, H., Behzadi, Y., Robertson, T.,
Costello, B., and Savage, G. 2012. "A Digital Health Solution for Using and Managing
Medications: Wirelessly Observed Therapy," Pulse, IEEE (3:5), pp. 23-26.
DiIorio, C., McCarty, F., DePadilla, L., Resnicow, K., Holstad, M.M., Yeager, K., Sharma, S.M.,
Morisky, D.E., and Lundberg, B. 2009. "Adherence to Antiretroviral Medication
Regimens: A Test of a Psychosocial Model," AIDS and Behavior (13:1), pp. 10-22.
Dombrowski, S.U., Sniehotta, F.F., Avenell, A., Johnston, M., MacLennan, G., and AraújoSoares, V. 2012. "Identifying Active Ingredients in Complex Behavioural Interventions
for Obese Adults with Obesity-Related Co-Morbidities or Additional Risk Factors for
Co-Morbidities: A Systematic Review," Health Psychology Review (6:1), pp. 7-32.
Duong, M., Piroth, L., Grappin, M., Forte, F., Peytavin, G., Buisson, M., Chavanet, P., and
Portier, H. 2001. "Evaluation of the Patient Medication Adherence Questionnaire as a
Tool for Self-Reported Adherence Assessment in Hiv-Infected Patients on Antiretroviral
Regimens," HIV clinical trials (2:2), pp. 128-135.
Easthall, C., Song, F., and Bhattacharya, D. 2013. "A Meta-Analysis of Cognitive-Based
Behaviour Change Techniques as Interventions to Improve Medication Adherence," BMJ
open (3:8), p. e002749.
Fongwa, M.N., Evangelista, L.S., Hays, R.D., Martins, D.S., Elashoff, D., Cowan, M.J., and
Morisky, D.E. 2008. "Adherence Treatment Factors in Hypertensive African American
Women," Vascular health and risk management (4:1), p. 157.

124

Friedman, R.H., Kazis, L.E., Jette, A., Smith, M.B., Stollerman, J., Torgerson, J., and Carey, K.
1996. "A Telecommunications System for Monitoring and Counseling Patients with
Hypertension: Impact on Medication Adherence and Blood Pressure Control," American
journal of hypertension (9:4), pp. 285-292.
Gadkari, A.S., and McHorney, C.A. 2012. "Unintentional Non-Adherence to Chronic
Prescription Medications: How Unintentional Is It Really?," BMC health services
research (12:1), p. 1.
George, J., Munro, K., McCaig, D.J., and Stewart, D.C. 2006. "Prescription Medications:
Beliefs, Experiences, Behavior, and Adherence of Sheltered Housing Residents," Annals
of Pharmacotherapy (40:12), pp. 2123-2129.
Gibson, T.B., Song, X., Alemayehu, B., Wang, S.S., Waddell, J.L., Bouchard, J.R., and Forma,
F. 2010. "Cost Sharing, Adherence, and Health Outcomes in Patients with Diabetes," The
American journal of managed care (16:8), p. 589.
Godin, G., and Kok, G. 1996. "The Theory of Planned Behavior: A Review of Its Applications to
Health-Related Behaviors," American journal of health promotion (11:2), pp. 87-98.
Gregor, S., and Hevner, A.R. 2013. "Positioning and Presenting Design Science Research for
Maximum Impact," MIS Quarterly (37:2), pp. 337-356.
Guerrero, H. 2010. Excel Data Analysis: Modeling and Simulation. Springer Science & Business
Media.
Gwadry-Sridhar, F.H., Manias, E., Zhang, Y., Roy, A., Yu-Isenberg, K., Hughes, D.A., and
Nichol, M.B. 2009. "A Framework for Planning and Critiquing Medication Compliance
and Persistence Research Using Prospective Study Designs," Clinical therapeutics (31:2),
pp. 421-435.
Hamilton, M.A. 1991. "Model Validation: An Annotated Bibliography," Communications in
Statistics-Theory and Methods (20:7), pp. 2207-2266.
Hayes, T.L., Hunt, J.M., Adami, A., and Kaye, J.A. 2006. "An Electronic Pillbox for Continuous
Monitoring of Medication Adherence," Engineering in Medicine and Biology Society,
2006. EMBS'06. 28th Annual International Conference of the IEEE: IEEE, pp. 64006403.
Haynes, R., Yao, X., Degani, A., Kripalani, S., Garg, A., and McDonald, H. 2005. "Interventions
for Enhancing Medication Adherence," The Cochrane Library.

125

Haynes, R.B., Ackloo, E., Sahota, N., McDonald, H.P., and Yao, X. 2008. "Interventions for
Enhancing Medication Adherence," Cochrane database syst Rev (2:2).
Haynes, R.B., Gibson, E., Hackett, B., Sackett, D., Taylor, D.W., Roberts, R., and Johnson, A.
1976. "Improvement of Medication Compliance in Uncontrolled Hypertension," The
Lancet (307:7972), pp. 1265-1268.
Hevner, A.R. 2007. "A Three Cycle View of Design Science Research," Scandinavian journal of
information systems (19:2), p. 4.
Hevner, A.R., March, S.T., Park, J., and Ram, S. 2004. "Design Science in Information Systems
Research," MIS Quarterly (28:1), pp. 75-105.
Ho, P.M., Bryson, C.L., and Rumsfeld, J.S. 2009. "Medication Adherence Its Importance in
Cardiovascular Outcomes," Circulation (119:23), pp. 3028-3035.
Holmes, M.S., D'Arcy, S., Costello, R.W., and Reilly, R.B. 2014. "Acoustic Analysis of Inhaler
Sounds from Community-Dwelling Asthmatic Patients for Automatic Assessment of
Adherence,".
Iivari, J. 2007. "A Paradigmatic Analysis of Information Systems as a Design Science,"
Scandinavian Journal of Information Systems (19:2), p. 5.
Iivari, J. 2015. "Distinguishing and Contrasting Two Strategies for Design Science Research,"
European Journal of Information Systems (24:1), pp. 107-115.
Ingersoll, K.S., and Cohen, J. 2008. "The Impact of Medication Regimen Factors on Adherence
to Chronic Treatment: A Review of Literature," Journal of behavioral medicine (31:3),
pp. 213-224.
Jen-pei, L. 2010. Encyclopedia of Biopharmaceutical Statistics. Taylor & Francis. p. 1493.
Kaplan, B. 2001. "Evaluating Informatics Applications—Some Alternative Approaches: Theory,
Social Interactionism, and Call for Methodological Pluralism," International journal of
medical informatics (64:1), pp. 39-56.
Knafl, G.J., Fennie, K.P., Bova, C., Dieckhaus, K., and Williams, A.B. 2004. "Electronic
Monitoring Device Event Modelling on an Individual-Subject Basis Using Adaptive
Poisson Regression," Statistics in medicine (23:5), pp. 783-801.
Krishna, S., Boren, S.A., and Balas, E.A. 2009. "Healthcare Via Cell Phones: A Systematic
Review," Telemedicine and e-Health (15:3), pp. 231-240.

126

Kuo, G.M., Buckley, T.E., Fitzsimmons, D.S., and Steinbauer, J.R. 2004. "Collaborative Drug
Therapy Management Services and Reimbursement in a Family Medicine Clinic,"
American Journal of Health System Pharmacy (61:4), pp. 343-354.
Lau, D.T., and Nau, D.P. 2004. "Oral Antihyperglycemic Medication Nonadherence and
Subsequent Hospitalization among Individuals with Type 2 Diabetes," Diabetes Care
(27:9), pp. 2149-2153.
Lehane, E., and McCarthy, G. 2007. "Intentional and Unintentional Medication Non-Adherence:
A Comprehensive Framework for Clinical Research and Practice? A Discussion Paper,"
International journal of nursing studies (44:8), pp. 1468-1477.
Lins, R.L., Matthys, K.E., Verpooten, G.A., Peeters, P.C., Dratwa, M., Stolear, J.C., and
Lameire, N.H. 2003. "Pharmacokinetics of Atorvastatin and Its Metabolites after Single
and Multiple Dosing in Hypercholesterolaemic Haemodialysis Patients," Nephrology
Dialysis Transplantation (18:5), pp. 967-976.
Lundell, J., Hayes, T.L., Vurgun, S., Ozertem, U., Kimel, J., Kaye, J., Guilak, F., and Pavel, M.
2007. "Continuous Activity Monitoring and Intelligent Contextual Prompting to Improve
Medication Adherence," Engineering in Medicine and Biology Society, 2007. EMBS
2007. 29th Annual International Conference of the IEEE: IEEE, pp. 6286-6289.
March, S.T., and Storey, V.C. 2008. "Design Science in the Information Systems Discipline: An
Introduction to the Special Issue on Design Science Research," Management Information
Systems Quarterly (32:4), p. 6.
Maulucci, R.A., and Somerville, D. 2011. "An Automated Medication Adherence Tool,"
Engineering in Medicine and Biology Society, EMBC, 2011 Annual International
Conference of the IEEE: IEEE, pp. 1165-1168.
McCall, C., Maynes, B., Zou, C.C., and Zhang, N.J. 2010. "Rmais: Rfid-Based Medication
Adherence Intelligence System," Engineering in Medicine and Biology Society (EMBC),
2010 Annual International Conference of the IEEE: IEEE, pp. 3768-3771.
McCarthy, J. 1980. "Circumscription-a Form of Non-Monotonic Reasoning," Artificial
Intelligence (13:1-2), pp. 27-39.
McCarthy, R. 1998. "The Price You Pay for the Drug Not Taken," Business and health (16:10),
p. 27.

127

McDonald, H.P., Garg, A.X., and Haynes, R.B. 2002. "Interventions to Enhance Patient
Adherence to Medication Prescriptions: Scientific Review," JAMA (288:22), pp. 28682879.
Meducation, A. 2006. "Improving Medication Adherence in Older Adults," American Society on
Aging and American Society of Consultant Pharmacists Foundation.
Michie, S., and Johnston, M. 2012. "Theories and Techniques of Behaviour Change: Developing
a Cumulative Science of Behaviour Change," Health Psychology Review (6:1), pp. 1-6.
Miscione, G. 2007. "Telemedicine in the Upper Amazon: Interplay with Local Health Care
Practices," MIS Quarterly, pp. 403-425.
Moore, G.C., and Benbasat, I. 1991. "Development of an Instrument to Measure the Perceptions
of Adopting an Information Technology Innovation," Information systems research (2:3),
pp. 192-222.
Moore, J.O., Hardy, H., Skolnik, P., and Moss, F. 2011. "A Collaborative Awareness System for
Chronic Disease Medication Adherence Applied to HIV Infection," Engineering in
Medicine and Biology Society, EMBC, 2011 Annual International Conference of the
IEEE: IEEE, pp. 1523-1527.
Morrissey, E.C., Corbett, T.K., Walsh, J.C., and Molloy, G.J. 2015. "Behavior Change
Techniques in Apps for Medication Adherence: A Content Analysis," American journal
of preventive medicine.
NACDS. 2010. Pharmacies: Improving Health, Reducing Costs. National Association of Chain
Drug Stores, Alexandria, VA.
NEHI. 2009. Thinking Outside the Pillbox: A System-Wide Approach to Improving Patient
Medication Adherence for Chronic Disease. New England Health Care Institute.
Nieuwlaat, R., Wilczynski, N., Navarro, T., Hobson, N., Jeffery, R., Keepanasseril, A.,
Agoritsas, T., Mistry, N., Iorio, A., and Jack, S. 2014. "Interventions for Enhancing
Medication Adherence," Cochrane Database Syst Rev (11).
Osterberg, L., and Blaschke, T. 2005. "Adherence to Medication," New England Journal of
Medicine (353:5), pp. 487-497.
Parsons, J., and Wand, Y. 2008. "Using Cognitive Principles to Guide Classification in
Information Systems Modeling," MIS Quarterly (32:4).

128

Peirce, C.S. 1931. "Collected Papers of Cs Peirce, Ed. By C. Hartshorne, P. Weiss, & A. Burks,
8 Vols." Harvard University Press, Cambridge, MA.
Peterson, A.M., Takiya, L., and Finley, R. 2003. "Meta-Analysis of Trials of Interventions to
Improve Medication Adherence," American Journal of Health-System Pharmacy (60:7),
pp. 657-665.
Phatak, H.M., and Thomas, J. 2006. "Relationships between Beliefs About Medications and
Nonadherence to Prescribed Chronic Medications," Annals of Pharmacotherapy (40:10),
pp. 1737-1742.
Pratt, R.J., Robinson, N., Loveday, H.P., Pellowe, C.M., Franks, P.J., Hankins, M., and Loveday,
C. 2001. "Adherence to Antiretroviral Therapy: Appropriate Use of Self-Reporting in
Clinical Practice," HIV Clinical Trials (2:2), pp. 146-159.
Pries-Heje, J., Baskerville, R., and Venable, J. 2007. "Soft Design Science Research: Extending
the Boundaries of Evaluation in Design Science Research," The 2nd International
Conference on Design Science Research in IT (DESRIST), pp. 18-38.
Pries-Heje, J., Baskerville, R., and Venable, J. 2008. "Strategies for Design Science Research
Evaluation," ECIS 2008 proceedings, pp. 1-12.
Prochaska, J., and Diclemente, C. 1983. "Stages and Procesess of Self-Change of Smoking:
Toward an Integrative Model of Change. J Consult Clin Psichol. 1983; 51: 390-5."
Revere, D., and Dunbar, P.J. 2001. "Review of Computer-Generated Outpatient Health Behavior
Interventions," Journal of the American Medical Informatics Association (8:1), pp. 6279.
Roebuck, M.C., Liberman, J.N., Gemmill-Toyama, M., and Brennan, T.A. 2011. "Medication
Adherence Leads to Lower Health Care Use and Costs Despite Increased Drug
Spending," Health Affairs (30:1), pp. 91-99.
Romanow, D., Cho, S., and Straub, D. 2012. "Editor's Comments: Riding the Wave: Past Trends
and Future Directions for Health IT Research," MIS Quarterly (36:3), pp. III-A18.
Rosen, R.K., Ranney, M.L., and Boyer, E.W. 2015. "Formative Research for Mhealth Hiv
Adherence: The Ihaart App," System Sciences (HICSS), 2015 48th Hawaii International
Conference on: IEEE, pp. 2778-2785.

129

Rosenstock, I.M., Strecher, V.J., and Becker, M.H. 1994. "The Health Belief Model and Hiv
Risk Behavior Change," Preventing AIDS: Theories and Methods of Behavioral
Interventions (2), p. 5.
Ruppar, T.M. 2010. "Randomized Pilot Study of a Behavioral Feedback Intervention to Improve
Medication Adherence in Older Adults with Hypertension," Journal of Cardiovascular
Nursing (25:6), pp. 470-479.
Saaty, T.L., and Vargas, L.G. 2012. Models, Methods, Concepts & Applications of the Analytic
Hierarchy Process. Springer Science & Business Media.
Sabate, E. 2007. "Adherence to Long-Term Therapies: Evidence for Action. Geneva: World
Health Organization; 2003." WHO/MNC/03.01.
Schreier, G., Schwarz, M., Modre-Osprian, R., Kastner, P., Scherr, D., and Fruhwald, F. 2013.
"Design and Evaluation of a Multimodal Mhealth Based Medication Management
System for Patient Self Administration," Engineering in Medicine and Biology Society
(EMBC), 2013 35th Annual International Conference of the IEEE: IEEE, pp. 7270-7273.
Sicre, A. 2007. "The Medication Non-Adherence Blog: White Coat Adherence." Retrieved 30
June, 2013
Sokol, M.C., McGuigan, K.A., Verbrugge, R.R., and Epstein, R.S. 2005. "Impact of Medication
Adherence on Hospitalization Risk and Healthcare Cost," Medical care (43:6), pp. 521530.
Steiner, J.F., and Earnest, M.A. 2000. "The Language of Medication-Taking," Annals of internal
medicine (132:11), pp. 926-930.
Tang, L., Zhou, X., Yu, Z., Liang, Y., Zhang, D., and Ni, H. 2011. "Mhs: A Multimedia System
for Improving Medication Adherence in Elderly Care," Systems Journal, IEEE (5:4), pp.
506-517.
Taylor, N., Conner, M., and Lawton, R. 2012. "The Impact of Theory on the Effectiveness of
Worksite Physical Activity Interventions: A Meta-Analysis and Meta-Regression,"
Health Psychology Review (6:1), pp. 33-73.
Tedeschi, L.O. 2006. "Assessment of the Adequacy of Mathematical Models," Agricultural
systems (89:2), pp. 225-247.

130

Thier, S.L., Yu-Isenberg, K., Leas, B., Cantrell, C., DeBussey, S., Goldfarb, N., and Nash, D.B.
2008. "In Chronic Disease, Nationwide Data Show Poor Adherence by Patients to
Medication and by Physicians to Guidelines," Manag. Care (17:2), pp. 48-52.
Vaishnavi, V.K., and Kuechler, W. 2015. Design Science Research Methods and Patterns:
Innovating Information and Communication Technology. CRC Press.
Vaishnavi, V.K., Kuechler, W., and Kuechler Jr, W. 2007. Design Science Research Methods
and Patterns: Innovating Information and Communication Technology. CRC Press.
Varshney, U. 2009. Pervasive Healthcare Computing: EMR/EHR, Wireless and Health
Monitoring. Springer Science & Business Media.
Varshney, U. 2011. "Wireless Medication Management System: Design and Performance
Evaluation," Wireless Telecommunications Symposium (WTS), 2011: IEEE, pp. 1-8.
Varshney, U. 2013. "Smart Medication Management System and Multiple Interventions for
Medication Adherence," Decision Support Systems (55:2), pp. 538-551.
Varshney, U., and Singh, N. 2013. "A Framework for Studying Patterns of Effective Medication
Adherence," International Journal of Interdisciplinary Telecommunications and
Networking (IJITN) (5:4), pp. 1-12.
Vrijens, B., Vincze, G., Kristanto, P., Urquhart, J., and Burnier, M. 2008. "Adherence to
Prescribed Antihypertensive Drug Treatments: Longitudinal Study of Electronically
Compiled Dosing Histories," BMJ (336:7653), pp. 1114-1117.
Webb, T., Joseph, J., Yardley, L., and Michie, S. 2010. "Using the Internet to Promote Health
Behavior Change: A Systematic Review and Meta-Analysis of the Impact of Theoretical
Basis, Use of Behavior Change Techniques, and Mode of Delivery on Efficacy," Journal
of medical Internet research (12:1), p. e4.
WHO. 2003. "Adherence to Long-Term Therapies: Evidence for Action," World Health
Organization.
Williams, A.B., Mertz, K., and Wilkins, T.L. 2014. "Issue Brief: Medication Adherence and
Health It," Washington, DC: Office of the National Coordinator for Health Information
Technology, Department of Health and Human Services.
Wroth, T.H., and Pathman, D.E. 2006. "Primary Medication Adherence in a Rural Population:
The Role of the Patient-Physician Relationship and Satisfaction with Care," The Journal
of the American Board of Family Medicine (19:5), pp. 478-486.

131

Zulman, D.M., Kerr, E.A., Hofer, T.P., Heisler, M., and Zikmund-Fisher, B.J. 2010. "PatientProvider Concordance in the Prioritization of Health Conditions among Hypertensive
Diabetes Patients," Journal of general internal medicine (25:5), pp. 408-414.

132

Appendices
A1. Empirical evaluation form used by domain experts
Instructions for Expert
There are two artifacts (Table 1) and their respective specifications. These artifacts constitute
the interventions for improving medication adherence among chronic disease patients. Artifact1
provides simple interventions/reminders to patients to take medications based on the prescription
information provided by the healthcare professional and dosing information provided by the
patient. Artifact2 provides smart interventions based on the prescription information provided by
the healthcare professional and dosing information provided by the patient. Artifact2 includes
some additional information, which is missing in Artifact1. So please examine Artifact1 and
Artifact2 for improving medication adherence and answer the questions in Table 2.

Note: We are aware of that Artifact2 is still partial and some information is missing. We ask
that you base your responses on the interventions as presented.
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Table 1

Artifact1(Simple intervention)

Artifact2(Smart Intervention)
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Table 2
Questions
(1) What differences can be
identified between the two
artifacts?

Response

(2) What questions could be
asked to clarify the
reasons for these
differences?

(3) Which of the two might be
more useful or realistic
based on your general
knowledge of the domain?

(4) Which one of these is
more reliable or less likely
to fail?

(5) Which one of these will
lead to overdose/over
medication?
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IRB Outcome Letter for Non-Human Subject Research
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A2 Analytical Model Implementation Using Excel
A2.1 Effective Medication Adherence (EMA) for Single Medication, Multiple Doses
Simple and Persistent Reminder
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Context-aware Reminder
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A2.2Effective Medication Adherence for Multiple Medication, Multiple Doses
Simple and Persistent Reminder Vs Context-aware Reminder
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A2.3 Undesirable Dose Event
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A2.4 Healthcare cost
Healthcare cost Nonadherent, Simple Intervention and Smart Intervention
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A3 Theoretical Background
A3.1 Factors reported affecting medication adherence (Meducation 2006)
1. SOCIAL AND ECONOMIC DIMENSION
• Limited English language proficiency
• Low health literacy
• Lack of family or social support network
• Unstable living conditions; homelessness
• Burdensome schedule
• Limited access to healthcare facilities
• Lack of healthcare insurance
• Inability or difficulty accessing pharmacy
• Medication cost
• Cultural and lay beliefs about illness and treatment
• Elder abuse
2. HEALTHCARE SYSTEM DIMENSION
• Provider-patient relationship
• Provider communication skills
• Disparity between the health beliefs of the healthcare provider and those of the patient
• Lack of positive reinforcement from the healthcare provider
• Weak capacity of the system to educate patients and provide follow-up
• Lack of knowledge on adherence and of effective interventions for improving it
• Patient information materials are written at too high literacy level
• Restricted formularies; changing medications covered on formularies
• High drug costs, copayments, or both
• Poor access or missed appointments
• Long wait times
• Lack of continuity of care
3. CONDITION-RELATED DIMENSION
• Chronic conditions
• Lack of symptoms
• Severity of symptoms
• Depression
• Psychotic disorders
• Mental retardation/developmental disability
4. THERAPY-RELATED DIMENSION
• Complexity of medication regimen (number of daily doses; number of concurrent medications)
• Treatment requires mastery of certain techniques (injections, inhalers)
• Duration of therapy
• Frequent changes in medication regimen
• Lack of immediate benefit of therapy
• Medications with social stigma attached to use
• Actual or perceived unpleasant side effects
• Treatment interferes with lifestyle or requires significant behavioral changes
5. PATIENT-RELATED DIMENSION
Physical Factors
• Visual impairment
• Hearing impairment
• Cognitive impairment
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• Impaired mobility or dexterity
• Swallowing problems
Psychological/Behavioral Factors
• Knowledge about disease
• Perceived risk/susceptibility to disease
• Understanding reason medication is needed
• Expectations or attitudes toward treatment
• Perceived benefit of treatment
• Confidence in ability to follow treatment regimen
• Motivation
• Fear of possible adverse effects
• Fear of dependence
• Feeling stigmatized by the disease
• Frustration with healthcare providers
• Psychosocial stress, anxiety, anger
• Alcohol or substance abuse
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A3.2 Models and Concepts for Health Behavior Change
(Revere and Dunbar 2001)
Concept
Definition
Health Belief Model (Rosenstock et al. 1994):
One's opinion of chances of getting a
Perceived susceptibility
condition
One's opinion of how serious a
Perceived severity
condition and its consequences are
One's opinion of the efficacy of the
Perceived benefits
advised action to reduce risk or
seriousness of impact
One's opinion of the tangible and
Perceived barriers
psycho- logical costs of the action
Cues to action

Strategies to activate “readiness.”

Confidence in one's ability to take
action
Stages-of-Change Model (Prochaska and Diclemente 1983):
Self-efficacy

Application
Personalize risk based on a person's
features or behavior.
Specify consequences of the risk and
the condition.
Define action to take; how, where,
when; clarify the positive effects to be
expected.
Identify and reduce barriers through
reassurance, incentives, assistance.
Provide how-to information, promote
awareness, and provide reminders.
Provide training, guidance in
performing an action.

Increase awareness of the need for
change, personalizes information on
risks and benefits.
Thinking about change, in the near Motivate, encourage to make specific
Contemplation
future.
plans.
Assist in developing concrete action
Preparation
Making a plan to change
plans, setting gradual goals.
Implementation of specific action
Assist with feedback, problem solving,
Action
plans
social support, reinforcement.
Continuation of desirable actions, or Assist in coping, reminders, finding
Maintenance
repeating periodic recommended
alternatives, avoiding slips/relapses (as
step(s)
applicable).
Theory of Planned Behavior (Godin and Kok 1996) and Theory of Reasoned Action (Ajzen and
Fishbein 1975):
Define action; identify how much effort
Perceived likelihood of performing
Behavioral intention
one is planning to exert to reach the
the behavior; prerequisite for action
goal.
One's favorable or unfavorable
Attitude
Identify outcomes of action.
evaluation of the behavior
Belief that behavioral performance is
Provide information about outcomes;
Behavioral belief
associated with certain attributes or
clarify positive effects to be expected.
outcomes
Subjective belief regarding approval Identify barriers and advantages of
Normative belief
or disapproval of the behavior
behavior.
Influence of perceived social
Identify specific groups or individuals
pressure; weighted by one's
Subjective norm
of influence; identify how much their
motivation to comply with perceived
approval or disapproval affects action.
expectations
Perceived behavioral
One's perception of how easy or
Incorporate information about likely
control (Theory of
difficult it will be to act
results of action in advice.
Reasoned Action only)
Social Cognitive Theory (Bandura 1977):
Pre-contemplation

Unaware of problem hasn't thought
about changes

146

Concept
Reciprocal determinism
Behavioral capability
Expectations
Self-efficacy
Observational learning
Reinforcement

Definition
Behavior changes result from
interaction between individual and
environment
Knowledge and skills to influence
behavior

Application
Work to change the environment.

Provide information and training about
action.
Incorporate information about likely
Beliefs about likely results of action
results of action into advice.
Point out strengths; use persuasion and
Confidence in ability to take action
encouragement; approach behavior
and persist in action
change in small steps.
Point out others' experience; identifies
Beliefs based on observing others
role models.
Responses to a person's behavior that
Provide incentives, rewards, praise;
increase or decrease chances of
encourage self-reward.
recurrence
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A3.3a Theoretical analysis of cognition
(Model Proposed by Albus and Meystel (1996))

A3.3b Control Techniques
(Control Theory 2016)
Control Technique
Adaptive control

Hierarchical control
system
Intelligent control
Optimal control

Robust control

Stochastic control

Energy-shaping
control
Self-organized
criticality control

Description
Uses on-line identification of the process parameters, or modification of
controller gains, thereby obtaining strong robustness properties. Adaptive
controls were applied for the first time in the aerospace industry in the
1950s and have found particular success in that field.
A type of control system in which a set of devices and governing software
is arranged in a hierarchical tree. When the links in the tree are
implemented by a computer network, then that hierarchical control system
is also a form of networked control system
Uses various AI computing approaches like neural networks, Bayesian
probability, fuzzy logic, machine learning, evolutionary computation and
genetic algorithms to control a dynamic system
A particular control technique in which the control signal optimizes a
certain "cost index": for example, in the case of a satellite, the jet thrusts
needed to bring it to the desired trajectory that consumes the least amount
of fuel
Deals explicitly with uncertainty in its approach to controller design.
Controllers designed using robust control methods tend to be able to cope
with small differences between the true system and the nominal model used
for design.
Deals with control design with uncertainty in the model. In typical
stochastic control problems, it is assumed that there exist random noise and
disturbances in the model and the controller, and the control design must
take into account these random deviations
View the plant and the controller as energy transformation devices. The
control strategy is formulated regarding interconnection (in a powerpreserving manner) to achieve the desired behavior.
May be defined as attempts to interfere in the processes by which the selforganized system dissipates energy.
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